<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Tissue Res</journal-id><journal-id journal-id-type="iso-abbrev">Cell Tissue Res</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Cell and Tissue Research</journal-title></journal-title-group><issn pub-type="ppub">0302-766X</issn><issn pub-type="epub">1432-0878</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9918406</article-id><article-id pub-id-type="pmcid-ver">PMC9918406.2</article-id><article-id pub-id-type="pmcaid">9918406</article-id><article-id pub-id-type="pmcaiid">10113304</article-id><article-id pub-id-type="pmid">36764940</article-id><article-id pub-id-type="doi">10.1007/s00441-023-03749-7</article-id><article-id pub-id-type="publisher-id">3749</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Vaccines for prion diseases: a realistic goal?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1948-4538</contrib-id><name name-style="western"><surname>Napper</surname><given-names initials="S">Scott</given-names></name><address><email>scott.napper@usask.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schatzl</surname><given-names initials="HM">Hermann M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.25152.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2154 235X</institution-id><institution>Vaccine and Infectious Disease Organization, </institution><institution>University of Saskatchewan, </institution></institution-wrap>Saskatoon, SK Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.25152.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2154 235X</institution-id><institution>Department of Biochemistry, Microbiology and Immunology, </institution><institution>University of Saskatchewan, </institution></institution-wrap>Saskatoon, SK Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.22072.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7697</institution-id><institution>Calgary Prion Research Unit, </institution><institution>Faculty of Veterinary Medicine, University of Calgary, </institution></institution-wrap>Calgary, AB Canada </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>2</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>392</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">433776</issue-id><fpage>367</fpage><lpage>392</lpage><history><date date-type="received"><day>3</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>02</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>02</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-25 12:25:14.430"><day>25</day><month>04</month><year>2023</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">9918406</article-id><article-id pub-id-type="doi">10.1007/s00441-023-03749-7</article-id><article-version>1</article-version><pub-date><day>11</day><month>02</month><year>2023</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10113304</article-id><article-id pub-id-type="doi">10.1007/s00441-023-03749-7</article-id><article-version>2</article-version><pub-date><day>11</day><month>02</month><year>2023</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="441_2023_Article_3749.pdf"/><abstract id="Abs1"><p id="Par1">Prion diseases are fatal infectious neurodegenerative disorders and prototypic conformational diseases, caused by the conformational conversion of the normal cellular prion protein (PrP<sup>C</sup>) into the pathological PrP<sup>Sc</sup> isoform. Examples are scrapie in sheep and goat, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in cervids, and Creutzfeldt&#8211;Jacob disease (CJD) in humans. There are no therapies available, and animal prion diseases like BSE and CWD can negatively affect the economy, ecology, animal health, and possibly human health. BSE is a confirmed threat to human health, and mounting evidence supports the zoonotic potential of CWD. CWD is continuously expanding in North America in numbers and distribution and was recently identified in Scandinavian countries. CWD is the only prion disease occurring both in wild and farmed animals, which, together with extensive shedding of infectivity into the environment, impedes containment strategies. There is currently a strong push to develop vaccines against CWD, including ones that can be used in wildlife. The immune system does not develop a bona fide immune response against prion infection, as PrP<sup>C</sup> and PrP<sup>Sc</sup> share an identical protein primary structure, and prions seem not to represent a trigger for immune responses. This asks for alternative vaccine strategies, which focus on PrP<sup>C</sup>-directed self-antibodies or exposure of disease-specific structures and epitopes. Several groups have established a proof-of-concept that such vaccine candidates can induce some levels of protective immunity in cervid and rodent models without inducing unwanted side effects. This review will highlight the most recent developments and discuss progress and challenges remaining.
</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prion</kwd><kwd>Chronic wasting disease</kwd><kwd>Vaccine</kwd><kwd>Immunotherapy</kwd><kwd>Wildlife vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><sec id="FPar1"><title>Prion mechanism</title><p id="Par2">Prion diseases are fatal transmissible spongiform encephalopathies (TSEs) in human and animals that are characterized by spongiform degeneration and progressive neuronal loss in the central nervous system (CNS) (Prusiner <xref ref-type="bibr" rid="CR183">1982</xref>, <xref ref-type="bibr" rid="CR184">1998</xref>; Wadsworth and Collinge <xref ref-type="bibr" rid="CR223">2011</xref>). These diseases are caused by the accumulation of the pathological isoform (PrP<sup>Sc</sup>) of the cellular prion protein (PrP<sup>C</sup>) (Aguzzi et al. <xref ref-type="bibr" rid="CR6">2008</xref>; Budka <xref ref-type="bibr" rid="CR41">2003</xref>; Prusiner <xref ref-type="bibr" rid="CR183">1982</xref>; Prusiner et al. <xref ref-type="bibr" rid="CR185">1998</xref>; Tatzelt and Schatzl&#160;<xref ref-type="bibr" rid="CR218">2007</xref>; Wadsworth and Collinge <xref ref-type="bibr" rid="CR223">2011</xref>). Prion diseases are prototypic conformational disorders, diseases where a normal cellular host protein changes its conformation in a way which usually results in gain of a toxic function. How exactly PrP<sup>c</sup> is converted into PrP<sup>Sc</sup> is not fully understood at the molecular level, and it depends on whether the manifestation is acquired by infection, genetic, or sporadic routes (Aguzzi et al. <xref ref-type="bibr" rid="CR6">2008</xref>; Budka <xref ref-type="bibr" rid="CR41">2003</xref>; Prusiner <xref ref-type="bibr" rid="CR183">1982</xref>; Prusiner et al. <xref ref-type="bibr" rid="CR185">1998</xref>; Tatzelt and Schatzl, <xref ref-type="bibr" rid="CR218">2007</xref>; Wadsworth and Collinge <xref ref-type="bibr" rid="CR223">2011</xref>). Most experimental evidence points to a molecular mechanism where seeds of PrP<sup>Sc</sup> incorporate PrP<sup>C</sup> molecules in a seeded aggregation process (Jarrett and Lansbury <xref ref-type="bibr" rid="CR118">1993</xref>; DeMarco and Daggett <xref ref-type="bibr" rid="CR57">2004</xref>; Igel-Egalon et al. <xref ref-type="bibr" rid="CR113">2019</xref>). The generation of initial seeds depends on the manifestation form, with intra-molecular conformational changes in PrP preceding inter-molecular ones for sporadic prion diseases (DeMarco and Daggett <xref ref-type="bibr" rid="CR57">2004</xref>; Igel-Egalon et al. <xref ref-type="bibr" rid="CR113">2019</xref>; Taguchi et al. <xref ref-type="bibr" rid="CR210">2018</xref>). In genetic forms, the underlying amino acid exchange seems to initiate and/or accelerate this mechanism. For acquired prion diseases, PrP<sup>Sc</sup> seeds are provided by the invading prions. In all three situations, the existing cellular clearance mechanisms dealing with aggregated proteins are bypassed or overwhelmed (Schatzl <xref ref-type="bibr" rid="CR201">2013</xref>; Marrero-Winkens et al. <xref ref-type="bibr" rid="CR151">2020</xref>).</p><p>When a certain threshold of PrP<sup>Sc</sup> seeds is exceeded, PrP<sup>Sc</sup> propagates in an autocatalytic process that increases the infectious load. Although this is a post-translational process that is strictly dependent on the availability of PrP<sup>c</sup> substrate (Bueler et al. <xref ref-type="bibr" rid="CR42">1993</xref>; Mallucci et al. <xref ref-type="bibr" rid="CR147">2003</xref>), it is not fully understood whether post-translational modifications in PrP isoforms are causally involved in this process (Aguilar-Calvo et al. <xref ref-type="bibr" rid="CR3">2021</xref>; Makarava and Baskakov <xref ref-type="bibr" rid="CR146">2022</xref>). The infectious character of prion diseases is reflected at the cellular level by transfer of prion infectivity from cell to cell, inside and outside of the CNS, which results in the infection of na&#239;ve cells. Since cell culture models exist that recapitulate acute and persistent prion infection, the cell biology of intracellular generation of prions, interaction with cellular pathways and clearance mechanisms, and infection of new cells are rather well studied and subject of many review articles (Heiseke et al. <xref ref-type="bibr" rid="CR101">2010</xref>; Priola <xref ref-type="bibr" rid="CR181">2017</xref>; Krance et al. <xref ref-type="bibr" rid="CR132">2020</xref>; Heum&#252;ller et al. <xref ref-type="bibr" rid="CR106">2022</xref>).</p><p>At the organism level, the manifestation of disease depends on where infection is initiated. For sporadic and genetic prion diseases, which represent the majority of human prion diseases, this seems to be the CNS, in an endogenous mechanism that does not involve infection from outside. This is different for acquired forms of disease, the ones usually found in animal prion diseases, which clearly involve an exogenous process of infection. For the latter, the route of infection decides on what cell types and tissues are initially involved. The most relevant route of infection for acquired prion diseases of man and animals is the oral one: prions are ingested and get access to lymphatic and nervous tissues that line the digestive tract. This process is well studied in rodent models or the relevant large animal models of prion infection, and many mechanistic insights were obtained using transgenic and knock-out mouse models (Prusiner et al. <xref ref-type="bibr" rid="CR185">1998</xref>; Weissmann et al. <xref ref-type="bibr" rid="CR229">2001</xref>; Groschup and Buschmann <xref ref-type="bibr" rid="CR87">2008</xref>; Wadsworth et al. <xref ref-type="bibr" rid="CR222">2010</xref>; Moreno and Telling <xref ref-type="bibr" rid="CR162">2017</xref>). Depending on the species and route of infection, propagation of prions involves lymphatic tissues and parts of the peripheral nervous system (PNS). From cranial nerves, there is a direct entry into the CNS from lymphatic tissues and secondary lymphoid organs (Bartz et al. <xref ref-type="bibr" rid="CR19">2005</xref>; Shearin and Bessen <xref ref-type="bibr" rid="CR206">2014</xref>; Beekes <xref ref-type="bibr" rid="CR21">2021</xref>). Prions can be detected in the blood with highly sensitive methods, but the extent to which prionemia plays a pathogenetic role in peripheral prion infection is unclear (Elder et al. <xref ref-type="bibr" rid="CR65">2015</xref>).</p><p>Similarly, there is an anterograde transport of prion infectivity from the infected CNS to the periphery, likely also from extra-CNS sites of prion propagation, which can result in prion shedding into body fluids and excretions and result in lateral infection from individual to individual (Saunders et al. <xref ref-type="bibr" rid="CR199">2008</xref>; Bessen et al. <xref ref-type="bibr" rid="CR31">2010</xref>; Haley et al. <xref ref-type="bibr" rid="CR89">2011</xref>). The type of prion disease and the species involved mostly dictate whether such a scenario can result in population-level relevant scenarios, with epidemics as most extreme situation. Most human prion disease patients are not contagious on a daily level to their fellow human beings, although certain medical procedures and devices can transmit prions, in particular when they had access to infected CNS (Brown et al. <xref ref-type="bibr" rid="CR38">2000</xref>). Similarly, BSE is not contagious from cow to cow under normal circumstances but can be transmitted between cattle by prion contaminated feed sources. Here, infection was caused by prion-tainted animal feed, most likely meat and bone meal (Kimberlin <xref ref-type="bibr" rid="CR126">1992</xref>; Wells and Wilesmith <xref ref-type="bibr" rid="CR230">1995</xref>). The potential for lateral infection is high for scrapie in sheep and chronic wasting disease (CWD) in cervids (Dickinson et al. <xref ref-type="bibr" rid="CR61">1974</xref>; Williams and Miller <xref ref-type="bibr" rid="CR236">2002</xref>; Mathiason et al. <xref ref-type="bibr" rid="CR155">2006</xref>). Besides such intra-species infection, selected prion diseases have the potential to infect other species, with BSE as most prominent example (Hill et al. <xref ref-type="bibr" rid="CR109">1997</xref>; Bruce et al. <xref ref-type="bibr" rid="CR40">2007</xref>). Although many species can be infected experimentally when using the intracerebral route of infection, there are natural limitations summarized under the concept of &#8220;species barrier&#8221; in prion disease research (Scott et al. <xref ref-type="bibr" rid="CR204">1989</xref>; Hill and Collinge <xref ref-type="bibr" rid="CR108">2001</xref>; B&#233;ringue et al. <xref ref-type="bibr" rid="CR27">2008</xref>). The molecular and cellular determinants of this species barrier are not fully understood, but it is likely that regional homologies or non-homologies in the tertiary structure of invading PrP<sup>Sc</sup> and PrP of the host species play a key role in this scenario (Prusiner et al. <xref ref-type="bibr" rid="CR186">1990</xref>; Collinge and Clarke <xref ref-type="bibr" rid="CR53">2007</xref>; Sigurdson et al. <xref ref-type="bibr" rid="CR207">2010</xref>).</p><p>Although prions can replicate in a variety of cell types and tissues outside the CNS, clinical disease manifestation is unique to the CNS, mainly because of progressive loss of neurons. Additional pathological hallmarks are vacuolation, reactive astrocytosis, and deposition of extracellular proteinaceous plaques consisting of PrP<sup>Sc</sup> (Kov&#225;cs et al. <xref ref-type="bibr" rid="CR130">2004</xref>). The type of prions influences these hallmarks, and a variety of different pathological signatures in the CNS can exist within a given species. In analogy to genetic variants as known for microbes, the concept of &#8220;prion strains&#8221; was introduced to describe this phenomenon (Bessen and Marsh <xref ref-type="bibr" rid="CR30">1992</xref>; Carlson et al. <xref ref-type="bibr" rid="CR48">1994</xref>; Bessen et al. <xref ref-type="bibr" rid="CR29">1995</xref>; Weissmann <xref ref-type="bibr" rid="CR227">2009</xref>). Since prions do not contain encoding nucleic acid and strictly use PrP<sup>C</sup> of the host species for their replication, conformational variability at the PrP level and existence of PrP<sup>Sc</sup> conformers is widely accepted as the underlying molecular mechanism (Bessen and Marsh <xref ref-type="bibr" rid="CR30">1992</xref>; Carlson et al. <xref ref-type="bibr" rid="CR48">1994</xref>; Bessen et al. <xref ref-type="bibr" rid="CR29">1995</xref>; Weissmann <xref ref-type="bibr" rid="CR227">2009</xref>; Collinge <xref ref-type="bibr" rid="CR52">2010</xref>; Carta and Aguzzi <xref ref-type="bibr" rid="CR49">2022</xref>). Molecular signatures that discriminate prion strains can be clinical symptoms, type of vacuolation, and PrP<sup>Sc</sup> plaque distribution in the brain, immunoblot profile, and resistance to denaturing agents and proteinase K (DeArmond et al. <xref ref-type="bibr" rid="CR55">1994</xref>; Aguzzi et al. <xref ref-type="bibr" rid="CR5">2007</xref>; Wadsworth and Collinge <xref ref-type="bibr" rid="CR223">2011</xref>). Similar as various RNA viruses exist as a dynamic quasi-species population in the host, a probably more restricted quasi-species nature of PrP<sup>Sc</sup> conformers is in place. The dynamic nature of these quasi-species conformers was evident in experimental drug treatment studies and indicates a selection process at the structural level (Li et al. <xref ref-type="bibr" rid="CR137">2010</xref>; Berry et al. <xref ref-type="bibr" rid="CR28">2013</xref>; Bian et al. <xref ref-type="bibr" rid="CR33">2014</xref>).</p></sec><sec id="FPar2"><title>Prion-like diseases</title><p id="Par7">There is a growing number of human neurodegenerative diseases which implicate a prion-like mechanism (Meyer-Luehmann et al. <xref ref-type="bibr" rid="CR157">2006</xref>; Eisele et al. <xref ref-type="bibr" rid="CR64">2010</xref>; Goedert et al. <xref ref-type="bibr" rid="CR80">2010</xref>; Jucker and Walker <xref ref-type="bibr" rid="CR120">2013</xref>; Ayers and Cashman <xref ref-type="bibr" rid="CR13">2018</xref>; Ayers et al. <xref ref-type="bibr" rid="CR14">2020</xref>; Kim et al. <xref ref-type="bibr" rid="CR125">2022</xref>). Whereas in prion diseases a bona vide infectious agent (prion) propagates and spreads within and between individuals, a prion-like mechanism is limited to the spread of disease-causing protein aggregates from cell to cell within a host. This concept was pioneered in mouse models in which disease was induced, or &#8220;seeded,&#8221; by experimental injection of brain homogenates from patients (Meyer-Luehmann et al. <xref ref-type="bibr" rid="CR157">2006</xref>; Eisele et al. <xref ref-type="bibr" rid="CR64">2010</xref>). This started with transgenic mouse models of Alzheimer&#8217;s disease (AD) and a focus on a-beta and was extended to a variety of other proteopathies (Meyer-Luehmann et al. <xref ref-type="bibr" rid="CR157">2006</xref>; Eisele et al. <xref ref-type="bibr" rid="CR64">2010</xref>; Goedert et al. <xref ref-type="bibr" rid="CR80">2010</xref>; Jucker and Walker <xref ref-type="bibr" rid="CR120">2013</xref>; Ayers and Cashman <xref ref-type="bibr" rid="CR13">2018</xref>; Ayers et al. <xref ref-type="bibr" rid="CR14">2020</xref>; Kim et al. <xref ref-type="bibr" rid="CR125">2022</xref>). The immediate implications of these experiments were emphasized by the transmission of disease in Parkinson&#8217;s disease (PD) patients that had received brain transplants, implicating transmission of &#945;-synuclein misfolding from host to transplant (Li et al. <xref ref-type="bibr" rid="CR138">2008</xref>).</p><p>The family of prion-like proteins is growing and includes now a-beta (AD), tau (tauopathies), &#945;-synuclein (PD), and SOD in amyotrophic lateral sclerosis (ALS) and often using the term prion for these proteins (e.g., tau prions) (Marciniuk et al. <xref ref-type="bibr" rid="CR149">2013</xref>). This &#8220;transmissibility&#8221; of the misfolded form of these proteins has been recapitulated at the cellular level in cell culture models, initially for a-syn and tau aggregates, and model prions (Ren et al. <xref ref-type="bibr" rid="CR190">2009</xref>; Frost et al. <xref ref-type="bibr" rid="CR70">2009</xref>; Krammer et al. <xref ref-type="bibr" rid="CR131">2009</xref>; Hofmann et al. <xref ref-type="bibr" rid="CR111">2013</xref>). The combination of in vivo and in vitro studies provides solid evidence for cellular uptake, release, and transport of protein seeds along neural pathways and networks. Another important similarity with prions is the existence of prion-like strains, which affect selective vulnerability and targeting in the brain and thereby influence the neuropathological and clinical attributes of disease.</p><p>While the risks of nosocomial transmission of the prion-like diseases are quite low, emerging evidence implicates situations which could lead to the de novo initiation of these diseases. For PD, disease progression seems to follow anatomical patterns and involve prion-like propagation events (Hawkes et al. <xref ref-type="bibr" rid="CR98">2009</xref>). The Braak hypothesis also proposes that PD pathogenesis starts outside the brain, triggered by exogenous insults in the gut and olfactory system (Hawkes et al. <xref ref-type="bibr" rid="CR98">2009</xref>; Braak and Del Tredici <xref ref-type="bibr" rid="CR37">2016</xref>), a scenario with striking similarities to peripheral prion infection. Others have suggested that bacterial amyloids may be responsible for initiating a variety of protein-misfolding neurodegenerative diseases, &#8220;mapranosis&#8221; for microbiota-associated proteopathy, and neuroinflammation (Friedland and Chapman <xref ref-type="bibr" rid="CR69">2017</xref>).</p></sec></sec><sec id="Sec2"><title>Prion diseases of different species</title><sec id="FPar3"><title>Human</title><p id="Par10">Human prion diseases are very rare, fatal neurodegenerative disorders that include Creutzfeldt&#8211;Jakob disease (CJD), Gerstmann&#8211;Str&#228;ussler&#8211;Scheinker syndrome (GSS), fatal familial insomnia (FFI), kuru, variant CJD (vCJD), and variably protease-sensitive prionopathy (VPSPr) (Goldfarb et al. <xref ref-type="bibr" rid="CR78">1994</xref>; Ghetti et al. <xref ref-type="bibr" rid="CR74">1995</xref>; Gambetti et al. <xref ref-type="bibr" rid="CR73">1995</xref>; Gajdusek <xref ref-type="bibr" rid="CR72">2008</xref>; Capellari et al. <xref ref-type="bibr" rid="CR47">2011</xref>; Notari et al. <xref ref-type="bibr" rid="CR170">2018</xref>). All three manifestations are found &#8212; sporadic, familial, and acquired by infection (which includes iatrogenic transmission and via consumption of prion-infected foodstuffs) &#8212; although the sporadic form of CJD is the most common, with an incidence of one case per million people per year worldwide. CJD is not contagious in normal social interactions; however, various scenarios for iatrogenic transmissions have been described, involving dura mater and cornea transplants, growth hormone therapies, and EEG electrodes (Brown et al. <xref ref-type="bibr" rid="CR38">2000</xref>). Sporadic CJD commonly becomes symptomatic after the age of 50&#8211;55&#160;years. From the first symptoms to the fatal outcome, the disease lasts only a few months, with usually longer clinical progression for the other human prion diseases.</p><p>vCJD appeared in the UK for the first time in 1996. More than 230 cases have been recorded, the vast majority of them the UK, with France coming next (Diack et al. <xref ref-type="bibr" rid="CR59">2014</xref>). The disease showed up in several European countries, Japan, Saudi Arabia, Taiwan, Canada, and the USA. The majority of these cases are probably &#8220;imported&#8221; ones, as the patients are thought to have been infected in the UK. At least four cases of secondary vCJD have occurred through blood transfusions or factor VIII preparations since 2004 (Llewelyn et al. <xref ref-type="bibr" rid="CR139">2004</xref>). It is currently unknown how many people in the UK might be infected with vCJD. Archived surgical materials like the tonsil and appendix were analyzed for markers of PrP<sup>Sc</sup> to get an estimate on the level of occult infections in the UK population to the conclusion that 0.1&#8211;1.0% of that at risk population might be asymptomatically infected (Hill et al. <xref ref-type="bibr" rid="CR107">1999</xref>). Whether these individuals would ever develop clinical disease would likely depend on a combination of aspects of the infectious dose (physical properties and dose) as well as genetic susceptibilities of the host. Defined single-nucleotide polymorphisms of the human prion gene have been shown to impact susceptibility to vCJD (Saba and Booth <xref ref-type="bibr" rid="CR195">2013</xref>) and kuru (Lee et al.&#160;<xref ref-type="bibr" rid="CR135">2001</xref>).</p><p>The incubation period of human prion diseases ranges from a minimum of 4&#160;years (some kuru and iatrogenic CJD cases) to more than 50&#160;years. The incubation period of vCJD is at least 10&#160;years, and periods of 20&#8211;30&#160;years are considered probable. In the genetic forms, the incubation period usually lasts four to five decades, providing a theoretical window of opportunity for treatment modalities. Unfortunately, only few potential anti-prion compounds were tested in clinical trials, with very limited success (Zafar et al. <xref ref-type="bibr" rid="CR247">2019</xref>). Active vaccination is currently not considered an option for human prion diseases, given the very rare incidence rates. The situation might be different for familial prion diseases which can be diagnosed long before clinical symptoms start. An experimental therapy with a monoclonal antibody was recently described for a small number of CJD patients (Mead et al. <xref ref-type="bibr" rid="CR156">2022</xref>). The treatment was able to penetrate the CNS without inducing neurological side effects, warranting the need for future formal clinical trials. Such a treatment could be also an option for post-exposure prophylaxis when the time of potential infection is known, for example, laboratory accidents.</p></sec><sec id="FPar4"><title>Animal</title><p id="Par13">Animal prion diseases are usually acquired by infection and can be associated with significant lateral transmission (Pattison <xref ref-type="bibr" rid="CR173">1970</xref>; Hunter <xref ref-type="bibr" rid="CR112">1991</xref>; Wells and Wilesmith <xref ref-type="bibr" rid="CR230">1995</xref>; Requena et al. <xref ref-type="bibr" rid="CR191">2016</xref>; Williams and Young <xref ref-type="bibr" rid="CR237">1980</xref>; Babelhadj et al. <xref ref-type="bibr" rid="CR15">2018</xref>). Food animal species like sheep, goat, deer, elk, camel, and cattle are affected. Prion infection in such species can have pronounced economic impacts, affecting the entire economies, consumer behaviors, and international trade and involving extensive active and passive surveillance mechanisms. The extreme example here is BSE in its epidemic form that devastated entire markets and cost billions of dollars in lost revenue and extra costs in many countries. Interestingly, prion diseases in sheep, goat, and cervids provided important insights into the role of amino acid polymorphisms in the prion protein, as a disease-modifying factor influencing susceptibility or providing a relative resistance. Many of the widely used prion strains for experimental research are derived from scrapie isolates, which had been passaged and adapted to mice and murine cells (e.g., RML, 22L, and Me7 prion strains). Finally, it was research in scrapie and then BSE that fuelled the concept of atypical prion diseases, which most likely have a sporadic origin and are not the result of infection from an external source (Benestad et al. <xref ref-type="bibr" rid="CR23">2008</xref>; Boujon et al. <xref ref-type="bibr" rid="CR36">2016</xref>).</p></sec><sec id="FPar5"><title>Scrapie</title><p id="Par14">has been described in small ruminants like sheep and goats (Pattison <xref ref-type="bibr" rid="CR173">1970</xref>; Hadlow <xref ref-type="bibr" rid="CR88">1999</xref>). Descriptions go back to the early eighteenth century, and linguistic research suggests that the disease was already known in ancient times. The disease has different names in various countries, referring to the two characteristic symptoms of the disease: itching and ataxia. For scrapie, groundbreaking work helped to define the concept of prion strains and the role of polymorphisms in PrP. As a result of the latter, sheep populations have been selected that were considered resistant against classical scrapie. Scrapie is spread worldwide, with exception of Australia and New Zealand. Scrapie is transmitted both vertically and horizontally, and transmission is promoted by direct, close contact between animals. The high stability of scrapie prions in the environment explains why the disease can recur in farms in which no sheep were kept for a year or longer after culling. Scrapie has an extensive involvement of the lymphatic system, and prion infectivity is found in the spleen, lymph nodes, small intestine, and tonsils. Scrapie is most often managed through culling of affected animals and herds, together with active and passive surveillance. Such efforts are complicated by the existence of atypical scrapie which means a high probability of ongoing cases despite any implemented control measures (Ac&#237;n et al. <xref ref-type="bibr" rid="CR2">2021</xref>). To date, there is no evidence that scrapie represents a zoonotic threat. Vaccination or therapy is generally not considered of importance for scrapie.</p></sec><sec id="FPar6"><title>BSE</title><p id="Par15">in its epidemic form was described for the first time in the UK in 1986 and has led to enormous financial losses for agriculture sectors and entire economies in several countries (Wells and Wilesmith <xref ref-type="bibr" rid="CR230">1995</xref>; Requena et al. <xref ref-type="bibr" rid="CR191">2016</xref>). This also started a critical discussion on the limitations of an &#8220;industrialization of agriculture,&#8221; first in Europe and then throughout the world. Upon the first descriptions in cows with a CNS disorder, an epidemic developed in the UK that reported up to 3500 new clinical cases per month at its peak in 1992. Since the mid-1980s, more than 184,000 clinical cases have been recorded, affecting over 50% of UK cattle farms. However, the real significance of BSE might be its zoonotic potential, as over 230 cases of BSE in humans (vCJD) have been described in England, France, and several other countries (Diack et al. <xref ref-type="bibr" rid="CR59">2014</xref>; Llewelyn et al. <xref ref-type="bibr" rid="CR139">2004</xref>). BSE has been detected almost worldwide, including countries like Canada, Israel, Oman, Japan, and the USA. In Europe, Ireland, Portugal, France, Spain, Switzerland, and Germany have exhibited the most detections of BSE besides the UK. BSE emerged due to repetitive feeding of scrapie- or BSE-contaminated meat and bone meal, the latter considered more likely as a source given the existence of atypical BSE. Two control measures by the British government are important to mention. In 1988, a feeding ban was imposed on meat and bone meal for ruminants. This action effectively broke the infection chain, although evident only after of 3&#8211;5&#160;years, the incubation period of BSE in cattle. Horizontal transmission plays no significant role in cattle, and BSE has no marked lymphotropism in bovines. Second, specified risk materials (SRM) from cattle were no longer allowed to enter the human food chain, starting in 1989. SRM include all parts of the CNS, the spine, and some visceral organs. This step dramatically reduced the exposure of the human population. In recent years, atypical BSE has been found in several countries worldwide, mostly in older cows and at a very low frequency. It comes in at least two forms and has altered histopathological and biophysical properties, such as a reduced proteinase K resistance (Casalone et al. <xref ref-type="bibr" rid="CR50">2004</xref>; Dudas and Czub <xref ref-type="bibr" rid="CR62">2017</xref>). Therefore, it could be overlooked with the usual tests for BSE. Although considered a sporadic form in etiology, one form of atypical BSE is clearly infectious in animal experiments, and zoonotic potential cannot be fully excluded at present time (Dudas and Czub <xref ref-type="bibr" rid="CR62">2017</xref>). For containment of epidemic BSE, bans on high-risk feed materials, culling, and surveillance strategies were very effective. Therapeutic or vaccination approaches are therefore not considered necessary.</p></sec><sec id="FPar7"><title>CWD</title><p id="Par16">has been detected in cervid species in North America, South Korea, and Scandinavia and poses a serious threat to animal health (Williams <xref ref-type="bibr" rid="CR235">2005</xref>; Gilch et al. <xref ref-type="bibr" rid="CR76">2011</xref>; Saunders et al. <xref ref-type="bibr" rid="CR200">2012</xref>; Benestad and Telling <xref ref-type="bibr" rid="CR25">2018</xref>). CWD is responsible for cervid population declines and has an adverse economic impact on cervid hunting and tourism industries (DeVivo et al. <xref ref-type="bibr" rid="CR58">2017</xref>; Hannaoui et al. <xref ref-type="bibr" rid="CR96">2017</xref>). CWD is considered the most contagious prion disease, and substantial shedding of CWD prion infectivity into the environment via urine, feces, and saliva significantly contributes to disease spreading (Tamg&#252;ney et al. <xref ref-type="bibr" rid="CR212">2009a</xref>, <xref ref-type="bibr" rid="CR213">b</xref>; Nichols et al. <xref ref-type="bibr" rid="CR166">2009</xref>; John et al. <xref ref-type="bibr" rid="CR119">2013</xref>). The long-term perseverance of CWD infectivity in environment reservoirs, including soil, water, and plants, makes disease management very challenging (Pritzkow et al. <xref ref-type="bibr" rid="CR182">2015</xref>). Whether CWD transmits naturally to other animal species or humans is a matter of concern that needs continued investigation. CWD was experimentally transmitted to cattle, pigs, cats, hamsters, and bank voles (Hamir et al. <xref ref-type="bibr" rid="CR93">2011</xref>; Mathiason et al. <xref ref-type="bibr" rid="CR154">2013</xref>; Di Bari et al. <xref ref-type="bibr" rid="CR60">2013</xref>; Moore et al. <xref ref-type="bibr" rid="CR161">2017</xref>). This raises the question whether the range of natural hosts of CWD prions can and will extend beyond cervids. Of particular importance is livestock that shares pastures contaminated with CWD prions. CWD prions would thereby indirectly have access to the human food chain. CWD transmission studies in transgenic mouse models expressing PrPs from various species including ovine, bovine, and human showed low or absent ability of CWD prions to cross relevant species barriers (Tamg&#252;ney et al. <xref ref-type="bibr" rid="CR213">2009b</xref>; Wilson et al. <xref ref-type="bibr" rid="CR239">2012</xref>; Kurt et al. <xref ref-type="bibr" rid="CR134">2015</xref>; Wadsworth et al. <xref ref-type="bibr" rid="CR224">2022</xref>). Interestingly, a more recent study found atypical disease and fecal prion shedding in transgenic mice expressing human PrP when infected with deer prions, indicating zoonotic potential of CWD (Hannaoui et al. <xref ref-type="bibr" rid="CR97">2022</xref>). In addition, transmission of CWD into non-human primates via the oral route (Marsh et al. <xref ref-type="bibr" rid="CR152">2005</xref>; Race et al. <xref ref-type="bibr" rid="CR187">2009</xref>, <xref ref-type="bibr" rid="CR188">2018</xref>) and efficient in vitro conversion of human PrP by CWD prions (Barria et al. <xref ref-type="bibr" rid="CR18">2011</xref>;&#160;Wang et al. <xref ref-type="bibr" rid="CR225">2021</xref>) should also not be ignored. Additionally, the existence of various CWD prion strains combined with the known PrP polymorphisms generates a dynamic, emerging, and complex scenario for future CWD transmission risks.</p></sec><sec id="FPar8"><title>Is there an expanding threat?</title><p id="Par17">The escalating threat posed by CWD includes a rather uncontrolled geographic expansion within cervids, uptake by plants and preservation in the environment by soils, unpredictable evolution of CWD prions, and possibly some zoonotic potential (Williams <xref ref-type="bibr" rid="CR235">2005</xref>; Gilch et al. <xref ref-type="bibr" rid="CR76">2011</xref>; Saunders et al. <xref ref-type="bibr" rid="CR200">2012</xref>; Benestad and Telling <xref ref-type="bibr" rid="CR25">2018</xref>). To put this into numbers, the US Fish and Wildlife Service estimates that in 2016 alone, 9 million Americans &#8212; roughly 1 in 36 &#8212; pursued big game such as deer and elk with&#8201;~&#8201;$26 billion spent on hunting. US and Canadian government agencies have collectively invested billions of dollars to manage CWD in free-ranging and farmed cervid populations, with little success so far. Elk, deer, and reindeer farming in Canada have emerged as an alternative livestock industry, and wild-living deer, elk, moose, and caribou are important economic drivers in Canada to attract tourists and hunters. There are around 55,000 farmed and more than 2 million wild cervids in Canada. CWD has significantly impaired the Canadian deer and elk farming industry when the first case of CWD was found in a deer farm in 1996. CWD will cost the Canadian cervid industry many millions for double fencing to separate free-ranging from captive deer and up to half a billion dollars to close CWD-infected cervid farms. Testing and disposal of carcasses and carcass parts are additional costs associated with the disease. Native cervid herds with high CWD prevalence are showing population declines (DeVivo et al. <xref ref-type="bibr" rid="CR58">2017</xref>; Hannaoui et al. <xref ref-type="bibr" rid="CR96">2017</xref>), threatening a robust hunting industry and wildlife conservation efforts. Regarding human health, it is estimated that between 7000 and 15,000 CWD-infected cervids are consumed in North America by humans annually, with an increase of&#8201;~&#8201;20% per year (Geist et al. <xref ref-type="bibr" rid="CR75">2017</xref>). CWD testing depends on jurisdiction and is not mandatory in all hunting units. The annual prevalence in Alberta, measured by testing for prions in hunted heads, steadily increased from&#8201;&lt;&#8201;1% in 2005 to&#8201;&gt;&#8201;15% in mule deer and 5% in white-tailed deer (WTD). Long considered a North American problem, CWD showed up more recently in three Scandinavian countries, Norway, Sweden, and Finland (Benestad et al. <xref ref-type="bibr" rid="CR24">2016</xref>; Benestad and Telling <xref ref-type="bibr" rid="CR25">2018</xref>). Comparative transmission studies in transgenic mice and bank voles so far indicate that North American and Scandinavian CWD isolates are different, basically excluding import from the USA and Canada as a source of the European infections (Tranulis et al. <xref ref-type="bibr" rid="CR220">2021</xref>; Bian et al. <xref ref-type="bibr" rid="CR34">2021</xref>). There are also gross differences between the CWD strains in the three affected species (wild reindeer, red deer, and moose), and some are discussed as examples for a sporadic origin, not acquired by infection, resembling atypical scrapie and atypical BSE. Depopulation was mostly used as a containment strategy in Norway, and it has yet to be seen how effective this will be.</p></sec><sec id="FPar9"><title>Is there a need for new tools?</title><p id="Par18">Containment strategies in wild cervids like depopulation and selective harvesting were not effective in stopping the expansion of CWD in North America. This asks for new tools, and active vaccination of wild cervids is now widely considered a promising strategy. Although there was initially skepticism whether vaccines can work for prion diseases in general, there is now solid experimental evidence of the feasibility of this approach. In contrast to prion diseases in other species, CWD is not controllable through routine animal management practices as wild-living animals are affected. This represents the next challenge, it must be a vaccine that works in a wildlife scenario. Even if active vaccination alone might not be able to fully protect cervids against CWD, it can be the central element of concerted containment strategies, aiming to reduce disease in animals, shedding of prions, and prion load in cervids and environment. CWD likely needs a One Health approach, and vaccination will be a perfect example to address health in animals, humans, and the environment.</p></sec><sec id="FPar10"><title>Opportunities and challenges to developing prion vaccines</title><p id="Par19">Historically, vaccines have been the most effective tactic for the management of infectious diseases in humans and animals. There is a clear need, and emerging optimism, for the potential to develop vaccines for prion diseases. Efforts to develop vaccines for other proteinopathies are showing encouraging progress, and relative to those diseases, the prion diseases have the advantage because they present a clearly defined, cell surface-accessible, immunotherapeutic target. Extensive investigations have demonstrated the ability of PrP-reactive antibodies to impair prion propagation in vitro as well as for passive and active immunization to delay disease progression in animal models. While encouraging, development of an effective prion vaccine remains an elusive goal that is challenged by several unique aspects of prion biology, including overcoming immunological tolerance, concerns of the safety of inducing immune responses to a self-protein, uncertainties of the mechanisms of immune protection, and establishing benchmarks of success of prion vaccines which may be unique for human and animal applications.</p></sec><sec id="FPar11"><title>Challenges to developing a prion vaccine (self-tolerance)</title><p id="Par20">For traditional infectious diseases, a distinct boundary exists between the host and infectious agent. That line is blurred in the prion diseases, even to the immune system. The ability of the immune system to protect the host depends on its remarkable capacity to induce a virtually unlimited range of highly specific responses, all the while avoiding reactivities with self-molecules. This unresponsiveness of the immune system to self-molecules is referred to as immune tolerance. PrP<sup>C</sup> falls within the realm of immune tolerance, and, as the transition to PrP<sup>Sc</sup> does not involve changes to the polypeptide sequence, this immune privilege also extends to the pathological isoform. With that, most prion infections proceed to their fatal outcomes in the absence of an immune response (Porter et al.&#160;<xref ref-type="bibr" rid="CR180">1973</xref>; Kasper et al. <xref ref-type="bibr" rid="CR123">1982</xref>). While anti-PrP antibodies have been detected in the end stages of disease (Sassa et al. <xref ref-type="bibr" rid="CR198">2010</xref>), more typically, the immune system does not perceive, nor respond to, PrP<sup>Sc</sup> as an infectious threat. Thus, the unique biology of prions shelters the infectious agent from immune activation, allowing unchecked progression of the disease and complicating the development of immunotherapies; overcoming immune tolerance to PrP is a central obstacle to the development of prion vaccines (Mabbott <xref ref-type="bibr" rid="CR141">2015</xref>).</p><p>Mechanistically, immune tolerance reflects the active depletion of those T and B lymphocytes whose receptors show reactivity to self-molecules (Zinkernagel et al. <xref ref-type="bibr" rid="CR248">2001</xref>) as well as active suppression of immune responses to self-molecules by Treg cells (Sakaguchi et al.&#160;<xref ref-type="bibr" rid="CR197">2008</xref>). The extent to which self-tolerance restricts immune responses to PrP is demonstrated by the ease of induction of PrP-reactive antibodies in PrP <sup>&#8211;/&#8211;</sup> mice (Kascsak et al. <xref ref-type="bibr" rid="CR122">1987</xref>; Williamson et al.&#160;<xref ref-type="bibr" rid="CR238">1996</xref>; Krasemann et al.&#160;<xref ref-type="bibr" rid="CR133">1996</xref>) as well as xenogenic systems (Rubenstein et al. <xref ref-type="bibr" rid="CR194">1999</xref>). In contrast, PrP vaccines that are not optimized for immunogenicity typically achieve only modest titers of low-affinity antibodies in wild-type animals (Paramithiotis et al.&#160;<xref ref-type="bibr" rid="CR172">2003</xref>).</p><p>Immunological tolerance to PrP can be overcome through recapitulation of the missing immune components; this includes the introduction of either PrP-sensitized CD4&#8201;+&#8201;T cells from PrP<sup>&#8211;/&#8211;</sup> donors (Gourdain et al.&#160;<xref ref-type="bibr" rid="CR86">2009</xref>) or transgenic T cells with a PrP-reactive T cell receptor (Iken et al.&#160;<xref ref-type="bibr" rid="CR114">2011</xref>). Similarly, administration of dendritic cells loaded with PrP peptides can result in protective immune responses (Bachy et al.&#160;<xref ref-type="bibr" rid="CR16">2010</xref>). While these studies highlight the potential to achieve immune activation to PrP, as well as associated degrees of protection, these approaches are inconsistent with real-world vaccines for either human or animals. Human prion diseases are an insufficient threat to justify vaccination of the general population. Instead, human prion immunotherapies would most commonly be initiated at the onset of clinical symptoms or to individuals with genetic predisposition to disease. The former is problematic as the clinical symptoms depend on disease progression to the CNS where opportunities for immunotherapy are limited. For animal prion diseases, due to restrictions of acceptable cost and intensiveness of administration, efforts to overcome immune tolerance are confined to more traditional approaches of vaccinology, including selection and optimization of vaccine targets (antigens, also called immunogens) as well as strategies of formulation and delivery.</p></sec><sec id="FPar12"><title>Overcoming self-tolerance (antigen selection and optimization)</title><p id="Par23">Prion vaccines can be broadly categorized as either subunit or peptide, depending on whether the vaccine antigen represents the entirety, domain, or a specific region of the PrP polypeptide. Each category of prion vaccine antigen presents distinct opportunities for overcoming immune tolerance.</p><p>For prion subunit vaccines, one approach to overcome immune tolerance is to use heterologous versions of PrP with species-specific sequence variations. For example, while mouse PrP was immunologically tolerated in BALB/c mice (Polymenidou et al.&#160;<xref ref-type="bibr" rid="CR179">2004</xref>), both bovine and sheep PrP were highly immunogenic (Ishibashi et al.&#160;<xref ref-type="bibr" rid="CR117">2007</xref>). A challenge to this approach is ensuring that the induced antibodies are reactive to the PrP isoforms of the host and/or infecting prion species as in some instances the antibodies induced by either recombinant or heterologous PrP antigens are unreactive with PrP<sup>C</sup> or PrP<sup>Sc</sup> (Heppner and Aguzzi <xref ref-type="bibr" rid="CR103">2004</xref>). Presentation of the PrP antigen as recombinant dimers can also overcome immune tolerance, even to homologous sequences (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Abdelaziz et al.&#160;<xref ref-type="bibr" rid="CR1">2017</xref>). Absorption of PrP to Dynabeads has also been employed as a delivery vehicle for prion subunit vaccines (Tayebi et al.&#160;<xref ref-type="bibr" rid="CR219">2009</xref>). Others have overcome self-tolerance through DNA vaccines that drive the expression of PrP that is coupled to either stimulatory T cell epitopes (Alexandrenne et al.&#160;<xref ref-type="bibr" rid="CR8">2010</xref>), carrier proteins that promote antigen uptake and MHC class I presentation (Han et al.&#160;<xref ref-type="bibr" rid="CR94">2011</xref>), or lysosomal targeting signal peptides (Fernandez-Borges et al.&#160;<xref ref-type="bibr" rid="CR67">2006</xref>).</p><p>Peptide-based prion vaccines allow for prioritization of specific regions of PrP. This specificity, however, is often at the further expense of immunogenicity as short peptides, especially those of self-proteins, are often weakly immunogenic. A vaccine based on a peptide target of PrP induced only weak IgM responses, even when coupled to an immunogenic carrier and formulated with harsh adjuvants (Paramithiotis et al.&#160;<xref ref-type="bibr" rid="CR172">2003</xref>). One approach to increase the immunogenicity of self-peptides is to increase their length through inclusion of additional, naturally occurring residues that flank the region of interest; the immunogenicity of the tripeptide TyrTyrArg (YYR) was increased by four orders of magnitude through the inclusion of additional residues on the N and C terminal sides of the core tripeptide (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>). The relationship between peptide length and immunogenicity is not, however, absolute; additional residues can even reduce immunogenicity (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>). Instead, the occurrence of B cell epitopes within the sequence better predicts immunogenicity. Software that forecasts the immunogenicity of regions of proteins based on endogenous B cell epitopes enables optimization of peptide epitope targets for their rapid translation into vaccines (Marciniuk et al.&#160;<xref ref-type="bibr" rid="CR150">2015</xref>).</p><p>Less conventional approaches of antigen selection have been taken to overcome immunological tolerance to PrP. Through a bioinformatic approach, Ishibashi et al. identified a non-mammalian protein, succinylarginine dihydrolase, that shared sequence similarity to those recognized by anti-PrP antibodies. Immunization of mice with this bacterial mimitope induced a PrP-specific antibody response with a modest degree of protection (Ishibashi et al.&#160;<xref ref-type="bibr" rid="CR116">2011</xref>). Wille and colleagues also employed a mimitope approach by introducing key residues of PrP into an immunogenic protein scaffold that enables the induction of conformation-specific immune responses against PrP<sup>Sc</sup> (Fleming et al.&#160;<xref ref-type="bibr" rid="CR68">2022</xref>).</p></sec><sec id="FPar13"><title>Overcoming self-tolerance (vaccine formulation and delivery)</title><p id="Par27">Following selection and optimization of a suitable antigen, there are additional parameters that can be utilized to overcome immune tolerance and facilitate vaccine delivery, including carrier proteins, adjuvants, and biological vectors.</p></sec><sec id="FPar14"><title>Carrier proteins</title><p id="Par28">Rationale selection and optimization of antigens are often insufficient to overcome immune tolerance. These targets, especially peptide epitopes, must often be presented in the context of an immunogenic carrier proteins to elicit the T cell help required for strong immune humoral responses and efficient IgM to IgG class switching. Numerous carrier proteins have been investigated for prion vaccines including leukotoxin (Lkt) protein of Mannheimia haemolytica (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>), rabies glycoprotein G (gG) (Taschuk <xref ref-type="bibr" rid="CR216">2017</xref>), blue carrier protein (Pilon et al.&#160;<xref ref-type="bibr" rid="CR176">2007</xref>), cholera toxin (Bade et al. <xref ref-type="bibr" rid="CR17">2006</xref>), heat-labile enterotoxin B subunit (Yamanaka et al.&#160;<xref ref-type="bibr" rid="CR244">2006</xref>), and heat shock proteins (Koller et al.&#160;<xref ref-type="bibr" rid="CR129">2002</xref>). While few investigations have considered attributes of the same prion epitope in the context of different carriers, there is evidence that carrier selection influences the magnitude, duration, and nature of the induced immune response (Taschuk et al.&#160;<xref ref-type="bibr" rid="CR214">2015a</xref>, <xref ref-type="bibr" rid="CR217">b</xref>). Further, certain carriers, such as cholera toxin and <italic toggle="yes">Escherichia coli</italic> heat-labile enterotoxin, seem better suited for mucosal vaccines (Bade et al. <xref ref-type="bibr" rid="CR17">2006</xref>;&#160;Sakaguchi and Arakawa <xref ref-type="bibr" rid="CR196">2007</xref>). Consideration is also required of whether peptide epitopes are added to the carrier through recombinant fusion or chemical conjugation. Expression as recombinant fusions is advantaged in terms of cost and consistency of epitope presentation, while chemical conjugation is often better suited for high-throughput screening of both carriers and peptides. In selecting a carrier, it is also important to consider compatibility with higher-order delivery vectors. For example, the ease of expression of Lkt recombinant fusions in bacteria, with subsequent purification as inclusion bodies, is well-suited to generate antigens for injected vaccines, but its poor expression in eukaryotic cells prohibits its use in viral vectored vaccines.</p></sec><sec id="FPar15"><title>Adjuvants</title><p id="Par29">Vaccine adjuvants are another important variable in overcoming immune tolerance to PrP. Numerous adjuvants have been investigated for prion vaccines including Emulsigen plus (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>), CpG (Rosset et al.&#160;<xref ref-type="bibr" rid="CR192">2004</xref>), complete Freund&#8217;s adjuvant (Tal et al.&#160;<xref ref-type="bibr" rid="CR211">2003</xref>), and Adjuvac&#8482; (Pilon et al.&#160;<xref ref-type="bibr" rid="CR176">2007</xref>). The success of these adjuvants is often measured in their ability to induce high-titer antibody responses, which seems an appropriate metric of success of vaccines that prioritize humoral responses. It is, however, also necessary to define the extent to which the adjuvant impacts prion disease progression; adjuvant, Adjuvac<sup>&#8482;</sup>, accelerated prion disease (Pilon et al.&#160;<xref ref-type="bibr" rid="CR176">2007</xref>), while the adjuvant-only control of Freund&#8217;s complete adjuvant delayed prion disease (Tal et al.&#160;<xref ref-type="bibr" rid="CR211">2003</xref>). Finally, the ease to which that adjuvant can be translated to licensed humans or animal vaccines, from both financial and regulatory perspectives, is an important longer-term consideration of adjuvant selection.</p></sec><sec id="FPar16"><title>Biological vectors</title><p id="Par30">The incorporation of PrP antigens into biological vectors can help overcome immune tolerance. A panel of hamster polyomavirus virus-like particles (VLPs) representing various PrP peptides induced epitope-specific immune responses, some of which offered protection from prion infection (Eiden et al.&#160;<xref ref-type="bibr" rid="CR63">2021</xref>). Others have used VLP based on bovine papillomavirus (BPV-1) in which a peptide sequence from murine PrP was inserted into a major capsid protein. This vector induced epitope-specific antibody responses that inhibited the replication of PrP<sup>Sc</sup> in a tissue&#8211;culture model (Handisurya et al.&#160;<xref ref-type="bibr" rid="CR95">2007</xref>). VLPs based on murine leukemia virus (MLV), engineered to target a C terminal region of PrP, induced PrP<sup>C</sup> reactive antibodies (Nikles et al.&#160;<xref ref-type="bibr" rid="CR169">2005</xref>). Parental administration of adenoviral vectors encoding a xenogenic PrP resulted in only marginal immunity against endogenous mPrP, although a moderate prolongation of survival was achieved (Rosset et al.&#160;<xref ref-type="bibr" rid="CR193">2009</xref>). Oral administration of a prion vaccine based on a replication-deficient human adenovirus induced both peripheral and mucosal epitope-specific immune responses (Taschuk et al.&#160;<xref ref-type="bibr" rid="CR216">2017</xref>). Mucosal delivery of PrP epitopes within <italic toggle="yes">Salmonella</italic>-based vectors induced protective responses in mice and cervids (Goni et al.&#160;<xref ref-type="bibr" rid="CR81">2005</xref>, <xref ref-type="bibr" rid="CR83">2008</xref>, <xref ref-type="bibr" rid="CR82">2015</xref>).</p></sec><sec id="FPar17"><title>Challenges to developing a prion vaccine (safety)</title><p id="Par31">Safety, a primary consideration of any vaccine, takes on even greater significance for the protein-misfolding diseases (proteinopathies) due to recognition that the induction of immune responses towards self-proteins can have pathological consequences. Most infamously, a subset of patients involved a clinical vaccine trial for Alzheimer&#8217;s disease developed encephalitis (Nicoll et al.&#160;<xref ref-type="bibr" rid="CR168">2003</xref>). Within the proteinopathies, these safety concerns become even more complex and nuanced for the prion diseases. It is complex due to evidence that lymphoid tissues offer a more permissive environment for prion amplification (Beringue et al. <xref ref-type="bibr" rid="CR26">2012</xref>), such that vaccine-associated immune responses could traffic the misfolded species to regions that promote prion amplification to accelerate disease. It is nuanced in that prion vaccines that prioritize either the PrP<sup>C</sup> or PrP<sup>Sc</sup> isoforms are associated with unique safety risks.</p></sec><sec id="FPar18"><title>Potential dangers of reactivity to PrP<sup>C</sup></title><p id="Par32">While developing vaccines that target the healthy isoform of PrP may seem counterintuitive, two characteristics of PrP-/- animals support the philosophy and safety of this approach. Firstly, PrP-/- animals are impervious to prion infection, highlighting the absolute requirement of PrP<sup>C</sup> for disease propagation (Bueler et al.&#160;<xref ref-type="bibr" rid="CR42">1993</xref>). Secondly, the absence of a severe loss-of-function phenotype with genetic ablation of PrP supports the safety of immunological depletion of this protein (Bueler et al.&#160;<xref ref-type="bibr" rid="CR43">1992</xref>). This must, however, be balanced with the appreciation that PrP<sup>C</sup> reactive antibodies could have gain of function rather than loss-of-function, consequences. Supportive of this, the presence of PrP<sup>C</sup> reactive antibodies, or their Fab fragments, in the brain resulted in neuronal apoptosis (Solforosi et al.&#160;<xref ref-type="bibr" rid="CR208">2004</xref>; Lefebvre-Roque et al. <xref ref-type="bibr" rid="CR136">2007</xref>) although subsequent investigations challenge this result (Klohn et al. <xref ref-type="bibr" rid="CR127">2012</xref>). PrP<sup>C</sup> reactive antibodies have also been shown to result in inappropriate cell signal events (Cashman et al.&#160;<xref ref-type="bibr" rid="CR51">1990</xref>; Mouillet-Richard et al.&#160;<xref ref-type="bibr" rid="CR163">2000</xref>; Arsenault et al.&#160;<xref ref-type="bibr" rid="CR11">2012</xref>), superoxide-mediated cytotoxicity (Sonati et al.&#160;<xref ref-type="bibr" rid="CR209">2013</xref>), and stimulation of suppressor T cell lymphocytes (Isaacs et al.&#160;<xref ref-type="bibr" rid="CR115">2006</xref>).</p><p>These concerns of the safety of PrP<sup>C</sup>-specific vaccines must be balanced with the appreciation that have numerous vaccine trials have utilized this approach with no reports of significant pathologies. While this is reassuring, it must be noted that most of these efforts were focused on vaccine efficacy rather than safety. Further, there may not be a singular answer to the question of the safety of targeting PrP<sup>C</sup> as antibodies with reactivities to different regions of PrP have unique pathological consequences; antibodies to the octarepeat are well tolerated, while those against the folded globular domain associate with neurotoxicity (Sonati et al.&#160;<xref ref-type="bibr" rid="CR209">2013</xref>). That it is possible to map the pathology-associated regions of PrP<sup>C</sup>, as well as those associated with neutralizing epitopes, offers the potential to generate peptide-based vaccines based on dual consideration of safety and efficacy (Reimann et al.&#160;<xref ref-type="bibr" rid="CR189">2016</xref>).</p></sec><sec id="FPar19"><title>Potential dangers of reactivity to PrP<sup>Sc</sup></title><p id="Par34">Targeting the misfolded species, whose presence is uniquely dependent on prion infection, appears a logical strategy to mitigate the safety concerns associated with auto-reactive antibodies. However, the events involved in the template-driven misfolding of PrP<sup>C</sup> to PrP<sup>Sc</sup> are not clearly understood, and there is the theoretical potential that PrP<sup>Sc</sup>-reactive antibodies could serve as chaperones that promote, or stabilize, misfolding intermediates, which could paradoxically lead to the induction of prion disease in otherwise healthy subjects.</p><p>Thus far, the concern that PrP<sup>Sc</sup>-specific vaccines could initiate prion disease have not been supported by experimental data. Antibodies to a region of PrP whose surface exposure was unique to misfolding did enhance the presentation of these regions but did not generate PrP<sup>Sc</sup> (Paramithiotis et al.&#160;<xref ref-type="bibr" rid="CR172">2003</xref>). Similarly, prolonged incubation of polyclonal PrP<sup>Sc</sup>-reactive antibodies with brain homogenates failed to generate protease-resistant isoforms (Marciniuk et al.&#160;<xref ref-type="bibr" rid="CR149">2013</xref>). Finally, that induction of high-titer PrP<sup>Sc</sup>-specific antibodies in tg20 mice, which are genetically sensitized to prion disease, did not result in clinical nor biochemical indications of prion disease after 250&#160;days (
M&#228;&#228;tt&#228;nen et al. <xref ref-type="bibr" rid="CR140">2013</xref>). While acceleration of disease was observed in elk receiving a PrP<sup>Sc</sup>-specific vaccination, it is uncertain of the extent to which the specificity of the vaccine contributed to that outcome (Wood et al. <xref ref-type="bibr" rid="CR240">2018</xref>).</p><p>While the absence of pathological consequences following prolonged incubation of PrP<sup>Sc</sup>-reactive antibodies in tg20 is reassuring, it should be noted that the sensitivity of these mice to prion disease is a consequence of overexpression of wild-type PrP rather than the introduction of PrP sequence variants with elevated risk for misfolding. The ability for PrP<sup>Sc</sup>-specific antibodies to promote misfolding may be conditional of the presence of misfolding prone PrP variants. Supportive of this, PrP<sup>Sc</sup>-specific antibodies reacted with a PrP variant associated with early onset familial dementia, but not wild-type PrP, in nanopore and immunoprecipitation experiments (Madampage et al.&#160;<xref ref-type="bibr" rid="CR143">2013</xref>). The reactivity of polyclonal PrP<sup>Sc</sup>-specific antibodies with this variant indicates the occurrence, and recognition, of subtle conformational differences and/or partially unfolded species. Prolonged incubation of the PrP<sup>Sc</sup>-specific antibodies with this misfolding prone PrP failed to generate protease-resistant PrP in vitro, although the extent to which these interactions could promote formation of PrP<sup>Sc</sup> in vivo is uncertain. The potential for PrP<sup>Sc</sup>-induced misfolding of naturally occurring PrP variants will be of greater significance should these vaccines advance to application to outbred populations.</p></sec><sec id="FPar20"><title>Challenges to developing a prion vaccine (achieving protective immune responses)</title><p id="Par37">The uncertainties regarding the mechanisms by which induced immune responses impact prion disease &#8212;initiation, progression, and pathology &#8212; is another challenge to the development of effective vaccines. It is difficult to develop and optimize vaccines in the absence of knowledge of the key determinants of protection. This includes consideration of humoral vs cellular responses and, within humoral responses, the relative importance of mucosal versus peripheral immunity. This situation is further complicated by species-specific differences of &#8220;what success look like&#8221; for an effective prion vaccine.</p></sec><sec id="FPar21"><title>Systemic vs mucosal responses</title><p id="Par38">Depending on the source of infection, prion diseases can involve up to three stages: uptake at mucosal surfaces, peripheral amplification, and transmission to the CNS. Each stage presents unique opportunities and obstacles for immunotherapeutic intervention (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Stages of progression of CWD and potential points of immunotherapeutic intervention. (1) Mucosal uptake. Following oral ingestion, environmental prions are taken up through mucosal surfaces. Induction of IgA antibodies through oral vaccines offers the best chance to block uptake. (2) Peripheral amplification. Following uptake, prions undergo a stage of peripheral amplification. Induction of IgG antibodies, through either oral or injected vaccines can inhibit this process. (3) Shedding. Prions generated in periphery and CNS of the infected host are shed in urine and feces. IgG antibodies, induced through injected or oral vaccines, may restrict prion amplification to reduce shedding. (4) CNS pathology. After peripheral amplification, prions migrate to the CNS where they exert pathological consequences. While the BBB limits access of antibodies to the CNS, IgG antibodies, induced through either oral or injected vaccination, may minimize pathology</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="441_2023_3749_Fig1_HTML.jpg"/></fig></p><p>For CWD, infection typically initiates following oral ingestion of prions with subsequent uptake at mucosal surfaces (Miller and Williams&#160;<xref ref-type="bibr" rid="CR158">2003</xref>; Beekes and McBride <xref ref-type="bibr" rid="CR22">2007</xref>). Consistent with the philosophy that the most effective way to deal with an infectious disease is to prevent it, blocking the uptake of gut-associated prions through induction of mucosal IgA responses may represent a critical line of defense (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). This seems particularly true as thus far immunotherapy has only been able to delay, rather than abolish, disease progression once prions reach the periphery. It is noteworthy that strong peripheral responses can offer degrees of protection to peripheral challenge but are often less effective in protecting from oral exposure (Pilon et al. <xref ref-type="bibr" rid="CR177">2013</xref>). The most efficient protection from oral challenge likely depends on induction of mucosal IgA responses.</p><p>Achieving high titers of IgA antibodies is heavily dependent on the route of vaccine administration; parenterally administered vaccines induce serum IgG antibodies with muted IgA responses. A parenterally delivered prion vaccine favored IgG over IgA epitope-specific antibodies by an order of magnitude but with no significant correlation between serum IgG and mucosal IgA epitope-specific titers (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>). Oral vaccination often results in a more balanced IgA to IgG profile (DeMagistris <xref ref-type="bibr" rid="CR56">2006</xref>); deer receiving an orally administered prion vaccine based on a human adenovirus delivery vector had an equalized titer and kinetics of responses of serum IgG to fecal IgA epitope-specific immunoglobins (Taschuk et al.&#160;<xref ref-type="bibr" rid="CR216">2017</xref>). Similarly, mucosal delivery of prion vaccines based on bacterial vectors induced both epitope-specific IgG and IgA responses (Goni et al. <xref ref-type="bibr" rid="CR81">2005</xref>, <xref ref-type="bibr" rid="CR83">2008</xref>, <xref ref-type="bibr" rid="CR82">2015</xref>) as did mucosal delivery of PrP epitopes conjugated to carrier proteins selected for their ability to induce mucosal responses (Yamanaka et al.&#160;<xref ref-type="bibr" rid="CR244">2006</xref>; Sakaguchi and Arakawa <xref ref-type="bibr" rid="CR196">2007</xref>).</p><p>The ability to induce both systemic and mucosal immune responses may be critical for an effective prion vaccine as the presence of both high-titer IgG and IgA antibodies, as compared to either high IgG or IgA antibodies alone, offered the greatest protection in a mouse oral infection model (Goni et al.&#160;<xref ref-type="bibr" rid="CR83">2008</xref>). Mucosal vaccination also delayed disease onset in an oral challenge model of cervids (Goni et al. <xref ref-type="bibr" rid="CR82">2015</xref>). Given these promising findings, and that oral immunization is the only viable option for wildlife vaccination, it is critical to explore the risks and benefits of orally administered prion vaccines. Most optimistically, IgA antibodies at the mucosal surface can prevent the uptake of consumed prions thereby preventing infection; in a worst-case scenario, the presence of PrP<sup>Sc</sup>-reactive mucosal immunoglobins could theoretically enhance the uptake of infectious particles from the gut to promote disease, as known as antibody-dependent enhancement (Xu et al.&#160;<xref ref-type="bibr" rid="CR243">2021</xref>).</p><p>In humans, other than the historic examples of kuru because of cannibalistic funeral practices or variant CJD resulting from consumption of prion-infected beef (Hill et al.&#160;<xref ref-type="bibr" rid="CR109">1997</xref>), most prion diseases originate in the periphery through either spontaneous or iatrogenic origins rather than initiating at mucosal surfaces (Will et al.&#160;<xref ref-type="bibr" rid="CR233">1998</xref>; Zou et al.&#160;<xref ref-type="bibr" rid="CR249">2008</xref>). Extensive trials utilizing parenterally administered prion vaccines support the ability of peripheral immune responses to slow the onset of clinical symptoms of disease. In these scenarios, systemic IgG responses likely restrict, but not eliminate, peripheral amplification of infectious particles. Following a period of peripheral amplification, which can last from weeks to decades depending on the species and nature of the challenge dose, prion disease migrate to the CNS where they exert their pathological consequences. Delaying the onset of symptoms of disease by minimizing peripheral amplification is certainly of importance in human patients, and minimizing the infectious load generated could be valuable to break the cycle of transmission in animals (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p>Once the infectious agent reaches the CNS, the options for immunotherapy are limited by the relative impermeability of the blood&#8211;brain barrier (BBB) to immunoglobins (Neuwelt et al.&#160;<xref ref-type="bibr" rid="CR165">2011</xref>). Penetration of IgG immunoglobins across the BBB is quite limited (Podusio et al. <xref ref-type="bibr" rid="CR178">2001</xref>) resulting in concentrations of IgG in CSF that are approximately 500- to 1000-fold lower than in serum (Katsinelos et al. <xref ref-type="bibr" rid="CR124">2019</xref>). Consistent with this, an investigation of a parenterally administered prion vaccine found that the titers of epitope-specific antibodies were approximately three orders of magnitude lower than in CSF than in serum with strong correlation between the serum and CSF epitope-specific titers (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>). Therefore, if limited to conventional vaccinology, achieving high-serum antibody titers may be critical to limit prion-induced neurodegeneration. There have also been efforts to translocate PrP-reactive immune responses past the BBB; camelid single-domain PrP-specific antibodies can cross the blood&#8211;brain barrier (David et al.&#160;<xref ref-type="bibr" rid="CR54">2014</xref>). Expression of a PrP-reactive antibody single-chain Fv fragment was achieved using a brain-engraftable microglial cell line with modest benefits on disease pathogenesis (Fujita et al.&#160;<xref ref-type="bibr" rid="CR71">2011</xref>). Further, vectored delivery of prion-specific single-chain fragment prolonged the survival time of prion-infected mice and decreased PrP<sup>Sc</sup> in the brain (Wuertzer et al.&#160;<xref ref-type="bibr" rid="CR242">2008</xref>; Moda et al.&#160;<xref ref-type="bibr" rid="CR160">2012</xref>).</p></sec><sec id="FPar22"><title>Achieving protective immune responses (Th1 vs Th2)</title><p id="Par44">Immunotherapy for prion diseases is typically based on the assumption that PrP-reactive immunoglobins offer therapeutic benefit through either destruction of the infectious isoform, neutralization of PrP<sup>Sc</sup> to prevent further misfolding, or depletion of PrP<sup>C</sup> to eliminate the substrate required for disease propagation, or a combination of these factors. This goes back to early studies in prion-infected cultured cells and in transgenic mice that showed that antibodies to PrP can block prion infection (Enari et al. <xref ref-type="bibr" rid="CR66">2001</xref>; Peretz et al. <xref ref-type="bibr" rid="CR174">2001</xref>; Heppner et al. <xref ref-type="bibr" rid="CR104">2001</xref>; Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>). Regardless of the mechanism, these outcomes all depend on Th2 humoral responses. The protective value of anti-PrP antibodies is supported by the degrees of protection achieved through passive immunization of PrP-reactive antibodies as well as the correlation between the magnitude of humoral immune responses and the extent of protection (White et al. <xref ref-type="bibr" rid="CR231">2003</xref>; Bachy et al.&#160;<xref ref-type="bibr" rid="CR16">2010</xref>; Goni et al.&#160;<xref ref-type="bibr" rid="CR83">2008</xref>). While cellular immunity is generally not considered a significant contributor to protection for prion disease, vaccine-induced antigen-specific CD4 and CD8 cells have been described (Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>). It is noteworthy that the transfer of either PrP-sensitized CD4&#8201;+&#8201;T cells from PrP&#8211;/&#8211; donors (Gourdain et al.&#160;<xref ref-type="bibr" rid="CR86">2009</xref>) or transgenic T cells with a PrP-specific T cell receptor (Iken et al.&#160;<xref ref-type="bibr" rid="CR114">2011</xref>) slowed disease progression in the absence of induced antibody production. Similarly, that an adjuvant-only control was found to delay prion disease further indicates a potential more generalized immune activation to limit prion disease (Tal et al.&#160;<xref ref-type="bibr" rid="CR211">2003</xref>).</p></sec></sec><sec id="Sec3"><title>Prion vaccine components</title><sec id="FPar23"><title>Prion vaccine components (antigens)</title><p id="Par45">The antigens of prion vaccines can be conceptually divided into three categories: those design to elicit antibodies which are specific for the PrP<sup>C</sup>, those prioritize response to the misfolded PrP<sup>Sc</sup> isoforms, and those which generate antibodies that do not discriminate the PrP conformations.</p></sec><sec id="FPar24"><title>PrP<sup>C</sup> as target</title><p id="Par46">For traditional infectious diseases, the vaccine antigen(s) represent the entirety, or select biomolecules, of the invading pathogen, and therefore recognized as &#8220;foreign&#8221; by the host immune system. This is different for prion diseases. Only in the very early phases and if invading prions are from a different species are some PrP epitopes potentially recognized as &#8220;foreign.&#8221; This changes when prions start to replicate in the host, as this process entirely depends on recruitment of endogenous PrP<sup>C</sup>, which is a self-antigen, into newly produced PrP<sup>Sc</sup>. This explains why prion infections are not accompanied by a bona fide and detectable immune response against prions (Aucouturier and Carnaud <xref ref-type="bibr" rid="CR12">2002</xref>; Aguzzi <xref ref-type="bibr" rid="CR4">2003</xref>; Zabel and Avery <xref ref-type="bibr" rid="CR246">2015</xref>; Mabbott et al. <xref ref-type="bibr" rid="CR142">2018</xref>). T cells and most B cells are restricted to presentation of linear peptide epitopes on MHC molecules of antigen-presenting cells to their B and T cell receptors. Even more, isotype switching, somatic hypermutation, and terminal differentiation into highly specific (and long-living) plasma cells need help by antigen-specific CD4 cells. This all explains why the immune system seems to be &#8220;blind&#8221; for prions, although the role of microglia in the CNS is still a matter of debate (Perry&#160;<xref ref-type="bibr" rid="CR175">2004</xref>). Targeting PrP<sup>C</sup> in active immunization is therefore complicated by the necessity to overcome self-tolerance against PrP.</p><p>A second problem is the risk to induce thereby undesirable side effects, both from over-reaching immune reactions and compromising the normal function of PrP<sup>C</sup>. For the latter, PrP<sup>C</sup> is widely accepted as an adequate target for anti-prion activities, as severe loss-of-function phenotypes were not found in animal models (Bueler et al. <xref ref-type="bibr" rid="CR42">1993</xref>; Mallucci et al. <xref ref-type="bibr" rid="CR147">2003</xref>; Nicoll and Collinge <xref ref-type="bibr" rid="CR167">2009</xref>). Overall, there is in the meantime solid proof-of-concept that active immunization can break the self-tolerance against PrP to produce self-antibodies, without inducing unwanted side effects in experimental animal models (Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>; Eiden et al. <xref ref-type="bibr" rid="CR63">2021</xref>; Fernandez-Borges et al. <xref ref-type="bibr" rid="CR67">2006</xref>; Goni et al. <xref ref-type="bibr" rid="CR81">2005</xref>, <xref ref-type="bibr" rid="CR83">2008</xref>, <xref ref-type="bibr" rid="CR82">2015</xref>; Ishibashi et al. <xref ref-type="bibr" rid="CR117">2007</xref>; Heppner et al. <xref ref-type="bibr" rid="CR104">2001</xref>; Polymenidou et al. <xref ref-type="bibr" rid="CR179">2004</xref>; Rosset et al. <xref ref-type="bibr" rid="CR193">2009</xref>; Taschuk et al. <xref ref-type="bibr" rid="CR214">2015a</xref>, <xref ref-type="bibr" rid="CR217">b</xref>, <xref ref-type="bibr" rid="CR216">2017</xref>).</p><p>Mechanistically, PrP<sup>C</sup>-targeted immunization aims at induction of self-antibodies that bind at cell surface-located PrP<sup>C</sup> and thereby remove or impede its conversion into PrP<sup>Sc</sup> (steric hindrance) (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). This works well outside the CNS, where self-antibodies do not have to cross the BBB and in situations where prions propagate in the periphery, e.g., in the process of primary infection (CNS invasion) or anterograde transport from the infected CNS to the periphery (prion shedding). To overcome self-tolerance, aggregation-prone and therefore stable recombinant dimeric or monomeric PrP isoforms were used as immunogens. For example, dimeric cervid PrP consists of two cervid PrP moieties (full-length minus signal peptides; aa 23&#8211;231), covalently linked by a 7-aa linker (AGAIGGA), and fused to an N-terminal poly-his tag (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). The moieties also encode epitope tags and can be used as potential DIVA vaccines. Quality control is done after refolding of protein, assessing quality and purity by gel electrophoresis, immunoblot, size exclusion chromatography, or FTIR. Such examinations showed that PrP dimers are aggregation-prone with more &#946;-sheet structure than monomers have (Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>). Aggregation can be enhanced when mixed with adjuvant (Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>). This may result in more stability in vivo and longer exposition to antigen-presenting cells. Recombinant PrP can also be efficiently encapsulated together with adjuvant into biodegradable polylactide-coglycolide (PLGA) nanospheres (Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>) and such nano-vaccines used for oral immunization.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Mechanisms of immunotherapeutic intervention.<bold> A</bold> Natural progression. PrP<sup>Sc</sup>, through physical interaction with PrP<sup>C</sup>, serves as a template for misfolding.<bold> B</bold> PrP<sup>Sc</sup>-specific immunotherapy. Antibodies to PrP<sup>Sc</sup>, through disruption of the interaction between PrP<sup>Sc</sup> and PrP<sup>C</sup> block induced misfolding of PrP<sup>C</sup>. <bold>C</bold> PrP<sup>C</sup>-specific immunotherapy. PrP<sup>C</sup>-specific antibodies can block the interaction with PrP<sup>Sc</sup> as well as causing depletion of PrP<sup>C</sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="441_2023_3749_Fig2_HTML.jpg"/></fig></p><p>Overall, there is now a solid proof of evidence that such vaccine candidates can overcome self-tolerance in rodent models and cervids, resulting in detectable humoral and cellular immune responses (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). Importantly, such targeting of PrP<sup>C</sup> does not result in adverse side effects (Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). Results in transgenic mouse models of CWD infection indicate that vaccines can extend prion incubation time up to 60% (Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>).</p></sec><sec id="FPar25"><title>PrP<sup>Sc</sup>-specific antigens</title><p id="Par50">Efforts to focus immune responses to PrP<sup>Sc</sup> are motivated by dual considerations of safety and efficacy. For safety, given the potential consequences of induction of immune responses to a widely expressed, cell surface protein, there is appeal for conformation-specific immunotherapy. In terms of efficacy, prioritizing the misfolded species could serve to focus the immune response to the most pressing threat (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Conformation-specific immunotherapy is dependent on the identification of epitopes that are specifically exposed for antibody binding in the misfolded state, disease-specific epitopes (DSEs). While conceptually appealing, the identification of these targets is complicated by the tendency of the misfolded PrP to form insoluble aggregates which are unsuitable for biophysical characterization. Despite these challenges, conformation-specific targets, representing both linear and conformational epitopes, have been identified.</p></sec><sec id="FPar26"><title>Disease-specific epitopes</title><p id="Par51">The first DSE of PrP was discovered from biophysical investigations of the refolding of PrP<sup>C</sup> into PrP<sup>Sc</sup> which revealed unique surface exposure of a YYR-motif. That antisera to this DSE immunoprecipitated PrP<sup>Sc</sup> from prion-infected brain with an absence of reactivity to PrP<sup>C</sup> from healthy brains supported the use of the epitope for PrP<sup>Sc</sup>-specific vaccines (Paramithiotis et al.&#160;<xref ref-type="bibr" rid="CR172">2003</xref>). Initial efforts to further translate this target into a vaccine were hampered by the limited immunogenicity of the tripeptide, but rationale expansion of the core DSE epitope, as well as presentation on a suitable carrier protein, resulted in a vaccine that induced robust PrP<sup>Sc</sup>-specific antibody responses (Hedlin et al.&#160;<xref ref-type="bibr" rid="CR99">2010</xref>). Parenteral administration of this vaccine delayed onset of scrapie in a sheep challenge model (Taschuk <xref ref-type="bibr" rid="CR215">2014</xref>) but accelerated disease onset in an environmental challenge model of elk (Wood <xref ref-type="bibr" rid="CR240">2018</xref>). Both challenge models utilized oral routes of infection: within the sheep model, animals were exposed to a large single dose of administered infectious material, while the elk were housed in a prion-infected environment with prolonged exposure to low-level prions. It is uncertain whether the unique outcomes of these trials reflect differences related to the species or the challenge models.</p><p>Based on the positioning of the YYR DSE on beta-strand 2 of PrP<sup>C</sup>, it was hypothesized that the opposing beta-strand may undergo similar repositioning to surface exposure upon misfolding. A region of the opposing beta-strand, corresponding to the sequence YML, was confirmed to meet the criteria of a DSE through induction of PrP<sup>Sc</sup>-specific immune responses (Marciniuk et al.&#160;<xref ref-type="bibr" rid="CR148">2014</xref>). A third DSE was identified through a bioinformatic algorithm that predicts regions of proteins most likely to unfold; the loop region between beta-strand 2 and alpha-helix 2 was implicated, and confirmed, to represent a DSE (Marciniuk et al.&#160;<xref ref-type="bibr" rid="CR148">2014</xref>). As structural investigations had noted unusual rigidity of this region in cervid PrP (Gossert et al.&#160;<xref ref-type="bibr" rid="CR85">2005</xref>), this DSE was designated as rigid loop (RL). Through optimization of these core sequences, these DSEs were translated into vaccines that exhibit strong immunogenicity, specificity, and safety profiles when administered individually or in a multivalent format (Marciniuk et al.&#160;<xref ref-type="bibr" rid="CR148">2014</xref>). Vaccines based on the YML and RL DSEs have not been evaluated for efficacy in animal challenge trials, but their associated antibodies have been shown to neutralize prions in vitro (Taschuk et al.&#160;<xref ref-type="bibr" rid="CR214">2015a</xref>, <xref ref-type="bibr" rid="CR217">b</xref>).</p></sec><sec id="FPar27"><title>Structurally restrained epitopes</title><p id="Par53">VPrP<sup>Sc</sup>-mimicking surface-exposed structures of PrP<sup>Sc</sup> are based on a 4-rung beta-solenoid fold of PrP<sup>Sc</sup> (Wille and Requena <xref ref-type="bibr" rid="CR234">2018</xref>), a model recently challenged by others. Seven discontinuous residues surface-exposed in PrP<sup>Sc</sup> but not in PrP<sup>C</sup> were selected and inserted into the fungal HET-s prion domain, which adopts a 2-rung beta-solenoid (Wasmer et al.&#160;<xref ref-type="bibr" rid="CR226">2008</xref>) and is an innocuous and non-pathogenic scaffold, well-suited as a vaccine carrier. Mice injected with VPrP<sup>Sc</sup> developed an immune response selectively recognizing PrP in prion-infected (but not non-infected) brain homogenates. An transgenic mouse model carrying a mutation in human PrP causing GSS syndrome in humans, immunized with VPrP<sup>Sc</sup>, remained free of clinical signs up to 450&#160;days of age, while unvaccinated controls developed disease at about 177&#160;days (Fleming et al. <xref ref-type="bibr" rid="CR68">2022</xref>; Nazor et al.&#160;<xref ref-type="bibr" rid="CR164">2005</xref>).</p></sec><sec id="FPar28"><title>Vaccine formulation and delivery</title><p id="Par54">Most of the efforts to develop prion vaccines have utilized parenteral routes of administration. This an effective approach for investigation of potentially protective epitopes, and an injected vaccine could have application for control of CWD in farmed cervids. However, given the importance of mucosal immunity in protection from oral routes of infection, that mucosal vaccines induce both peripheral and mucosal responses, and that control of CWD in wild cervids will likely depend on the use of oral vaccines; the clear priority is to develop oral prion vaccines. Control of wildlife diseases through oral, self-administered vaccines is an achievable goal, as demonstrated by the highly successful example of rabies (Mahl et al.&#160;<xref ref-type="bibr" rid="CR145">2014</xref>). Three biological vector platforms have been shown to be effective in inducing mucosal and systemic antibody responses for prion vaccines, including within cervids (Goni et al.&#160;<xref ref-type="bibr" rid="CR82">2015</xref>, <xref ref-type="bibr" rid="CR83">2008</xref>, <xref ref-type="bibr" rid="CR81">2005</xref>; Taschuk et al. <xref ref-type="bibr" rid="CR216">2017</xref>; Gonzales-Cano et al. <xref ref-type="bibr" rid="CR84">2017</xref>).</p></sec><sec id="FPar29"><title>Adenovirus vectors</title><p id="Par55">A replication-incompetent human adenovirus serotype 5 (hAd5) was investigated as a platform for an oral CWD vaccine as it has a broad species and tissue tropism, induces systemic and humoral immunity, and can be dosed orally (Buge et al.&#160;<xref ref-type="bibr" rid="CR44">1997</xref>; Alejo et al. <xref ref-type="bibr" rid="CR7">2013</xref>). One of the commercialized oral wildlife vaccines for rabies, OnRab, is based on a human adenovirus platform (Yarosh et al.&#160;<xref ref-type="bibr" rid="CR245">1996</xref>). Oral delivery of a hAd5 encoding the RL DSE fused to truncated rabies glycoprotein G carrier protein to white-tailed deer-induced PrP<sup>Sc</sup>-specific systemic and mucosal immune responses after two immunizations (Taschuk et al.&#160;<xref ref-type="bibr" rid="CR216">2017</xref>). The induction of epitope-specific antibody responses confirms the ability of the replication-defective vector to infect cells within the gastrointestinal tract of white-tailed deer. While a replication-competent virus would likely result in higher levels of antigen expression, and therefor elevated immune responses, such a vector presents increased safety risks of environmental contamination and/or unanticipated immunization of non-target species. The hAd5-RL-tgG vaccine showed an encouraging safety profile with no indications of adverse health effects and a limited duration of vector shedding (Taschuk et al.&#160;<xref ref-type="bibr" rid="CR216">2017</xref>).</p></sec><sec id="FPar30"><title>Lambda phage</title><p id="Par56">Bacteriophage have many characteristics consist with delivery platforms for oral vaccines. They are structurally stable in the gastrointestinal tract, are amenable to genetic manipulation, and possess favorable immunogenicity traits. As bacteriophage are ubiquitous within mammalian digestive systems and replicate within bacteria, they are generally regarded as safe to eukaryotic hosts (Hodyra-Stefaniak et al.&#160;<xref ref-type="bibr" rid="CR110">2015</xref>). To investigate the capacity of phages to induce mucosal immune responses, three prion DSEs were presented as recombinant fusions of the phage capsid head protein D. Following targeted delivery to intestinal segments of calves, the phage particles were taken up from the small intestine into Peyer&#8217;s patches to the induction of strong IgA responses to each of the three epitopes, in the absence of a mucosal adjuvant (Gonzales-Cano&#160;et al. <xref ref-type="bibr" rid="CR84">2017</xref>).</p></sec><sec id="FPar31"><title>Bacterial delivery</title><p id="Par57">Live-attenuated strains of <italic toggle="yes">Salmonella enterica</italic> have been used as mucosal vaccines against <italic toggle="yes">Salmonella</italic> infection and as delivery systems for vaccines in human and veterinary medicine (Hegazy and Hensel <xref ref-type="bibr" rid="CR100">2012</xref>). The first use of a <italic toggle="yes">Salmonella</italic> delivery system for mucosal vaccination in prion disease was described as early as 2005 (Goni et al. <xref ref-type="bibr" rid="CR81">2005</xref>). Such vectors are considered safe, as they are genetically modified in a way to prevent reversion into a disease-inducing state. Goni and colleagues used the <italic toggle="yes">Salmonella enterica</italic> serovar <italic toggle="yes">Typhimurium</italic> strain LVR01 that is attenuated by deleting the gene that encodes for the essential enzyme chorismate synthase. The deleted strain can reach lymphoid follicles in the gut of animals, thereby delivering antigens without any associated virulence (Goni et al. <xref ref-type="bibr" rid="CR83">2008</xref>). Interestingly, this vector vaccine expressed tandem copies of PrP, and a higher copy number yielded better results (Goni et al. <xref ref-type="bibr" rid="CR83">2008</xref>). It is unclear whether this added only more expression units or whether the expressed PrPs were also tandems at the protein level. This mucosal vaccine was tested in a CWD-infected cervid model, indoor-housed white-tailed deer, for protection against clinical prion disease (Goni et al. <xref ref-type="bibr" rid="CR82">2015</xref>) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Deer received up to eight immunizations using different routes, mainly oral exposition by gavage, to <italic toggle="yes">Salmonella</italic> vaccine with alum as adjuvant. The immunized group showed a significant prolongation of incubation time compared to the control group, with one out of 5 animals not showing signs of infection after 3&#160;years (Goni et al. <xref ref-type="bibr" rid="CR82">2015</xref>). This animal also had high anti-PrP IgA titers in saliva and IgG in blood. Overall, this provides a proof-of-concept that oral vaccination can provide protection against CWD infection in cervids.</p></sec></sec><sec id="Sec4"><title>Evaluating prion vaccines</title><sec id="FPar32"><title>Available animal models</title><p id="Par58">Evaluation of prion vaccines depends strictly on appropriate in vivo models. Whereas immunological parameters and side effects of vaccination can be evaluated in uninfected animals, determination and quantification of protection from infection require animal infection, ideally within a target species and with characteristics of infection that most closely mimic real-world transmission in terms of the prion strains, dose, and routes of infection. Consequently, while prion vaccines intended for ungulates should be tested in the homologous large animal model, this is often not feasible and rodent models can provide viable alternatives.</p><p>Mouse-adapted sheep prion strains replicate well in wild-type mice and provided a first animal platform to study prion vaccines. Prions from ungulates and humans often do not replicate well in non-transgenic mice and hamsters, and the more broadly susceptible bank voles were not studied so far for vaccine purposes. On the other hand, there are transgenic mouse models that overexpress bovine, ovine, cervid, or human PrP, which replicate prions of the respective species and develop a clinical prion disease with known and predictable incubation times (Buschmann et al. <xref ref-type="bibr" rid="CR45">2000</xref>; Vilotte et al. <xref ref-type="bibr" rid="CR221">2001</xref>; Browning et al. <xref ref-type="bibr" rid="CR39">2004</xref>; Wadsworth et al. <xref ref-type="bibr" rid="CR222">2010</xref>). The disadvantage is that overexpressing transgenic mice usually do not fully recapitulate prion biogenesis and pathology as found in the source animal. For example, they cannot be infected using oral or intraperitoneal routes or do not provide a 100% attack rate, making it difficult to compare vaccinated with non-vaccinated control groups (Seelig et al. <xref ref-type="bibr" rid="CR205">2010</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). Very often, they also do not shed prions like a natural host; a prime example are transgenic mouse models for CWD.</p><p>Knock-in (KI) mice can overcome these important drawbacks of overexpressing transgenic mice. They express the PrP transgene under the authentic PrP promoter, with correct spatial and temporal expression levels. For cervidized mice, two groups have produced such mice, encoding various cervid genotypes (e.g., deer, elk, and caribou/reindeer) (Bian et al. <xref ref-type="bibr" rid="CR32">2019</xref>; Arifin et al. <xref ref-type="bibr" rid="CR10">2022</xref>). As expected, such mice develop clinical prion disease with a 100% attack rate upon oral and intraperitoneal inoculation, with incubation times only slightly longer than for intracerebral (i.c.) infection. KI mice come down with disease later than transgenic mice upon i.c. inoculation, as they do not overexpress PrP. Importantly, they seem to fully recapitulate CWD pathogenesis and prion lateralization as found in the cervid host, which includes shedding of CWD prions into feces, saliva, and urine (Bian et al. <xref ref-type="bibr" rid="CR32">2019</xref>). This allows usage of cervid PrP KI mice to study vaccine effects on CWD prion shedding, which was not possible to do in existing transgenic mice.</p></sec><sec id="FPar33"><title>Mouse versus large animal models</title><p id="Par61">Whereas rodent models have the advantage of feasibility, including large number study sizes (and both sexes), appropriate biosafety and well-controlled, and reproducible experimental conditions, they are still a &#8220;model.&#8221; The gold standard to study vaccine efficacy for ungulate prions would be the respective large animal, similar as an animal model cannot substitute for phase 2 and 3 trials in humans. In ruminants, the gastrointestinal tract is very different from the one in rodents, which is relevant for vaccine stability upon oral delivery as well as various immunological parameters. In addition, what we know from mouse and human immunology can be different for innate and adaptive immunity in ungulates. For example, the proportions of non-conventional B and T cell populations, which can impact reactivity to conformational versus linear epitopes, non-peptide-based antigens, and immunological memory, are different and less well studied.</p><p>For experimental studies in cervids, there are two basic scenarios. One is controlled oral challenge studies in cervid species kept inside, for example, WTD and reindeer (Mathiason et al. <xref ref-type="bibr" rid="CR155">2006</xref>; Mathiason <xref ref-type="bibr" rid="CR153">2022</xref>; Mitchell et al. <xref ref-type="bibr" rid="CR159">2012</xref>). Similar studies have been done with outdoor-held captive elk in appropriate confinements (Basu et al. <xref ref-type="bibr" rid="CR20">2012</xref>). Each individual animal receives a well-defined oral dose of characterized CWD prions, usually via gavage and under anesthesia. This results in a 100% attack rate, with predictable incubation time to clinical disease, which facilitates appropriate sampling of biological materials (e.g., lymph node biopsies, saliva, urine and feces) (Haley et al. <xref ref-type="bibr" rid="CR90">2009</xref>, <xref ref-type="bibr" rid="CR89">2011</xref>; Henderson et al. <xref ref-type="bibr" rid="CR102">2013</xref>). Since a vaccinated population is compared to controls only receiving adjuvant, such studies allow assessing vaccine efficacy with regard to protection, mitigation, and prion reduction in biological materials (Goni et al. <xref ref-type="bibr" rid="CR82">2015</xref>). The time frame for such costly studies is in the 2&#8211;3&#160;years range at minimum and can only be performed in a handful of facilities worldwide. The alternative model uses captive or even free-ranging cervids, vaccinates, and exposes them/keeps them exposed to CWD in the environment, with controls not receiving vaccination. This can be pastures of recently depopulated farms or areas with high CWD prevalence in free-ranging animals in an environmental setting. When using free-ranging cervids, some animals likely are already inoculated and in various stages of infection. The environmental exposure mimics naturally occurring CWD infection, likely smaller doses over longer periods, and is therefore closer to the real-life scenario (Taschuk et al. <xref ref-type="bibr" rid="CR216">2017</xref>; Wood et al. <xref ref-type="bibr" rid="CR240">2018</xref>). The drawback is that it remains unknown whether, when and how much CWD inoculum is taken up. Therefore, incubation time and attack rate cannot be predicted with accuracy, and additional animal numbers are necessary to obtain statistically significant differences between vaccinated and unvaccinated groups. There might also be regulatory challenges, and a certain level of confinement is necessary, to exclude release of vaccines to unvaccinated animals or other species. Since the challenge with CWD is an uncontrolled spreading of CWD in wild, free-ranging animals, e.g., deer, elk, and soon caribou in North America, there will be no way around such a real-world scenario with appropriate oral delivery, which might need to be tailored towards a given species.</p></sec><sec id="FPar34"><title>Routes of prion infection</title><p id="Par63">When inoculating animals in experimental prion research, the gold standard is using the intracerebral (i.c.) route, because it usually provides the highest attack rates and the shortest incubation times to clinical prion disease (Scott et al. <xref ref-type="bibr" rid="CR204">1989</xref>; Weissmann et al. <xref ref-type="bibr" rid="CR228">1996</xref>). Whether this is the most appropriate route of infection for prion vaccine studies depends on the objectives of the investigation. In instances where the objective to is evaluate protective effects of vaccination in the CNS, i.c. infection is appropriate. In other scenarios, vaccination targets early events in peripheral prion infection and/or extra-CNS prion propagation, and therefore, infection is better performed by either intraperitioneal (i.p.) or oral routes. The first recapitulates the process of neuroinvasion and the roles the lymphatic and peripheral nervous systems play. The latter addresses mucosal immunity, and the potential interplay between prions taken up orally and Peyer&#8217;s patches as part of the mucosal-associated lymphatic tissue (MALT), M cells, and secretory IgA, for example. Cervids, sheep, and cattle are ruminants, and how orally ingested prions must pass their digestive tract and when innate and adaptive immunity could come into play is very different from the situation in experimentally infected rodent models. Most importantly, wildlife vaccination of cervids will need an effective oral vaccine strategy, so oral vaccination in the natural host must be the goal.</p></sec><sec id="FPar35"><title>Parameters to assess vaccine success</title><p id="Par64">Given the time, expense, and difficulties associated with prion challenge trials, it is often useful to have immunological markers of vaccine-induced responses that can be used to prioritize and optimize vaccine candidates. On the immunological side, typically humoral responses are studied, which can be done in the absence of infection. Antibodies reacting with PrP (PrP<sup>C</sup> or PrP<sup>Sc</sup>) are usually tested in ELISA or immunoblot, in quantitative and qualitative formats. For ELISA, recombinant PrP or purified PrP<sup>Sc</sup> can be used as antigen, keeping in mind whether the PrP conformation is native, renatured, or denatured. An intra-individual increase of specific reactivity (above cut-off) compared to pre-immune sera is measured, and it is important to include also adjuvant-only treated controls (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Taschuk et al. <xref ref-type="bibr" rid="CR216">2017</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). The ability to bind to native PrP can also be quantified by flow cytometry using PrP<sup>C</sup>-expressing cells (Polymenidou et al. <xref ref-type="bibr" rid="CR179">2004</xref>). Since reliable detection of PrP<sup>Sc</sup> on the outer leaflet of the cell membrane of prion-infected cells is still a matter of debate, this approach is not established for assessing antibodies binding to native PrP<sup>Sc</sup>. Reactivity to linear epitopes is mapped in peptide-based ELISA assays. Such reactivity does not, however, indicate whether the anti-PrP antibodies are &#8220;protective,&#8221; like neutralization assays in virology, the prion infection-neutralizing capacity can be studied in cell culture and in vitro prion conversion assays (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>).</p></sec></sec><sec id="Sec5"><title>In vitro neutralization assays</title><sec id="FPar36"><title>RT-QuIC interference assay</title><p id="Par65">Since this assay allows to discriminate substrate (recombinant PrP) and template (PrP<sup>Sc</sup> seed) (Wilham et al. <xref ref-type="bibr" rid="CR232">2010</xref>; Orr&#249; et al. <xref ref-type="bibr" rid="CR171">2012</xref>; Haley et al. <xref ref-type="bibr" rid="CR91">2018</xref>), it is almost ideal to dissect whether humoral immune responses are directed against PrP<sup>C</sup>, PrP<sup>Sc</sup>, or both. This can be achieved by simply pre-incubating either of the two components with a dilution series of the post-immune antisera (Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). Quadruplicate reactions are analyzed on plate readers by measuring ThT fluorescence increase. RT-QuIC data are plotted against reaction time and scored positive if at least 50% of replicates reach the fluorescence cut-off. In a convenient 3-day format, this assay demonstrates if antisera can partially sequester prions in the prion seed and decrease conversion activity or if they block the PrP substrate.</p></sec><sec id="FPar37"><title>Cell culture neutralization assay</title><p id="Par66">This assay studies the effect of anti-PrP antibodies in the context of a cellular prion infection and usually uses persistently prion-infected cell lines (Butler et al. <xref ref-type="bibr" rid="CR46">1988</xref>; Sch&#228;tzl et al. <xref ref-type="bibr" rid="CR203">1997</xref>; Mahal et al. <xref ref-type="bibr" rid="CR144">2007</xref>). Typically, cells are cultured for several days in medium with diluted serum of vaccinated animals, using pre-immune sera as a control. Aliquots of cells are lysed or further passaged in the presence or absence of antibodies. This assay is complex, can take several weeks when cells are passaged, and is mostly semi-quantitative as changes in PrP<sup>Sc</sup> levels are assayed in immunoblot (Gilch et al. <xref ref-type="bibr" rid="CR77">2003</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). Results demonstrate whether the vaccine-induced antibodies can disrupt cellular prion propagation. Alternatively, a more standardized scrapie cell assay (SCA) can be employed that tests new infection of susceptible cells (Kl&#246;hn et al. <xref ref-type="bibr" rid="CR128">2003</xref>; Bian et al. <xref ref-type="bibr" rid="CR35">2010</xref>). The assay is very sensitive, has a short turn-around time (days), and is quantitative. Similar to RT-QuIC, prion inoculum and recipient PrP<sup>C</sup>-expressing cells can be separately pre-incubated, dissecting reactivity towards the different isoforms. Available cells can propagate mouse-adapted, scrapie, and cervid prions, which limits applicability. T cell responses are less often analyzed, using, e.g., classical flow cytometry-based assays for intracellular cytokine staining or EliSPOT-based assays. It is likely that in future studies, single-cell RNASeq analysis will play a prominent role to address the quality of immune responses.</p><p>To address the protective effect of prion vaccination on a whole-animal level, animal models that can be infected with the respective prions are necessary. Usually, animals are vaccinated followed by prion challenge, and experimental modalities were described above. Incubation time to clinical prion disease is the main read-out. A relative effect would be some prolongation; full protection would mean vaccinated animals do not develop a clinical prion disease. Additional readouts are levels of PrP<sup>Sc</sup> in certain tissues are body fluids, e.g., lymph nodes or saliva, which can be done intra vitam (Haley et al. <xref ref-type="bibr" rid="CR90">2009</xref>, <xref ref-type="bibr" rid="CR89">2011</xref>; Henderson et al. <xref ref-type="bibr" rid="CR102">2013</xref>). Besides prion lateralization in peripheral tissues, the effects of vaccination on shedding of prions into feces and urine is another important read-out, which can be done by using ultra-sensitive prion conversion assays like PMCA and RT-QuIC.</p><p>Finally, it is important to exclude unwanted side effects, by clinical observation and/or lab testing. Whereas lymph nodes can be assessed by biopsies, more detailed histopathological analysis needs euthanasia of the animal (Kaiser-Schulz et al. <xref ref-type="bibr" rid="CR121">2007</xref>). The spectrum of side effects can range from signs of acute or hyper-acute inflammation to severe pathologies in tissues like the kidney and brain (e.g., autoimmune-encephalitis). For the latter, it plays a role whether induced antibodies are supposed to cross the blood&#8211;brain barrier and penetrate effectively into the CNS. Another problem could be the induction of antibody-dependent enhancement (ADE), which was observed for several viral vaccines (Halstead et al. <xref ref-type="bibr" rid="CR92">2010</xref>). In this situation, vaccination does not reduce the infection process but instead enhances it. For the prion diseases, this could potentially occur through the antibodies promoting the misfolding of PrP into an infectious conformation. Alternatively, the presence of PrP<sup>Sc</sup>-reactive IgA antibodies in the mucosal surfaces of the intestine could serve to increase uptake of ingested prions. Another potential mechanism of vaccine enhanced prion disease could be by non-neutralizing antibody decoration of the agent, with improved uptake by certain immune cells in a Trojan horse mechanism. Since the role of macrophages is not fully clarified in prion infection, such a possibility needs attention. Finally, there is the possibility that vaccine-induced responses could result in the trafficking of prions to lymphoid tissues which offer a more permissive environment for prion amplification, thereby accelerating disease (Beringue et al. <xref ref-type="bibr" rid="CR26">2012</xref>). In summary, with the potential for a variety of negative effects with prion vaccination, researchers must place high priority on evaluation of the safety of all vaccine candidates.</p></sec></sec><sec id="Sec6"><title>What does success look like?</title><sec id="FPar38"><title>Is there a universal prion vaccine?</title><p id="Par69">Since prions strictly use endogenous PrP<sup>C</sup> of the host for their propagation, prions generated in humans, ungulates, and rodents differ in their primary sequence. For example, ruminant PrPs differ by&#8201;~&#8201;8% compared to human PrP at the amino acid level and rodent PrPs by up to 15% (Schatzl et al. <xref ref-type="bibr" rid="CR202">1995</xref>). Although the overall identity seems high for PrP<sup>C</sup>, there could be important structural differences in the PrP<sup>Sc</sup> scaffold that might affect immunological outcomes. Whether the prion disease is sporadic, genetic, or acquired by infection may impact the success of vaccination efforts as origins in either the periphery or CNS will impact the accessibility of the prions to the immune system. Prima vista, acquired prion diseases appear more prone to vaccine success, but it has to be seen whether this assumption holds true.</p><p>For vaccines targeting PrP<sup>Sc</sup>, a universal vaccine depends on how &#8220;conserved&#8221; disease-specific or structurally restrained epitopes are. While the core epitopes of the three prion DSEs characterized to date are highly conserved across species, the expansions of these regions to improve immunogenicity often introduce species-specific sequence variations that could potentially impact the ability of the induced antibodies to react with PrP<sup>Sc</sup> molecules from different species or even naturally occurring polymorphisms from within the same species. This would need to be investigated and potentially accounted for through multivalent vaccines that either target multiple DSEs or multiple sequence variants of the same DSE.</p><p>For vaccines targeting PrP<sup>C</sup>, this is not unlikely, as PrP<sup>C</sup> is a protein highly conserved within mammals (Schatzl et al. <xref ref-type="bibr" rid="CR202">1995</xref>; Wopfner et al. <xref ref-type="bibr" rid="CR241">1999</xref>). In addition, since a conserved cellular protein is targeted, there is no immune evasion to expect. Apart from the design of the immunogen itself, delivery and route of application of vaccines will play a role. For example, free-ranging cervids will need an oral vaccine strategy, maybe delivered by a vector, whereas vaccination of farmed cervids can be done by injection. Oral vaccines in cervids will likely need delivery by baits, and MD, WTD, elk, or caribou has different needs in this respect. Taken together, although a prion vaccine likely will have some &#8220;universal&#8221; character, its packaging and delivery must be optimized for the target population.</p></sec><sec id="FPar39"><title>Impact of prion strains</title><p id="Par72">Another variable which might affect vaccine success is the existence of prion strains (Bessen and Marsh <xref ref-type="bibr" rid="CR30">1992</xref>; Carlson et al. <xref ref-type="bibr" rid="CR48">1994</xref>; Bessen et al. <xref ref-type="bibr" rid="CR29">1995</xref>; Weissmann <xref ref-type="bibr" rid="CR227">2009</xref>). Within a given species, there can be a variety of prion strains that differ in conformation and biophysical properties (Collinge <xref ref-type="bibr" rid="CR52">2010</xref>; Carta and Aguzzi <xref ref-type="bibr" rid="CR49">2022</xref>). Strains are not static; they can change, evolve, and undergo selection under pressure (Li et al. <xref ref-type="bibr" rid="CR137">2010</xref>; Wadsworth and Collinge <xref ref-type="bibr" rid="CR223">2011</xref>). This dynamic scenario is further complicated by extensive genotypic variability in certain species, known as PrP polymorphisms (Goldmann <xref ref-type="bibr" rid="CR79">2008</xref>; Arifin et al. <xref ref-type="bibr" rid="CR9">2021</xref>). The proposed quasi-species nature of prion strains might affect vaccine success and predispose, at least in theory, to the development of immune escape populations over time, solely based on selection of protein conformations (Li et al. <xref ref-type="bibr" rid="CR137">2010</xref>; Wadsworth and Collinge <xref ref-type="bibr" rid="CR223">2011</xref>). This is a well-known scenario for viral diseases, here based on mutations on the nucleic acid level, and the failed vaccine attempts in HIV-1 are an extreme example. Another possibility is the before mentioned ADE, based on suboptimal antibody affinities. Univalent vaccines based on minimal epitopes could potentially be at higher risk for loss of efficacy in the face of escape variants, although the extent of structurally variability of prion strains impacts reactivity with such antibodies has yet to be determined. Vaccines targeting PrP<sup>C</sup> may have greater opportunity to maintain efficacy in the face of evolving strains and may be less predisposed to such resistance or ADE scenarios.</p></sec><sec id="FPar40"><title>Absolute protection vs slowing of disease/reduced shedding</title><p id="Par73">Given the 100% fatal nature of prion diseases and the suboptimal recognition of prions by the host immune system, sterilizing immunity from prion infection is likely an unrealistic goal. From what we have seen in experimental vaccination studies published so far, it is more likely that protection is relative, translating into a prolongation of incubation time (Polymenidou et al. <xref ref-type="bibr" rid="CR179">2004</xref>; Goni et al. <xref ref-type="bibr" rid="CR82">2015</xref>; Taschuk et al. <xref ref-type="bibr" rid="CR216">2017</xref>; Abdelaziz et al. <xref ref-type="bibr" rid="CR1">2017</xref>). Nevertheless, these results are very encouraging, and active vaccination could be a cornerstone in the attempts to contain CWD, both in wild-living and farmed cervid populations. Slowing down CWD development would create less casualties, take away pressure from populations, and allow them to cope and come up with countermeasures (one is starting the reproduction age earlier). This would also positively affect food security in regions depending heavily on hunted cervids. As a note of caution, an increase in lifetime could result in dissemination of more infectivity into the environment over time, if the vaccine does not also reduce CWD shedding. This is reminiscent of similar examples in veterinary medicine, where vaccines do not eliminate the agent in vaccinated animals, resulting in persistently infected and chronic active carriers. A CWD vaccine that also reduces CWD prion shedding would reduce the load of prions in the environment over time, result in less infections in the future, and thereby also reduce the zoonotic risk. Taken together, a vaccine that combines increased survival, better population fitness and reduced shedding of CWD infectivity will be a great success and a key element in successful CWD management.</p></sec><sec id="FPar41"><title>Vaccines for animal prion diseases</title><p id="Par74">CWD is currently the most pressing prion disease of animals. Within that, both farmed and wild cervids are impacted, and vaccines for each of those populations faces unique technical requirements as well as different standards of &#8220;what success looks like.&#8221; For farmed cervids, there is greater opportunity to control vaccination parameters to achieve a protective response. This includes the option for either oral or injected vaccines, as well as control over the number and timing of vaccinations. In contrast, vaccination of wild cervids is limited to oral vaccines with minimal control to ensure that all animals are vaccinated, the dose of vaccine received by each animal, and uncertainty over whether animals receive booster immunizations. Vaccines released into the environment also face conditions that could compromise their efficacy. With this, there is greater requirement for wildlife vaccines to be durable, with the induction of long-lasting immune responses, even after a single vaccination.</p><p>While prion vaccines for farmed cervids face less stringent technical requirements, they also face a higher standard of success. For farmed cervids, particularly those utilized as sources of food or alternative medical products, there is priority to ensure the health of individual animals. This reflects the inability of infected animals to recover from disease, as well as resistance of prions to treatments that neutralize the infectious agent without compromising the quality of the associated animal product. Should CWD ever be confirmed as a zoonotic disease, as emerging evidence suggests, these standards are certain to become even more stringent. In contrast, for wild cervids, the priority is to protect populations rather than individual animals. This can theoretically be achieved by reducing the amount of infectious material that is generated and spread by infected animals. The reduced burden of prions in the environment, in combination with other disease control measures, will hopefully break the cycle of disease transmission and eventually reducing CWD to manageable levels.</p></sec><sec id="FPar42"><title>Vaccines for human prion diseases</title><p id="Par76">Sporadic CJD, the main form in humans, is a very rare disease without preclinical biomarkers (Hermann et al. <xref ref-type="bibr" rid="CR105">2021</xref>). To protect humans from sporadic CJD mass vaccinations would be required, which is not realistic given the low disease prevalence. When clinical symptoms are already present in a patient, vaccination most likely would be too late. In addition, such a vaccine would have to exert its protective effect in the CNS. Human prion diseases acquired by infection, for example, vCJD or iatrogenic CJD, would have similar challenges as sporadic CJD and not provide a valid medical indication for vaccination. Certain post-exposure situations might be different, as here the potential time point of infection is known, and given the very slow process of neuroinvasion until establishment of infection in the CNS, vaccination could exert positive effects. A potential example could be a laboratory accident with human prions or potentially zoonotic prions.</p><p>The situation for genetic prion diseases, which includes familial CJD, GSS, and familial FFI, might represent opportunities for vaccination. These diseases are inherited within families and can be diagnosed by simple DNA analysis, and incubation times to clinical disease are roughly known, although with great inter-individual variations. Vaccination could start long before clinical manifestations, with administration of necessary vaccine boosters over time, and laboratory testing for induced immune responses as well as careful monitoring for potential side effects. In fact, experimental vaccine candidates based on structurally restrained epitopes have been tested in two transgenic mouse models of GSS, showing impressive prolongations of survival time (Fleming et al. <xref ref-type="bibr" rid="CR68">2022</xref>). This looks very promising, and this approach might even work for other familial neurodegenerative diseases that involve prion-like mechanisms, for example, AD and PD.</p></sec><sec id="FPar43"><title>Potential impacts of a vaccine for control of CWD</title><p id="Par78">It is important not to underestimate the threat presented by CWD nor the challenges to its effective management. This includes the widespread geographic occurrence, CWD has been spreading aggressively through North America (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A), environmental persistence of the agent, the unique molecular mechanism of propagation, occurrence in wildlife species, and evolving nature of the threat. With that, it is important to set realistic expectations of the extent and time frames in which the trajectory of the disease can be impacted. While an effective oral vaccine would represent a critical resource, the challenges of CWD are likely too great to rely on a single tool for disease control. Instead, vaccines are envisioned as a component of a multi-pronged approach that could include strategic culling, understanding/influencing genetic susceptibilities to infection, and neutralization of environmental prions. Within those efforts, vaccines will likely contribute within two realms. Firstly, by reducing the quantity of prions generated within an infected animal, it may be possible to begin to reverse the trend of the increasing environmental burden of prions. Given the extended survival of environmental prions, this will be a slow process. The second area where vaccines could serve to manage prion disease is through limiting the geographical spread. Given the gradual, predictable, pattern of migration of the disease, the priority might be strategic vaccination in regions where the disease is feared to spread, for example, limiting the spread into northern regions where it may threaten caribou populations (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). A second phase of vaccine distribution could involve attempting to establish rings of vaccination around regions where CWD is already endemic in effort to limit further spread of the disease. As a third phase, the vaccine could then be distributed within these endemic regions to minimize new cases and minimize shedding from existing cases. Once these phases are complete, it is likely that prolonged and ongoing distribution of the vaccine will be required to achieve control of the disease. The timing, location, and intensiveness of vaccine release being informed by characteristics of vaccine in terms of environmental durability and duration of the induced response, consideration for wildlife specialists who can provide information of the timing of patterns of animal movement, and contributions of disease modeling to monitor the impacts of the disease and further define parameters of vaccine utilization to achieve the determined goals.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Progression of CWD and potential deployment strategies of CWD vaccines.<bold> A</bold> Incidence of CWD over the past 15&#160;years.<bold> B</bold> Strategies for control of CWD through vaccination. Phase I. Strategic deployment of oral vaccines in the wild to limit the spread of disease into critical regions such as the northern regions home to caribou. Vaccination of farmed cervids with either oral or injected vaccine. Phase II. Establish complete vaccination rings around regions where CWD is endemic. Phase III. Distribution of oral vaccines within vaccination rings to reduce incidence of disease. Maps are adapted from the US Geographical Survey (USGS)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="441_2023_3749_Fig3_HTML.jpg"/></fig></p></sec></sec><sec id="Sec7"><title>Conclusions</title><p id="Par79">The field of vaccinology is pushing into new frontiers of vaccine development and application. This includes&#160;rapid acceleration of vaccine technologies, like mRNA vaccines, to deal with the COVID-19 pandemic as well as the development of vaccines for new realms of application like cancer or drug addiction. There is optimism that we have only begun to actualize the potential of vaccines. This includes encouraging progress into the development of vaccines for prion and prion-like diseases. Given the tremendous toll of these diseases on human and animal health, it is critical that we build on these successes to develop essential new tools for these diseases.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Published as VIDO manuscript series no. 1002.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>VIDO receives operational funding from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture and from the Canada Foundation for Innovation through the Major Science Initiatives for its CL3 facility.</p></notes><notes><title>Declarations</title><notes id="FPar45"><title>Ethical approval</title><p id="Par80">Not applicable.</p></notes><notes id="FPar46"><title>Consent to participate</title><p id="Par81">Not applicable.
</p></notes><notes id="FPar47" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par82">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names>DH</given-names></name><name name-style="western"><surname>Thapa</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>AB</given-names></name><name name-style="western"><surname>L, Jain S, Schatzl H, </surname></name></person-group><article-title>Immunization of cervidized transgenic mice with multimeric deer prion protein induces self-antibodies that antagonize chronic wasting disease infectivity in vitro</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>10538</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-11235-8</pub-id><pub-id pub-id-type="pmid">28874781</pub-id><pub-id pub-id-type="pmcid">PMC5585258</pub-id></element-citation></ref><ref id="CR2"><mixed-citation publication-type="other">Ac&#237;n C, Bolea R, Monz&#243;n M, Monle&#243;n E, Moreno B, Filali H, Mar&#237;n B, Sola D, Betancor M, Guijarro IM, Garc&#237;a M, Vargas A, Badiola JJ (2021) Classical and atypical scrapie in sheep and goats. Review on the etiology, genetic factors, pathogenesis, diagnosis, and control measures of both diseases. Animals (Basel) 11:691<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ani11030691</pub-id><pub-id pub-id-type="pmcid">PMC7999988</pub-id><pub-id pub-id-type="pmid">33806658</pub-id></mixed-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilar-Calvo</surname><given-names>P</given-names></name><name name-style="western"><surname>Callender</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>CJ</given-names></name></person-group><article-title>Short and sweet: how glycans impact prion conversion, cofactor interactions, and cross-species transmission</article-title><source>PLoS Pathog</source><year>2021</year><volume>17</volume><issue>1</issue><fpage>e1009123</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1009123</pub-id><pub-id pub-id-type="pmid">33444414</pub-id><pub-id pub-id-type="pmcid">PMC7808606</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Prions and the immune system: a journey through gut, spleen, and nerves</article-title><source>Adv Immunol</source><year>2003</year><volume>81</volume><fpage>123</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0065-2776(03)81004-0</pub-id><pub-id pub-id-type="pmid">14711055</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Heikenwalder</surname><given-names>M</given-names></name><name name-style="western"><surname>Polymenidou</surname><given-names>M</given-names></name></person-group><article-title>Insights into prion strains and neurotoxicity</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1038/nrm2204</pub-id><pub-id pub-id-type="pmid">17585315</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>C</given-names></name><name name-style="western"><surname>Heikenwaelder</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms of prion pathogenesis</article-title><source>Annu Rev Pathol Mech Dis</source><year>2008</year><volume>3</volume><fpage>11</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathmechdis.3.121806.154326</pub-id><pub-id pub-id-type="pmid">18233951</pub-id></element-citation></ref><ref id="CR7"><mixed-citation publication-type="other">Alejo DM, Moraes MP, Liao X, Dias CC, Tulman ER, Diaz-San S, Rood D, Grubman MJ, Silbart LK (2013) An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. Vaccine 26:2302&#8211;09<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.02.060</pub-id><pub-id pub-id-type="pmid">23499593</pub-id></mixed-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandrenne</surname><given-names>C</given-names></name><name name-style="western"><surname>Wijkhuisen</surname><given-names>A</given-names></name><name name-style="western"><surname>Dkhissi</surname><given-names>F</given-names></name><name name-style="western"><surname>Hanoux</surname><given-names>V</given-names></name><name name-style="western"><surname>Priam</surname><given-names>F</given-names></name><name name-style="western"><surname>Allard</surname><given-names>B</given-names></name><name name-style="western"><surname>Boquet</surname><given-names>D</given-names></name><name name-style="western"><surname>Couraud</surname><given-names>JY</given-names></name></person-group><article-title>Electrotransfer of cDNA coding for a heterologous prion protein generates autoantibodies against native murine prion protein in wild-type mice</article-title><source>DNA Cell Biol</source><year>2010</year><volume>29</volume><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1089/dna.2009.0940</pub-id><pub-id pub-id-type="pmid">20025536</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arifin</surname><given-names>MI</given-names></name><name name-style="western"><surname>Hannaoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Thapa</surname><given-names>S</given-names></name><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name></person-group><article-title>Cervid prion protein polymorphisms: role in chronic wasting disease pathogenesis</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>2271</fpage><pub-id pub-id-type="doi">10.3390/ijms22052271</pub-id><pub-id pub-id-type="pmid">33668798</pub-id><pub-id pub-id-type="pmcid">PMC7956812</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arifin</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>D</given-names></name><name name-style="western"><surname>Hannaoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Beekes</surname><given-names>M</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>G</given-names></name><name name-style="western"><surname>Benestad</surname><given-names>S</given-names></name><name name-style="western"><surname>Kacmarczyk</surname><given-names>L</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>W</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name></person-group><article-title>Heterozygosity at cervid Prnp codon 138 progressively blocks prion conversion in vitro and partly confines prion propagation to the periphery in knock-in mice</article-title><source>Prion</source><year>2022</year><volume>16</volume><fpage>95</fpage><lpage>253</lpage></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arsenault</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Kusalik</surname><given-names>A</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Induction of ligand-specific PrPC signaling in human neuronal cells</article-title><source>Prion</source><year>2012</year><volume>6</volume><fpage>477</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.4161/pri.21914</pub-id><pub-id pub-id-type="pmid">22918447</pub-id><pub-id pub-id-type="pmcid">PMC3510852</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aucouturier</surname><given-names>P</given-names></name><name name-style="western"><surname>Carnaud</surname><given-names>C</given-names></name></person-group><article-title>The immune system and prion diseases: a relationship of complicity and blindness</article-title><source>J Leukoc Biol</source><year>2002</year><volume>72</volume><fpage>1075</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1189/jlb.72.6.1075</pub-id><pub-id pub-id-type="pmid">12488488</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayers</surname><given-names>JI</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>NR</given-names></name></person-group><article-title>Prion-like mechanisms in amyotrophic lateral sclerosis</article-title><source>Handb Clin Neurol</source><year>2018</year><volume>153</volume><fpage>337</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63945-5.00018-0</pub-id><pub-id pub-id-type="pmid">29887144</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayers</surname><given-names>JI</given-names></name><name name-style="western"><surname>Paras</surname><given-names>NA</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Expanding spectrum of prion diseases</article-title><source>Emerg Top Life Sci</source><year>2020</year><volume>4</volume><fpage>155</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1042/ETLS20200037</pub-id><pub-id pub-id-type="pmid">32803268</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babelhadj</surname><given-names>B</given-names></name><name name-style="western"><surname>Di Bari</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pirisinu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chiappini</surname><given-names>B</given-names></name><name name-style="western"><surname>Gaouar</surname><given-names>SBS</given-names></name><name name-style="western"><surname>Riccardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Marcon</surname><given-names>S</given-names></name><name name-style="western"><surname>Agrimi</surname><given-names>U</given-names></name><name name-style="western"><surname>Nonno</surname><given-names>R</given-names></name><name name-style="western"><surname>Vaccari</surname><given-names>G</given-names></name></person-group><article-title>Prion disease in dromedary camels, algeria</article-title><source>Emerg Infect Dis</source><year>2018</year><volume>24</volume><fpage>1029</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.3201/eid2406.172007</pub-id><pub-id pub-id-type="pmid">29652245</pub-id><pub-id pub-id-type="pmcid">PMC6004840</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachy</surname><given-names>V</given-names></name><name name-style="western"><surname>Ballerini</surname><given-names>C</given-names></name><name name-style="western"><surname>Gourdain</surname><given-names>P</given-names></name><name name-style="western"><surname>Prignon</surname><given-names>A</given-names></name><name name-style="western"><surname>Iken</surname><given-names>S</given-names></name><name name-style="western"><surname>Antoine</surname><given-names>N</given-names></name><name name-style="western"><surname>Rosset</surname><given-names>M</given-names></name><name name-style="western"><surname>Carnaud</surname><given-names>C</given-names></name></person-group><article-title>Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie</article-title><source>J Gen Virol</source><year>2010</year><volume>91</volume><fpage>809</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1099/vir.0.013417-0</pub-id><pub-id pub-id-type="pmid">19864503</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bade</surname><given-names>S</given-names></name><name name-style="western"><surname>Baier</surname><given-names>M</given-names></name><name name-style="western"><surname>Boetel</surname><given-names>T</given-names></name><name name-style="western"><surname>Frey</surname><given-names>A</given-names></name></person-group><article-title>Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired bovine spongiform encephalopathy</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>1242</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.051</pub-id><pub-id pub-id-type="pmid">16455168</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barria</surname><given-names>MA</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name><name name-style="western"><surname>Gambetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Mastrianni</surname><given-names>JA</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C</given-names></name></person-group><article-title>Generation of a new form of human PrP(Sc) in vitro by interspecies transmission from cervid prions</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>7490</fpage><lpage>7495</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.198465</pub-id><pub-id pub-id-type="pmid">21209079</pub-id><pub-id pub-id-type="pmcid">PMC3045004</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartz</surname><given-names>JC</given-names></name><name name-style="western"><surname>Dejoia</surname><given-names>C</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>T</given-names></name><name name-style="western"><surname>Kincaid</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name></person-group><article-title>Extraneural prion neuroinvasion without lymphoreticular system infection</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>11858</fpage><lpage>11863</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.18.11858-11863.2005</pub-id><pub-id pub-id-type="pmid">16140762</pub-id><pub-id pub-id-type="pmcid">PMC1212615</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basu</surname><given-names>U</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>LM</given-names></name><name name-style="western"><surname>Dudas</surname><given-names>S</given-names></name><name name-style="western"><surname>Graham</surname><given-names>CE</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S</given-names></name><name name-style="western"><surname>Moore</surname><given-names>SS</given-names></name><name name-style="western"><surname>Guan</surname><given-names>LL</given-names></name></person-group><article-title>Gene expression alterations in Rocky Mountain elk infected with chronic wasting disease</article-title><source>Prion</source><year>2012</year><volume>6</volume><fpage>282</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.4161/pri.19915</pub-id><pub-id pub-id-type="pmid">22561165</pub-id><pub-id pub-id-type="pmcid">PMC3399530</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beekes</surname><given-names>M</given-names></name></person-group><article-title>The neural gut-brain axis of pathological protein aggregation in Parkinson&#8217;s disease and its counterpart in peroral prion infections</article-title><source>Viruses</source><year>2021</year><volume>3</volume><fpage>1394</fpage><pub-id pub-id-type="doi">10.3390/v13071394</pub-id><pub-id pub-id-type="pmcid">PMC8310171</pub-id><pub-id pub-id-type="pmid">34372600</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beekes</surname><given-names>M</given-names></name><name name-style="western"><surname>McBride</surname><given-names>PA</given-names></name></person-group><article-title>The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies</article-title><source>FEBS J</source><year>2007</year><volume>274</volume><fpage>588</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.05631.x</pub-id><pub-id pub-id-type="pmid">17288548</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name><name name-style="western"><surname>Arsac</surname><given-names>JN</given-names></name><name name-style="western"><surname>Goldmann</surname><given-names>W</given-names></name><name name-style="western"><surname>N&#246;remark</surname><given-names>M</given-names></name></person-group><article-title>Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology</article-title><source>Vet Res</source><year>2008</year><volume>39</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1051/vetres:2007056</pub-id><pub-id pub-id-type="pmid">18187032</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>G</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M</given-names></name><name name-style="western"><surname>Ytrehus</surname><given-names>B</given-names></name><name name-style="western"><surname>Vik&#248;ren</surname><given-names>T</given-names></name></person-group><article-title>First case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer</article-title><source>Vet Res</source><year>2016</year><volume>47</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s13567-016-0375-4</pub-id><pub-id pub-id-type="pmid">27641251</pub-id><pub-id pub-id-type="pmcid">PMC5024462</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Chronic wasting disease: an evolving prion disease of cervids</article-title><source>Handb Clin Neurol</source><year>2018</year><volume>153</volume><fpage>135</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63945-5.00008-8</pub-id><pub-id pub-id-type="pmid">29887133</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;ringue</surname><given-names>V</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>L</given-names></name><name name-style="western"><surname>Jaumain</surname><given-names>E</given-names></name><name name-style="western"><surname>Reine</surname><given-names>F</given-names></name><name name-style="western"><surname>Sibille</surname><given-names>P</given-names></name><name name-style="western"><surname>Le Dur</surname><given-names>A</given-names></name><name name-style="western"><surname>Vilotte</surname><given-names>JL</given-names></name><name name-style="western"><surname>Laude</surname><given-names>H</given-names></name></person-group><article-title>Facilitated crossspecies transmission of prions in extraneural tissue</article-title><source>Science</source><year>2012</year><volume>335</volume><fpage>472</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1126/science.1215659</pub-id><pub-id pub-id-type="pmid">22282814</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;ringue</surname><given-names>V</given-names></name><name name-style="western"><surname>Vilotte</surname><given-names>JL</given-names></name><name name-style="western"><surname>Laude</surname><given-names>H</given-names></name></person-group><article-title>Prion agent diversity and species barrier</article-title><source>Vet Res</source><year>2008</year><volume>39</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1051/vetres:2008024</pub-id><pub-id pub-id-type="pmid">18519020</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>DB</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><name name-style="western"><surname>Geva</surname><given-names>M</given-names></name><name name-style="western"><surname>Watts</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>S</given-names></name><name name-style="western"><surname>Oehler</surname><given-names>A</given-names></name><name name-style="western"><surname>Renslo</surname><given-names>AR</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name><name name-style="western"><surname>Giles</surname><given-names>K</given-names></name></person-group><article-title>Drug resistance confounding prion therapeutics</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>E4160</fpage><lpage>E4169</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317164110</pub-id><pub-id pub-id-type="pmid">24128760</pub-id><pub-id pub-id-type="pmcid">PMC3816483</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kocisko</surname><given-names>DA</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Nandan</surname><given-names>S</given-names></name><name name-style="western"><surname>Lansbury</surname><given-names>PT</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name></person-group><article-title>Non-genetic propagation of strain-specific properties of scrapie prion protein</article-title><source>Nature</source><year>1995</year><volume>375</volume><fpage>698</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1038/375698a0</pub-id><pub-id pub-id-type="pmid">7791905</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>RF</given-names></name></person-group><article-title>Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent</article-title><source>J Virol</source><year>1992</year><volume>66</volume><fpage>2096</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1128/jvi.66.4.2096-2101.1992</pub-id><pub-id pub-id-type="pmid">1347795</pub-id><pub-id pub-id-type="pmcid">PMC289000</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Shearin</surname><given-names>H</given-names></name><name name-style="western"><surname>Martinka</surname><given-names>S</given-names></name><name name-style="western"><surname>Boharski</surname><given-names>R</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>D</given-names></name><name name-style="western"><surname>Wilham</surname><given-names>JM</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>JA</given-names></name></person-group><article-title>Prion shedding from olfactory neurons into nasal secretions</article-title><source>PLoS Pathog</source><year>2010</year><volume>15</volume><fpage>e1000837</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000837</pub-id><pub-id pub-id-type="pmcid">PMC2855443</pub-id><pub-id pub-id-type="pmid">20419120</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>J</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>JR</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kane</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Khaychuk</surname><given-names>V</given-names></name><name name-style="western"><surname>Gallegos</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Primary structural differences at residue 226 of deer and elk PrP dictate selection of distinct CWD prion strains in gene-targeted mice</article-title><source>Proc Natl Acad Sci USA</source><year>2019</year><volume>116</volume><fpage>12478</fpage><lpage>12487</lpage><pub-id pub-id-type="doi">10.1073/pnas.1903947116</pub-id><pub-id pub-id-type="pmid">31147460</pub-id><pub-id pub-id-type="pmcid">PMC6589652</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>HE</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Quinacrine promotes replication and conformational mutation of chronic wasting disease prions</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>6028</fpage><lpage>6033</lpage><pub-id pub-id-type="doi">10.1073/pnas.1322377111</pub-id><pub-id pub-id-type="pmid">24711410</pub-id><pub-id pub-id-type="pmcid">PMC4000840</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Kane</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Crowell</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>JL</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>J</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>E</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>JA</given-names></name><name name-style="western"><surname>DiLisio</surname><given-names>J</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>E</given-names></name><name name-style="western"><surname>Pritzkow</surname><given-names>S</given-names></name><name name-style="western"><surname>Gorski</surname><given-names>D</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C</given-names></name><name name-style="western"><surname>Kreeger</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>A</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>G</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Nonno</surname><given-names>R</given-names></name><name name-style="western"><surname>Vik&#248;ren</surname><given-names>T</given-names></name><name name-style="western"><surname>V&#229;ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Madslien</surname><given-names>K</given-names></name><name name-style="western"><surname>Tran</surname><given-names>L</given-names></name><name name-style="western"><surname>Vuong</surname><given-names>TT</given-names></name><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Adaptive selection of a prion strain conformer corresponding to established North American CWD during propagation of novel emergent Norwegian strains in mice expressing elk or deer prion protein</article-title><source>PLoS Pathog</source><year>2021</year><volume>17</volume><issue>7</issue><fpage>e1009748</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1009748</pub-id><pub-id pub-id-type="pmid">34310663</pub-id><pub-id pub-id-type="pmcid">PMC8341702</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>J</given-names></name><name name-style="western"><surname>Napier</surname><given-names>D</given-names></name><name name-style="western"><surname>Khaychuck</surname><given-names>V</given-names></name><name name-style="western"><surname>Angers</surname><given-names>R</given-names></name><name name-style="western"><surname>Graham</surname><given-names>C</given-names></name><name name-style="western"><surname>Telling</surname><given-names>G</given-names></name></person-group><article-title>Cell-based quantification of chronic wasting disease prions</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>8322</fpage><lpage>8326</lpage><pub-id pub-id-type="doi">10.1128/JVI.00633-10</pub-id><pub-id pub-id-type="pmid">20519392</pub-id><pub-id pub-id-type="pmcid">PMC2916541</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boujon</surname><given-names>C</given-names></name><name name-style="western"><surname>Serra</surname><given-names>F</given-names></name><name name-style="western"><surname>Seuberlich</surname><given-names>T</given-names></name></person-group><article-title>Atypical variants of bovine spongiform encephalopathy: rare diseases with consequences for BSE surveillance and control</article-title><source>Schweiz Arch Tierheilkd</source><year>2016</year><volume>158</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.17236/sat00053</pub-id><pub-id pub-id-type="pmid">27518312</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Potential pathways of abnormal tau and &#945;-synuclein dissemination in sporadic Alzheimer&#8217;s and Parkinson&#8217;s diseases</article-title><source>Cold Spring Harb Perspect Biol</source><year>2016</year><volume>8</volume><issue>11</issue><fpage>a023630</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a023630</pub-id><pub-id pub-id-type="pmid">27580631</pub-id><pub-id pub-id-type="pmcid">PMC5088528</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>P</given-names></name><name name-style="western"><surname>Preece</surname><given-names>M</given-names></name><name name-style="western"><surname>Brandel</surname><given-names>JP</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T</given-names></name><name name-style="western"><surname>McShane</surname><given-names>L</given-names></name><name name-style="western"><surname>Zerr</surname><given-names>I</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>A</given-names></name><name name-style="western"><surname>Will</surname><given-names>RG</given-names></name><name name-style="western"><surname>Pocchiari</surname><given-names>M</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>NR</given-names></name><name name-style="western"><surname>d'Aignaux</surname><given-names>JH</given-names></name><name name-style="western"><surname>Cerven&#225;kov&#225;</surname><given-names>L</given-names></name><name name-style="western"><surname>Fradkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Schonberger</surname><given-names>LB</given-names></name><name name-style="western"><surname>Collins</surname><given-names>SJ</given-names></name></person-group><article-title>Iatrogenic Creutzfeldt-Jakob disease at the millennium</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>1075</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1212/WNL.55.8.1075</pub-id><pub-id pub-id-type="pmid">11071481</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browning</surname><given-names>SR</given-names></name><name name-style="western"><surname>Mason</surname><given-names>GL</given-names></name><name name-style="western"><surname>Seward</surname><given-names>T</given-names></name><name name-style="western"><surname>Green</surname><given-names>M</given-names></name><name name-style="western"><surname>Eliason</surname><given-names>GA</given-names></name><name name-style="western"><surname>Mathiason</surname><given-names>C</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Williams</surname><given-names>ES</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>E</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid PrP</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>13345</fpage><lpage>13350</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.23.13345-13350.2004</pub-id><pub-id pub-id-type="pmid">15542685</pub-id><pub-id pub-id-type="pmcid">PMC524991</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruce</surname><given-names>ME</given-names></name><name name-style="western"><surname>Will</surname><given-names>RG</given-names></name><name name-style="western"><surname>Ironside</surname><given-names>JW</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>I</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>D</given-names></name><name name-style="western"><surname>Suttie</surname><given-names>A</given-names></name><name name-style="western"><surname>McCardle</surname><given-names>L</given-names></name><name name-style="western"><surname>Chree</surname><given-names>A</given-names></name><name name-style="western"><surname>Hope</surname><given-names>J</given-names></name><name name-style="western"><surname>Birkett</surname><given-names>C</given-names></name><name name-style="western"><surname>Cousens</surname><given-names>S</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>H</given-names></name><name name-style="western"><surname>Bostock</surname><given-names>CJ</given-names></name></person-group><article-title>Transmissions to mice indicate that &#8216;new variant&#8217; CJD is caused by the BSE agent</article-title><source>Nature</source><year>2007</year><volume>389</volume><fpage>498</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/39057</pub-id><pub-id pub-id-type="pmid">9333239</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Neuropathology of prion diseases</article-title><source>Br Med Bull</source><year>2003</year><volume>66</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1093/bmb/66.1.121</pub-id><pub-id pub-id-type="pmid">14522854</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bueler</surname><given-names>H</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sailer</surname><given-names>A</given-names></name><name name-style="western"><surname>Greiner</surname><given-names>RA</given-names></name><name name-style="western"><surname>Autenried</surname><given-names>P</given-names></name><name name-style="western"><surname>Aguet</surname><given-names>M</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Mice devoid of PrP are resistant to scrapie</article-title><source>Cell</source><year>1993</year><volume>73</volume><fpage>1339</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90360-3</pub-id><pub-id pub-id-type="pmid">8100741</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bueler</surname><given-names>H</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M</given-names></name><name name-style="western"><surname>Lang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bluethmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>HP</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name><name name-style="western"><surname>Aguet</surname><given-names>M</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/356577a0</pub-id><pub-id pub-id-type="pmid">1373228</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buge</surname><given-names>SL</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>E</given-names></name><name name-style="western"><surname>Alipanah</surname><given-names>S</given-names></name><name name-style="western"><surname>Markham</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalyan</surname><given-names>N</given-names></name><name name-style="western"><surname>Miller</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lubeck</surname><given-names>M</given-names></name><name name-style="western"><surname>Udem</surname><given-names>S</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>J</given-names></name><name name-style="western"><surname>Robert-Guroff</surname><given-names>M</given-names></name></person-group><article-title>An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge</article-title><source>J Virol</source><year>1997</year><volume>71</volume><fpage>8531</fpage><lpage>8541</lpage><pub-id pub-id-type="doi">10.1128/jvi.71.11.8531-8541.1997</pub-id><pub-id pub-id-type="pmid">9343211</pub-id><pub-id pub-id-type="pmcid">PMC192317</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buschmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Pfaff</surname><given-names>E</given-names></name><name name-style="western"><surname>Reifenberg</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>HM</given-names></name><name name-style="western"><surname>Groschup</surname><given-names>MH</given-names></name></person-group><article-title>Detection of cattle-derived BSE prions using transgenic mice overexpressing bovine PrP(C)</article-title><source>Arch Virol Suppl</source><year>2000</year><volume>16</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-7091-6308-5_6</pub-id><pub-id pub-id-type="pmid">11214936</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>DA</given-names></name><name name-style="western"><surname>Scott</surname><given-names>MR</given-names></name><name name-style="western"><surname>Bockman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Borchelt</surname><given-names>DR</given-names></name><name name-style="western"><surname>Taraboulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>KK</given-names></name><name name-style="western"><surname>Kingsbury</surname><given-names>DT</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins</article-title><source>J Virol</source><year>1988</year><volume>62</volume><fpage>1558</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1128/jvi.62.5.1558-1564.1988</pub-id><pub-id pub-id-type="pmid">3282080</pub-id><pub-id pub-id-type="pmcid">PMC253182</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capellari</surname><given-names>S</given-names></name><name name-style="western"><surname>Strammiello</surname><given-names>R</given-names></name><name name-style="western"><surname>Saverioni</surname><given-names>D</given-names></name><name name-style="western"><surname>Kretzschmar</surname><given-names>H</given-names></name><name name-style="western"><surname>Parchi</surname><given-names>P</given-names></name></person-group><article-title>Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis</article-title><source>Acta Neuropathol</source><year>2011</year><volume>121</volume><fpage>21</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0760-4</pub-id><pub-id pub-id-type="pmid">20978903</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlson</surname><given-names>GA</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Torchia</surname><given-names>M</given-names></name><name name-style="western"><surname>Westaway</surname><given-names>D</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Genetics of prion diseases and prion diversity in mice</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>1994</year><volume>343</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1098/rstb.1994.0030</pub-id><pub-id pub-id-type="pmid">7913753</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carta</surname><given-names>M</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Molecular foundations of prion strain diversity</article-title><source>Curr Opin Neurobiol</source><year>2022</year><volume>72</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2021.07.010</pub-id><pub-id pub-id-type="pmid">34416480</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casalone</surname><given-names>C</given-names></name><name name-style="western"><surname>Zanusso</surname><given-names>G</given-names></name><name name-style="western"><surname>Acutis</surname><given-names>P</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>S</given-names></name><name name-style="western"><surname>Capucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Tagliavini</surname><given-names>F</given-names></name><name name-style="western"><surname>Monaco</surname><given-names>S</given-names></name><name name-style="western"><surname>Caramelli</surname><given-names>M</given-names></name></person-group><article-title>Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>3065</fpage><lpage>3070</lpage><pub-id pub-id-type="doi">10.1073/pnas.0305777101</pub-id><pub-id pub-id-type="pmid">14970340</pub-id><pub-id pub-id-type="pmcid">PMC365745</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cashman</surname><given-names>NR</given-names></name><name name-style="western"><surname>Loertscher</surname><given-names>R</given-names></name><name name-style="western"><surname>Nalbantoglu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>I</given-names></name><name name-style="western"><surname>Kascsak</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>DC</given-names></name><name name-style="western"><surname>Bendheim</surname><given-names>PE</given-names></name></person-group><article-title>Cellular isoform of the scrapie agent protein participates in lymphocyte activation</article-title><source>Cell</source><year>1990</year><volume>61</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90225-4</pub-id><pub-id pub-id-type="pmid">1969332</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Prion strain mutation and selection</article-title><source>Science</source><year>2010</year><volume>328</volume><fpage>1111</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1126/science.1190815</pub-id><pub-id pub-id-type="pmid">20508117</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>AR</given-names></name></person-group><article-title>A general model of prion strains and their pathogenicity</article-title><source>Science</source><year>2007</year><volume>318</volume><fpage>930</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1126/science.1138718</pub-id><pub-id pub-id-type="pmid">17991853</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jones</surname><given-names>DR</given-names></name><name name-style="western"><surname>Tayebi</surname><given-names>M</given-names></name></person-group><article-title>Potential candidate camelid antibodies for the treatment of protein-misfolding diseases</article-title><source>J Neuroimmunol</source><year>2014</year><volume>272</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2014.05.001</pub-id><pub-id pub-id-type="pmid">24864011</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>SL</given-names></name><name name-style="western"><surname>Cayetano-Canlas</surname><given-names>J</given-names></name><name name-style="western"><surname>Groth</surname><given-names>D</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>The neuropathological phenotype in transgenic mice expressing different prion protein constructs</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>1994</year><volume>43</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.1994.0038</pub-id><pub-id pub-id-type="pmid">7913760</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMagistris</surname><given-names>MT</given-names></name></person-group><article-title>Mucosal delivery of vaccine antigens and its advantages in pediatrics</article-title><source>Adv Drug Deliv Rev</source><year>2006</year><volume>58</volume><fpage>52</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2006.01.002</pub-id><pub-id pub-id-type="pmid">16516335</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMarco</surname><given-names>ML</given-names></name><name name-style="western"><surname>Daggett</surname><given-names>V</given-names></name></person-group><article-title>From conversion to aggregation: protofibril formation of the prion protein</article-title><source>PNAS</source><year>2004</year><volume>101</volume><fpage>2293</fpage><lpage>2298</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307178101</pub-id><pub-id pub-id-type="pmid">14983003</pub-id><pub-id pub-id-type="pmcid">PMC356944</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVivo</surname><given-names>MT</given-names></name><name name-style="western"><surname>Edmunds</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schumaker</surname><given-names>BA</given-names></name><name name-style="western"><surname>Binfet</surname><given-names>J</given-names></name><name name-style="western"><surname>Kreeger</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Richards</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Cornish</surname><given-names>TE</given-names></name></person-group><article-title>Endemic chronic wasting disease causes mule deer population decline in Wyoming</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><issue>10</issue><fpage>e0186512</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0186512</pub-id><pub-id pub-id-type="pmid">29049389</pub-id><pub-id pub-id-type="pmcid">PMC5648191</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diack</surname><given-names>AB</given-names></name><name name-style="western"><surname>Head</surname><given-names>MW</given-names></name><name name-style="western"><surname>McCutcheon</surname><given-names>S</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>A</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R</given-names></name><name name-style="western"><surname>Ironside</surname><given-names>JW</given-names></name><name name-style="western"><surname>Manson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Will</surname><given-names>RG</given-names></name></person-group><article-title>Variant CJD. 18 years of research and surveillance</article-title><source>Prion</source><year>2014</year><volume>8</volume><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.4161/pri.29237</pub-id><pub-id pub-id-type="pmid">25495404</pub-id><pub-id pub-id-type="pmcid">PMC4601215</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiBari</surname><given-names>MA</given-names></name><name name-style="western"><surname>Nonno</surname><given-names>R</given-names></name><name name-style="western"><surname>Castilla</surname><given-names>J</given-names></name><name name-style="western"><surname>D'Agostino</surname><given-names>C</given-names></name><name name-style="western"><surname>Pirisinu</surname><given-names>L</given-names></name><name name-style="western"><surname>Riccardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Conte</surname><given-names>M</given-names></name><name name-style="western"><surname>Richt</surname><given-names>J</given-names></name><name name-style="western"><surname>Kunkle</surname><given-names>R</given-names></name><name name-style="western"><surname>Langeveld</surname><given-names>J</given-names></name><name name-style="western"><surname>Vaccari</surname><given-names>G</given-names></name><name name-style="western"><surname>Agrimi</surname><given-names>U</given-names></name></person-group><article-title>Chronic wasting disease in bank voles: characterisation of the shortest incubation time model for prion diseases</article-title><source>PLoS Pathog</source><year>2013</year><volume>9</volume><issue>3</issue><fpage>e1003219</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003219</pub-id><pub-id pub-id-type="pmid">23505374</pub-id><pub-id pub-id-type="pmcid">PMC3591354</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Stamp</surname><given-names>JT</given-names></name><name name-style="western"><surname>Renwick</surname><given-names>CC</given-names></name></person-group><article-title>Maternal and lateral transmission of scrapie in sheep</article-title><source>J Comp Pathol</source><year>1974</year><volume>84</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/0021-9975(74)90023-1</pub-id><pub-id pub-id-type="pmid">4212154</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudas</surname><given-names>S</given-names></name><name name-style="western"><surname>Czub</surname><given-names>S</given-names></name></person-group><article-title>Atypical BSE: current knowledge and knowledge gaps</article-title><source>Food Saf (tokyo)</source><year>2017</year><volume>5</volume><fpage>10</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.14252/foodsafetyfscj.2016028</pub-id><pub-id pub-id-type="pmid">32231923</pub-id><pub-id pub-id-type="pmcid">PMC6989174</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eiden</surname><given-names>M</given-names></name><name name-style="western"><surname>Gedvilaite</surname><given-names>A</given-names></name><name name-style="western"><surname>Leidel</surname><given-names>F</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>RG</given-names></name><name name-style="western"><surname>Groschup</surname><given-names>MH</given-names></name></person-group><article-title>Vaccination with prion peptide-displaying polyomavirus-like particles prolongs incubation time in scrapie-infected mice</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>811</fpage><pub-id pub-id-type="doi">10.3390/v13050811</pub-id><pub-id pub-id-type="pmid">33946367</pub-id><pub-id pub-id-type="pmcid">PMC8147134</pub-id></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisele</surname><given-names>YS</given-names></name><name name-style="western"><surname>Oberm&#252;ller</surname><given-names>U</given-names></name><name name-style="western"><surname>Heilbronner</surname><given-names>G</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>F</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wolburg</surname><given-names>H</given-names></name><name name-style="western"><surname>Walker</surname><given-names>LC</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M</given-names></name><name name-style="western"><surname>Heikenwalder</surname><given-names>M</given-names></name><name name-style="western"><surname>Jucker</surname><given-names>M</given-names></name></person-group><article-title>Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>980</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1126/science.1194516</pub-id><pub-id pub-id-type="pmid">20966215</pub-id><pub-id pub-id-type="pmcid">PMC3233904</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elder</surname><given-names>AM</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>DM</given-names></name><name name-style="western"><surname>Nalls</surname><given-names>AV</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name><name name-style="western"><surname>Kincaid</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bartz</surname><given-names>JC</given-names></name><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name></person-group><article-title>Immediate and ongoing detection of prions in the blood of hamsters and deer following oral, nasal, or blood inoculations</article-title><source>J Virol</source><year>2015</year><volume>89</volume><fpage>7421</fpage><lpage>7424</lpage><pub-id pub-id-type="doi">10.1128/JVI.00760-15</pub-id><pub-id pub-id-type="pmid">25926635</pub-id><pub-id pub-id-type="pmcid">PMC4473550</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enari</surname><given-names>M</given-names></name><name name-style="western"><surname>Flechsig</surname><given-names>E</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>9295</fpage><lpage>9299</lpage><pub-id pub-id-type="doi">10.1073/pnas.151242598</pub-id><pub-id pub-id-type="pmid">11470893</pub-id><pub-id pub-id-type="pmcid">PMC55414</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Borges</surname><given-names>N</given-names></name><name name-style="western"><surname>Brun</surname><given-names>A</given-names></name><name name-style="western"><surname>Whitton</surname><given-names>JL</given-names></name><name name-style="western"><surname>Parra</surname><given-names>B</given-names></name><name name-style="western"><surname>Diaz-San Segundo</surname><given-names>F</given-names></name><name name-style="western"><surname>Salguero</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Torres</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>F</given-names></name></person-group><article-title>DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge</article-title><source>J Virol</source><year>2006</year><volume>80</volume><issue>20</issue><fpage>9970</fpage><lpage>9976</lpage><pub-id pub-id-type="doi">10.1128/JVI.01210-06</pub-id><pub-id pub-id-type="pmid">17005675</pub-id><pub-id pub-id-type="pmcid">PMC1617305</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>A</given-names></name><name name-style="western"><surname>Tancowny</surname><given-names>B</given-names></name><name name-style="western"><surname>Telling</surname><given-names>G</given-names></name><name name-style="western"><surname>Wille</surname><given-names>H</given-names></name></person-group><article-title>Optimizing prion vaccination in a transgenic mouse model of Gerstmann-Str&#228;ussler-Scheinker disease</article-title><source>Prion</source><year>2022</year><volume>16</volume><fpage>95</fpage><lpage>253</lpage></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedland</surname><given-names>RP</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>MR</given-names></name></person-group><article-title>The role of microbial amyloid in neurodegeneration</article-title><source>PLoS Pathog</source><year>2017</year><volume>13</volume><issue>12</issue><fpage>e1006654</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1006654</pub-id><pub-id pub-id-type="pmid">29267402</pub-id><pub-id pub-id-type="pmcid">PMC5739464</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>B</given-names></name><name name-style="western"><surname>Jacks</surname><given-names>RL</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>MI</given-names></name></person-group><article-title>Propagation of tau misfolding from the outside to the inside of a cell</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>12845</fpage><lpage>12852</lpage><pub-id pub-id-type="doi">10.1074/jbc.M808759200</pub-id><pub-id pub-id-type="pmid">19282288</pub-id><pub-id pub-id-type="pmcid">PMC2676015</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>N</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Yano</surname><given-names>M</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>H</given-names></name><name name-style="western"><surname>Ootsuyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>M</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaji</surname><given-names>R</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Effects of a brain-engraftable microglial cell line expressing anti-prion scFv antibodies on survival times of mice infected with scrapie prions</article-title><source>Cell Mol Neurobiol</source><year>2011</year><volume>31</volume><fpage>999</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1007/s10571-011-9696-z</pub-id><pub-id pub-id-type="pmid">21516351</pub-id><pub-id pub-id-type="pmcid">PMC11498557</pub-id></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajdusek</surname><given-names>DC</given-names></name></person-group><article-title>Review. Kuru and its contribution to medicine</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2008</year><volume>363</volume><fpage>3697</fpage><lpage>3700</lpage><pub-id pub-id-type="doi">10.1098/rstb.2008.0070</pub-id><pub-id pub-id-type="pmid">18849284</pub-id><pub-id pub-id-type="pmcid">PMC2575417</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Parchi</surname><given-names>P</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RB</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SG</given-names></name><name name-style="western"><surname>Lugaresi</surname><given-names>E</given-names></name></person-group><article-title>Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features</article-title><source>Brain Pathol</source><year>1995</year><volume>5</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.1995.tb00576.x</pub-id><pub-id pub-id-type="pmid">7767490</pub-id></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghetti</surname><given-names>B</given-names></name><name name-style="western"><surname>Dlouhy</surname><given-names>SR</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G</given-names></name><name name-style="western"><surname>Bugiani</surname><given-names>O</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>MR</given-names></name><name name-style="western"><surname>Tagliavini</surname><given-names>F</given-names></name></person-group><article-title>Gerstmann-Str&#228;ussler-Scheinker disease and the Indiana kindred</article-title><source>Brain Pathol</source><year>1995</year><volume>15</volume><fpage>61</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.1995.tb00578.x</pub-id><pub-id pub-id-type="pmid">7767492</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Geist</surname><given-names>V</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>D</given-names></name><name name-style="western"><surname>Crichton</surname><given-names>V</given-names></name><name name-style="western"><surname>Rowledge</surname><given-names>D</given-names></name></person-group><source>The challenge of CWD: insidious and dire</source><year>2017</year><publisher-loc>Alliance for Public Wildlife</publisher-loc><publisher-name>Alliance for Public Wildlife Living Legacy Paper</publisher-name></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name><name name-style="western"><surname>Chitoor</surname><given-names>N</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>M</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name></person-group><article-title>Chronic wasting disease</article-title><source>Top Curr Chem</source><year>2011</year><volume>305</volume><fpage>51</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/128_2011_159</pub-id><pub-id pub-id-type="pmid">21598099</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name><name name-style="western"><surname>Wopfner</surname><given-names>F</given-names></name><name name-style="western"><surname>Renner-M&#252;ller</surname><given-names>I</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>C</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>E</given-names></name><name name-style="western"><surname>Brem</surname><given-names>G</given-names></name><name name-style="western"><surname>Groschup</surname><given-names>MH</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name></person-group><article-title>Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>18524</fpage><lpage>18531</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210723200</pub-id><pub-id pub-id-type="pmid">12637572</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldfarb</surname><given-names>LG</given-names></name><name name-style="western"><surname>Brown</surname><given-names>P</given-names></name><name name-style="western"><surname>Cervenakova</surname><given-names>L</given-names></name><name name-style="western"><surname>Gajdusek</surname><given-names>DC</given-names></name></person-group><article-title>Molecular genetic studies of Creutzfeldt-Jakob disease</article-title><source>Mol Neurobiol</source><year>1994</year><volume>8</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1007/BF02780658</pub-id><pub-id pub-id-type="pmid">7999318</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldmann</surname><given-names>W</given-names></name></person-group><article-title>PrP genetics in ruminant transmissible spongiform encephalopathies</article-title><source>Vet Res</source><year>2008</year><volume>39</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1051/vetres:2008010</pub-id><pub-id pub-id-type="pmid">18284908</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goedert</surname><given-names>M</given-names></name><name name-style="western"><surname>Clavaguera</surname><given-names>F</given-names></name><name name-style="western"><surname>Tolnay</surname><given-names>M</given-names></name></person-group><article-title>The propagation of prion-like protein inclusions in neurodegenerative diseases</article-title><source>Trends Neurosci</source><year>2010</year><volume>33</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2010.04.003</pub-id><pub-id pub-id-type="pmid">20493564</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goni</surname><given-names>F</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>F</given-names></name><name name-style="western"><surname>Scholtzova</surname><given-names>H</given-names></name><name name-style="western"><surname>Pankiewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Carp</surname><given-names>R</given-names></name><name name-style="western"><surname>Meeker</surname><given-names>HC</given-names></name><name name-style="western"><surname>Rubenstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Brown</surname><given-names>DR</given-names></name><name name-style="western"><surname>Sy</surname><given-names>MS</given-names></name><name name-style="western"><surname>Chabalgoity</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sigurdsson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T</given-names></name></person-group><article-title>Mucosal vaccination delays or prevents prion infection via an oral route</article-title><source>Neurosci</source><year>2005</year><volume>133</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.02.031</pub-id><pub-id pub-id-type="pmid">15878645</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goni</surname><given-names>F</given-names></name><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name><name name-style="western"><surname>YimL</surname><given-names>WK</given-names></name><name name-style="western"><surname>Hayes-Klug</surname><given-names>J</given-names></name><name name-style="western"><surname>Nalls</surname><given-names>A</given-names></name><name name-style="western"><surname>Peyser</surname><given-names>D</given-names></name><name name-style="western"><surname>Estevez</surname><given-names>V</given-names></name><name name-style="western"><surname>Denkers</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>DA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KV</given-names></name><name name-style="western"><surname>Warren</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Brown</surname><given-names>DR</given-names></name><name name-style="western"><surname>Chabalgoity</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T</given-names></name></person-group><article-title>Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>726</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.11.035</pub-id><pub-id pub-id-type="pmid">25539804</pub-id><pub-id pub-id-type="pmcid">PMC4304998</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goni</surname><given-names>F</given-names></name><name name-style="western"><surname>Prelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>F</given-names></name><name name-style="western"><surname>Scholtzova</surname><given-names>H</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><name name-style="western"><surname>Kascsak</surname><given-names>R</given-names></name><name name-style="western"><surname>Brown</surname><given-names>DR</given-names></name><name name-style="western"><surname>Sigurdsson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Chabalgoity</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T</given-names></name></person-group><article-title>High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice</article-title><source>Neuroscience</source><year>2008</year><volume>15</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.02.051</pub-id><pub-id pub-id-type="pmcid">PMC2474749</pub-id><pub-id pub-id-type="pmid">18407424</pub-id></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Cano</surname><given-names>P</given-names></name><name name-style="western"><surname>Gamage</surname><given-names>L</given-names></name><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>S</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P</given-names></name></person-group><article-title>Lambda display phage as a mucosal vaccine delivery vehicle for peptide antigens</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>7256</fpage><lpage>7263</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.11.010</pub-id><pub-id pub-id-type="pmid">29153779</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gossert</surname><given-names>AD</given-names></name><name name-style="western"><surname>Bonjour</surname><given-names>S</given-names></name><name name-style="western"><surname>Lysek</surname><given-names>DA</given-names></name><name name-style="western"><surname>Fiorito</surname><given-names>F</given-names></name><name name-style="western"><surname>W&#252;thrich</surname><given-names>K</given-names></name></person-group><article-title>Prion protein NMR structures of elk and of mouse/elk hybrids</article-title><source>Proc Nat Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409008102</pub-id><pub-id pub-id-type="pmid">15647363</pub-id><pub-id pub-id-type="pmcid">PMC545551</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gourdain</surname><given-names>P</given-names></name><name name-style="western"><surname>Gregoire</surname><given-names>S</given-names></name><name name-style="western"><surname>Iken</surname><given-names>S</given-names></name><name name-style="western"><surname>Bachy</surname><given-names>V</given-names></name><name name-style="western"><surname>Dorban</surname><given-names>G</given-names></name><name name-style="western"><surname>Chaigneau</surname><given-names>T</given-names></name><name name-style="western"><surname>Debiec</surname><given-names>H</given-names></name><name name-style="western"><surname>Bergot</surname><given-names>A</given-names></name><name name-style="western"><surname>Renault</surname><given-names>I</given-names></name><name name-style="western"><surname>Aucouturier</surname><given-names>P</given-names></name><name name-style="western"><surname>Carnaud</surname><given-names>C</given-names></name></person-group><article-title>Adoptive transfer of T lymphocytes sensitized against the prion protein attenuates prion invasion in scrapie-infected mice</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>6619</fpage><lpage>6628</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0804385</pub-id><pub-id pub-id-type="pmid">19846876</pub-id></element-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groschup</surname><given-names>MH</given-names></name><name name-style="western"><surname>Buschmann</surname><given-names>A</given-names></name></person-group><article-title>Rodent models for prion diseases</article-title><source>Vet Res</source><year>2008</year><volume>39</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1051/vetres:2008008</pub-id><pub-id pub-id-type="pmid">18284909</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadlow</surname><given-names>WJ</given-names></name></person-group><article-title>Reflections on the transmissible spongiform encephalopathies</article-title><source>Vet Pathol</source><year>1999</year><volume>36</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1354/vp.36-6-523</pub-id><pub-id pub-id-type="pmid">10568433</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haley</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name><name name-style="western"><surname>Carver</surname><given-names>S</given-names></name><name name-style="western"><surname>Zabel</surname><given-names>M</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name></person-group><article-title>Detection of chronic wasting disease prions in salivary, urinary, and intestinal tissues of deer: potential mechanisms of prion shedding and transmission</article-title><source>J Virol</source><year>2011</year><volume>85</volume><fpage>6309</fpage><lpage>6318</lpage><pub-id pub-id-type="doi">10.1128/JVI.00425-11</pub-id><pub-id pub-id-type="pmid">21525361</pub-id><pub-id pub-id-type="pmcid">PMC3126547</pub-id></element-citation></ref><ref id="CR90"><mixed-citation publication-type="other">Haley NJ, Mathiason CK, Zabel MD, Telling GC, Hoover EA (2009) Detection of sub-clinical CWD infection in conventional test-negative deer long after oral exposure to urine and feces from CWD+ deer.&#160;PLoS One 4(11):e7990<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0007990</pub-id><pub-id pub-id-type="pmcid">PMC2776529</pub-id><pub-id pub-id-type="pmid">19956732</pub-id></mixed-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haley</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Richt</surname><given-names>JA</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>KA</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name><name name-style="western"><surname>Manca</surname><given-names>M</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name><name name-style="western"><surname>Marthaler</surname><given-names>D</given-names></name><name name-style="western"><surname>Bartz</surname><given-names>J</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name></person-group><article-title>Design, implementation, and interpretation of amplification studies for prion detection</article-title><source>Prion</source><year>2018</year><volume>12</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1080/19336896.2018.1443000</pub-id><pub-id pub-id-type="pmid">29468946</pub-id><pub-id pub-id-type="pmcid">PMC6016519</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>SB</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S</given-names></name><name name-style="western"><surname>Marovich</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ubol</surname><given-names>S</given-names></name><name name-style="western"><surname>Mosser</surname><given-names>DM</given-names></name></person-group><article-title>Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes</article-title><source>Lancet Infect Dis</source><year>2010</year><volume>10</volume><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(10)70166-3</pub-id><pub-id pub-id-type="pmid">20883967</pub-id><pub-id pub-id-type="pmcid">PMC3057165</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamir</surname><given-names>AN</given-names></name><name name-style="western"><surname>Kehrli</surname><given-names>ME</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Kunkle</surname><given-names>RA</given-names></name><name name-style="western"><surname>Greenlee</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>EM</given-names></name><name name-style="western"><surname>Richt</surname><given-names>JA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cutlip</surname><given-names>RC</given-names></name></person-group><article-title>Experimental interspecies transmission studies of the transmissible spongiform encephalopathies to cattle: comparison to bovine spongiform encephalopathy in cattle</article-title><source>J Vet Diagn Invest</source><year>2011</year><volume>23</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1177/1040638711403404</pub-id><pub-id pub-id-type="pmid">21908269</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name></person-group><article-title>Immune responses in wild-type mice against prion proteins induced using a DNA prime-protein boost strategy</article-title><source>Biomed Environ Sci</source><year>2011</year><volume>24</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">22108419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3967/0895-3988.2011.05.011</pub-id></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handisurya</surname><given-names>A</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name><name name-style="western"><surname>Winter</surname><given-names>D</given-names></name><name name-style="western"><surname>Shafti-Keramat</surname><given-names>S</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>D</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Kirnbauer</surname><given-names>R</given-names></name></person-group><article-title>Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells</article-title><source>FEBS J</source><year>2007</year><volume>274</volume><fpage>1747</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.05721.x</pub-id><pub-id pub-id-type="pmid">17313482</pub-id><pub-id pub-id-type="pmcid">PMC3792370</pub-id></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannaoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name></person-group><article-title>Chronic wasting disease: emerging prions and their potential risk</article-title><source>PLoS Pathog</source><year>2017</year><volume>13</volume><issue>11</issue><fpage>e1006619</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1006619</pub-id><pub-id pub-id-type="pmid">29095921</pub-id><pub-id pub-id-type="pmcid">PMC5667731</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannaoui</surname><given-names>S</given-names></name><name name-style="western"><surname>Zemlyankina</surname><given-names>I</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Arifin</surname><given-names>MI</given-names></name><name name-style="western"><surname>B&#233;ringue</surname><given-names>V</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>D</given-names></name><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name></person-group><article-title>Transmission of cervid prions to humanized mice demonstrates the zoonotic potential of CWD</article-title><source>Acta Neuropathol</source><year>2022</year><volume>144</volume><issue>4</issue><fpage>767</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1007/s00401-022-02482-9</pub-id><pub-id pub-id-type="pmid">35996016</pub-id><pub-id pub-id-type="pmcid">PMC9468132</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawkes</surname><given-names>CH</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K</given-names></name><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name></person-group><article-title>Parkinson&#8217;s disease: the dual hit theory revisited</article-title><source>Ann N Y Acad Sci</source><year>2009</year><volume>1170</volume><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04365.x</pub-id><pub-id pub-id-type="pmid">19686202</pub-id></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedlin</surname><given-names>P</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>J</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Design and delivery of a cryptic PrP<sup>C</sup> epitope for induction of PrP<sup>Sc</sup>-specific antibody responses</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>981</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.134</pub-id><pub-id pub-id-type="pmid">19925901</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hegazy</surname><given-names>WA</given-names></name><name name-style="western"><surname>Hensel</surname><given-names>M</given-names></name></person-group><article-title>Salmonella enterica as a vaccine carrier</article-title><source>Future Microbiol</source><year>2012</year><volume>7</volume><fpage>111</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.2217/fmb.11.144</pub-id><pub-id pub-id-type="pmid">22191450</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heiseke</surname><given-names>A</given-names></name><name name-style="western"><surname>Aguib</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name></person-group><article-title>Autophagy, prion infection and their mutual interactions</article-title><source>Curr Issues Mol Biol</source><year>2010</year><volume>12</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">19767652</pub-id></element-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>DM</given-names></name><name name-style="western"><surname>Manca</surname><given-names>M</given-names></name><name name-style="western"><surname>Haley</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Denkers</surname><given-names>ND</given-names></name><name name-style="western"><surname>Nalls</surname><given-names>AV</given-names></name><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name></person-group><article-title>Rapid antemortem detection of CWD prions in deer saliva</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>9</issue><fpage>e74377</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0074377</pub-id><pub-id pub-id-type="pmid">24040235</pub-id><pub-id pub-id-type="pmcid">PMC3770611</pub-id></element-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heppner</surname><given-names>FL</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Recent developments in prion immunotherapy</article-title><source>Curr Opin Immunol</source><year>2004</year><volume>16</volume><fpage>594</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2004.07.008</pub-id><pub-id pub-id-type="pmid">15342005</pub-id></element-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heppner</surname><given-names>FL</given-names></name><name name-style="western"><surname>Musahl</surname><given-names>AI</given-names></name><name name-style="western"><surname>Klein</surname><given-names>MA</given-names></name><name name-style="western"><surname>R&#252;licke</surname><given-names>T</given-names></name><name name-style="western"><surname>Oesch</surname><given-names>B</given-names></name><name name-style="western"><surname>Zinkernagel</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kalinke</surname><given-names>U</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1126/science.1063093</pub-id><pub-id pub-id-type="pmid">11546838</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermann</surname><given-names>P</given-names></name><name name-style="western"><surname>Appleby</surname><given-names>B</given-names></name><name name-style="western"><surname>Brandel</surname><given-names>JP</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S</given-names></name><name name-style="western"><surname>Geschwind</surname><given-names>MD</given-names></name><name name-style="western"><surname>Green</surname><given-names>A</given-names></name><name name-style="western"><surname>Ha&#239;k</surname><given-names>S</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>GG</given-names></name><name name-style="western"><surname>Ladogana</surname><given-names>A</given-names></name><name name-style="western"><surname>Llorens</surname><given-names>F</given-names></name><name name-style="western"><surname>Mead</surname><given-names>S</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>N</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S</given-names></name><name name-style="western"><surname>Parchi</surname><given-names>P</given-names></name><name name-style="western"><surname>Pocchiari</surname><given-names>M</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>K</given-names></name><name name-style="western"><surname>Zanusso</surname><given-names>G</given-names></name><name name-style="western"><surname>Zerr</surname><given-names>I</given-names></name></person-group><article-title>Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease</article-title><source>Lancet Neurol</source><year>2021</year><volume>20</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30477-4</pub-id><pub-id pub-id-type="pmid">33609480</pub-id><pub-id pub-id-type="pmcid">PMC8285036</pub-id></element-citation></ref><ref id="CR106"><mixed-citation publication-type="other">Heum&#252;ller SE, Hornberger AC, Hebestreit AS, Hossinger A, Vorberg IM (2022) Propagation and dissemination strategies of transmissible spongiform encephalopathy agents in mammalian cells.&#160;Int J Mol Sci 23:2909<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23062909</pub-id><pub-id pub-id-type="pmcid">PMC8949484</pub-id><pub-id pub-id-type="pmid">35328330</pub-id></mixed-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>AF</given-names></name><name name-style="western"><surname>Butterworth</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Joiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>G</given-names></name><name name-style="western"><surname>Rossor</surname><given-names>MN</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Frosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>N</given-names></name><name name-style="western"><surname>Bell</surname><given-names>JE</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>M</given-names></name><name name-style="western"><surname>King</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Sarraj</surname><given-names>S</given-names></name><name name-style="western"><surname>Ironside</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lantos</surname><given-names>PL</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)12075-5</pub-id><pub-id pub-id-type="pmid">9923873</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>AF</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Strain variations and species barriers</article-title><source>Contrib Microbiol</source><year>2001</year><volume>7</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1159/000060375</pub-id><pub-id pub-id-type="pmid">11923935</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>AF</given-names></name><name name-style="western"><surname>Desbruslais</surname><given-names>M</given-names></name><name name-style="western"><surname>Joiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Sidle</surname><given-names>KC</given-names></name><name name-style="western"><surname>Gowland</surname><given-names>I</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name><name name-style="western"><surname>Doey</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Lantos</surname><given-names>P</given-names></name></person-group><article-title>The same prion strain causes vCJD and BSE</article-title><source>Nature</source><year>1997</year><volume>2</volume><fpage>448</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/38925</pub-id><pub-id pub-id-type="pmid">9333232</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodyra-Stefaniak</surname><given-names>K</given-names></name><name name-style="western"><surname>Miernikiewicz</surname><given-names>P</given-names></name><name name-style="western"><surname>Drapala</surname><given-names>J</given-names></name><name name-style="western"><surname>Drab</surname><given-names>M</given-names></name><name name-style="western"><surname>Jonczyk-Matysiak</surname><given-names>E</given-names></name><name name-style="western"><surname>Lecion</surname><given-names>D</given-names></name><name name-style="western"><surname>Ka&#378;mierczak</surname><given-names>Z</given-names></name><name name-style="western"><surname>Beta</surname><given-names>W</given-names></name><name name-style="western"><surname>Majewska</surname><given-names>J</given-names></name><name name-style="western"><surname>Harhala</surname><given-names>M</given-names></name><name name-style="western"><surname>Bubak</surname><given-names>B</given-names></name><name name-style="western"><surname>K&#322;opot</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#243;rski</surname><given-names>A</given-names></name><name name-style="western"><surname>D&#261;browska</surname><given-names>K</given-names></name></person-group><article-title>Mammalian host-versus-phage immune response determines phage fate in vivo</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>14802</fpage><pub-id pub-id-type="doi">10.1038/srep14802</pub-id><pub-id pub-id-type="pmid">26440922</pub-id><pub-id pub-id-type="pmcid">PMC4594097</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Denner</surname><given-names>P</given-names></name><name name-style="western"><surname>Nussbaum-Krammer</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>PH</given-names></name><name name-style="western"><surname>Suhre</surname><given-names>MH</given-names></name><name name-style="western"><surname>Scheibel</surname><given-names>T</given-names></name><name name-style="western"><surname>Lichtenthaler</surname><given-names>SF</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Bano</surname><given-names>D</given-names></name><name name-style="western"><surname>Vorberg</surname><given-names>IM</given-names></name></person-group><article-title>Cell-to-cell propagation of infectious cytosolic protein aggregates</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>5951</fpage><lpage>5956</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217321110</pub-id><pub-id pub-id-type="pmid">23509289</pub-id><pub-id pub-id-type="pmcid">PMC3625284</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunter</surname><given-names>N</given-names></name></person-group><article-title>Natural transmission and genetic control of susceptibility of sheep to scrapie</article-title><source>Curr Top Microbiol Immunol</source><year>1991</year><volume>172</volume><fpage>165</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">1810708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-642-76540-7_11</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igel-Egalon</surname><given-names>A</given-names></name><name name-style="western"><surname>Bohl</surname><given-names>J</given-names></name><name name-style="western"><surname>Moudjou</surname><given-names>M</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>L</given-names></name><name name-style="western"><surname>Reine</surname><given-names>F</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>H</given-names></name><name name-style="western"><surname>B&#233;ringue</surname><given-names>V</given-names></name></person-group><article-title>Heterogeneity and architecture of pathological prion protein assemblies: time to revisit the molecular basis of the prion replication process?</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>429</fpage><pub-id pub-id-type="doi">10.3390/v11050429</pub-id><pub-id pub-id-type="pmid">31083283</pub-id><pub-id pub-id-type="pmcid">PMC6563208</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iken</surname><given-names>S</given-names></name><name name-style="western"><surname>Bachy</surname><given-names>V</given-names></name><name name-style="western"><surname>Gourdain</surname><given-names>P</given-names></name><name name-style="western"><surname>Lim</surname><given-names>A</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaigneau</surname><given-names>T</given-names></name><name name-style="western"><surname>Aucouturier</surname><given-names>P</given-names></name><name name-style="western"><surname>Carnaud</surname><given-names>C</given-names></name></person-group><article-title>Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie</article-title><source>PLoS Pathog</source><year>2011</year><volume>7</volume><issue>9</issue><fpage>e1002216</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002216</pub-id><pub-id pub-id-type="pmid">21909267</pub-id><pub-id pub-id-type="pmcid">PMC3164648</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isaacs</surname><given-names>JD</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>GS</given-names></name><name name-style="western"><surname>Altmann</surname><given-names>DM</given-names></name></person-group><article-title>The role of the cellular prion protein in the immune system</article-title><source>Clin Exp Immunol</source><year>2006</year><volume>146</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03194.x</pub-id><pub-id pub-id-type="pmid">16968391</pub-id><pub-id pub-id-type="pmcid">PMC1809729</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>D</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>N</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Antigen mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>9321</fpage><lpage>9328</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.017</pub-id><pub-id pub-id-type="pmid">22008817</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>D</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>D</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>R</given-names></name><name name-style="western"><surname>Okimura</surname><given-names>N</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shigematsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Katamine</surname><given-names>S</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.078</pub-id><pub-id pub-id-type="pmid">17055125</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarrett</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lansbury</surname><given-names>PT</given-names></name></person-group><article-title>Seeding &#8220;one-dimensional crystallization&#8221; of amyloid: a pathogenic mechanism in Alzheimer&#8217;s disease and scrapie?</article-title><source>Cell</source><year>1993</year><volume>73</volume><fpage>1055</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90635-4</pub-id><pub-id pub-id-type="pmid">8513491</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>TR</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name></person-group><article-title>Early detection of chronic wasting disease prions in urine of pre-symptomatic deer by real-time quaking-induced conversion assay</article-title><source>Prion</source><year>2013</year><volume>7</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.4161/pri.24430</pub-id><pub-id pub-id-type="pmid">23764839</pub-id><pub-id pub-id-type="pmcid">PMC3783112</pub-id></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jucker</surname><given-names>M</given-names></name><name name-style="western"><surname>Walker</surname><given-names>LC</given-names></name></person-group><article-title>Self-propagation of pathogenic protein aggregates in neurodegenerative diseases</article-title><source>Nature</source><year>2013</year><volume>501</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nature12481</pub-id><pub-id pub-id-type="pmid">24005412</pub-id><pub-id pub-id-type="pmcid">PMC3963807</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser-Schulz</surname><given-names>G</given-names></name><name name-style="western"><surname>Heit</surname><given-names>A</given-names></name><name name-style="western"><surname>Quintanilla-Martinez</surname><given-names>L</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>F</given-names></name><name name-style="western"><surname>Hess</surname><given-names>S</given-names></name><name name-style="western"><surname>Jennen</surname><given-names>L</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>H</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name></person-group><article-title>Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>2797</fpage><lpage>2807</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.5.2797</pub-id><pub-id pub-id-type="pmid">17709493</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kascsak</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rubenstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Merz</surname><given-names>PA</given-names></name><name name-style="western"><surname>Tonna-DeMasi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fersko</surname><given-names>MR</given-names></name><name name-style="western"><surname>Carp</surname><given-names>RI</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>HM</given-names></name><name name-style="western"><surname>Diringer</surname><given-names>H</given-names></name></person-group><article-title>Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins</article-title><source>J Virol</source><year>1987</year><volume>61</volume><fpage>3688</fpage><pub-id pub-id-type="doi">10.1128/jvi.61.12.3688-3693.1987</pub-id><pub-id pub-id-type="pmid">2446004</pub-id><pub-id pub-id-type="pmcid">PMC255980</pub-id></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasper</surname><given-names>KC</given-names></name><name name-style="western"><surname>Stites</surname><given-names>DP</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>KA</given-names></name><name name-style="western"><surname>Panitch</surname><given-names>H</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Immunological studies of scrapie infection</article-title><source>J Neuroimmunol</source><year>1982</year><volume>3</volume><fpage>187</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/0165-5728(82)90022-4</pub-id><pub-id pub-id-type="pmid">6183292</pub-id></element-citation></ref><ref id="CR124"><mixed-citation publication-type="other">Katsinelos T, Tuck BJ, Mukadam S, McEwan WA (2019) The role of antibodies and their receptors in protection against ordered protein assembly in neurodegeneration. Frontiers Immun 10:1139<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01139</pub-id><pub-id pub-id-type="pmcid">PMC6554282</pub-id><pub-id pub-id-type="pmid">31214163</pub-id></mixed-citation></ref><ref id="CR125"><mixed-citation publication-type="other">Kim C, Haldiman T, Kang SG, Hromadkova L, Han ZZ, Chen W, Lissemore F, Lerner A, de Silva R, Cohen ML, Westaway D, Safar JG (2022) Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer&#8217;s disease. Sci Transl Med 14:eabg0253<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abg0253</pub-id><pub-id pub-id-type="pmcid">PMC9549419</pub-id><pub-id pub-id-type="pmid">34985969</pub-id></mixed-citation></ref><ref id="CR126"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimberlin</surname><given-names>RH</given-names></name></person-group><article-title>Bovine spongiform encephalopathy</article-title><source>Rev Sci Tech</source><year>1992</year><volume>11</volume><fpage>347</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.20506/rst.11.2.608</pub-id><pub-id pub-id-type="pmid">1617201</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kl&#246;hn</surname><given-names>PC</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>M</given-names></name><name name-style="western"><surname>Linehan</surname><given-names>JM</given-names></name><name name-style="western"><surname>O'Malley</surname><given-names>C</given-names></name><name name-style="western"><surname>Fernandez de Marco</surname><given-names>M</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>W</given-names></name><name name-style="western"><surname>Farrow</surname><given-names>M</given-names></name><name name-style="western"><surname>Khalli-Shirazi</surname><given-names>A</given-names></name><name name-style="western"><surname>Brandner</surname><given-names>S</given-names></name><name name-style="western"><surname>Cllinge</surname><given-names>J</given-names></name></person-group><article-title>PrP antibodies do not trigger mouse hippocampal neuron apoptosis</article-title><source>Science</source><year>2012</year><volume>335</volume><issue>6064</issue><fpage>52</fpage><pub-id pub-id-type="doi">10.1126/science.1215579</pub-id><pub-id pub-id-type="pmid">22223800</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kl&#246;hn</surname><given-names>PC</given-names></name><name name-style="western"><surname>Stoltze</surname><given-names>L</given-names></name><name name-style="western"><surname>Flechsig</surname><given-names>E</given-names></name><name name-style="western"><surname>Enari</surname><given-names>M</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>11666</fpage><lpage>11667</lpage><pub-id pub-id-type="doi">10.1073/pnas.1834432100</pub-id><pub-id pub-id-type="pmid">14504404</pub-id><pub-id pub-id-type="pmcid">PMC208815</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koller</surname><given-names>MF</given-names></name><name name-style="western"><surname>Grau</surname><given-names>T</given-names></name><name name-style="western"><surname>Christen</surname><given-names>P</given-names></name></person-group><article-title>Induction of antibodies against murine full-length prion protein in wild-type mice</article-title><source>J Neuroimmunol</source><year>2002</year><volume>132</volume><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(02)00316-8</pub-id><pub-id pub-id-type="pmid">12417440</pub-id></element-citation></ref><ref id="CR130"><mixed-citation publication-type="other">Kov&#225;cs GG, Kalev O, Budka H (2004) Contribution of neuropathology to the understanding of human prion disease. Folia Neuropathol 42 Suppl A:69&#8211;76<pub-id pub-id-type="pmid">15449461</pub-id></mixed-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>C</given-names></name><name name-style="western"><surname>Kryndushkin</surname><given-names>D</given-names></name><name name-style="western"><surname>Suhre</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>A</given-names></name><name name-style="western"><surname>Scheibel</surname><given-names>T</given-names></name><name name-style="western"><surname>Wickner</surname><given-names>RB</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Vorberg</surname><given-names>I</given-names></name></person-group><article-title>The yeast Sup35NM domain propagates as a prion in mammalian cells</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811571106</pub-id><pub-id pub-id-type="pmid">19114662</pub-id><pub-id pub-id-type="pmcid">PMC2626725</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krance</surname><given-names>SH</given-names></name><name name-style="western"><surname>Luke</surname><given-names>R</given-names></name><name name-style="western"><surname>Shenouda</surname><given-names>M</given-names></name><name name-style="western"><surname>Israwi</surname><given-names>AR</given-names></name><name name-style="western"><surname>Colpitts</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Darwish</surname><given-names>L</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>M</given-names></name><name name-style="western"><surname>Watts</surname><given-names>JC</given-names></name></person-group><article-title>Cellular models for discovering prion disease therapeutics: progress and challenges</article-title><source>J Neurochem</source><year>2020</year><volume>153</volume><fpage>150</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1111/jnc.14956</pub-id><pub-id pub-id-type="pmid">31943194</pub-id></element-citation></ref><ref id="CR133"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krasemann</surname><given-names>S</given-names></name><name name-style="western"><surname>Groschup</surname><given-names>MH</given-names></name><name name-style="western"><surname>Harmeyer</surname><given-names>S</given-names></name><name name-style="western"><surname>Hunsmann</surname><given-names>G</given-names></name><name name-style="western"><surname>Bodemer</surname><given-names>W</given-names></name></person-group><article-title>Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice</article-title><source>Mol Med</source><year>1996</year><volume>2</volume><issue>6</issue><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1007/BF03401656</pub-id><pub-id pub-id-type="pmid">8972487</pub-id><pub-id pub-id-type="pmcid">PMC2230140</pub-id></element-citation></ref><ref id="CR134"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurt</surname><given-names>TD</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Borges</surname><given-names>N</given-names></name><name name-style="western"><surname>Bett</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Spraker</surname><given-names>TR</given-names></name><name name-style="western"><surname>Castilla</surname><given-names>J</given-names></name><name name-style="western"><surname>Eisenberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>CJ</given-names></name></person-group><article-title>Human prion protein sequence elements impede cross-species chronic wasting disease transmission</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>1485</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1172/JCI79408</pub-id><pub-id pub-id-type="pmid">25705888</pub-id><pub-id pub-id-type="pmcid">PMC4396485</pub-id></element-citation></ref><ref id="CR135"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Brown</surname><given-names>P</given-names></name><name name-style="western"><surname>Cerven&#225;kov&#225;</surname><given-names>L</given-names></name><name name-style="western"><surname>Garruto</surname><given-names>RM</given-names></name><name name-style="western"><surname>Alpers</surname><given-names>MP</given-names></name><name name-style="western"><surname>Gajdusek</surname><given-names>CD</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>LG</given-names></name></person-group><article-title>Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype</article-title><source>J Infect Dis</source><year>2001</year><volume>183</volume><fpage>192</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1086/317935</pub-id><pub-id pub-id-type="pmid">11120925</pub-id></element-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre-Roque</surname><given-names>M</given-names></name><name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name><name name-style="western"><surname>Zou</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Feraudet</surname><given-names>C</given-names></name><name name-style="western"><surname>Gilles</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sales</surname><given-names>N</given-names></name><name name-style="western"><surname>Grassi</surname><given-names>J</given-names></name><name name-style="western"><surname>Gambetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Baron</surname><given-names>T</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>H</given-names></name><name name-style="western"><surname>Lasm&#233;zas</surname><given-names>CI</given-names></name></person-group><article-title>Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice</article-title><source>Prion</source><year>2007</year><volume>1</volume><fpage>198</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.4161/pri.1.3.4870</pub-id><pub-id pub-id-type="pmid">19164902</pub-id><pub-id pub-id-type="pmcid">PMC2634593</pub-id></element-citation></ref><ref id="CR137"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>JY</given-names></name><name name-style="western"><surname>Browning</surname><given-names>S</given-names></name><name name-style="western"><surname>Mahal</surname><given-names>SP</given-names></name><name name-style="western"><surname>Oelschlegel</surname><given-names>AM</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Darwinian evolution of prions in cell culture</article-title><source>Science</source><year>2010</year><volume>327</volume><fpage>869</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1126/science.1183218</pub-id><pub-id pub-id-type="pmid">20044542</pub-id><pub-id pub-id-type="pmcid">PMC2848070</pub-id></element-citation></ref><ref id="CR138"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>JY</given-names></name><name name-style="western"><surname>Englund</surname><given-names>E</given-names></name><name name-style="western"><surname>Holton</surname><given-names>JL</given-names></name><name name-style="western"><surname>Soulet</surname><given-names>D</given-names></name><name name-style="western"><surname>Hagell</surname><given-names>P</given-names></name><name name-style="western"><surname>Lees</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lashley</surname><given-names>T</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>NP</given-names></name><name name-style="western"><surname>Rehncrona</surname><given-names>S</given-names></name><name name-style="western"><surname>Bj&#246;rklund</surname><given-names>A</given-names></name><name name-style="western"><surname>Widner</surname><given-names>H</given-names></name><name name-style="western"><surname>Revesz</surname><given-names>T</given-names></name><name name-style="western"><surname>Lindvall</surname><given-names>O</given-names></name><name name-style="western"><surname>Brundin</surname><given-names>P</given-names></name></person-group><article-title>Lewy bodies in grafted neurons in subjects with Parkinson&#8217;s disease suggest host-to-graft disease propagation</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>501</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/nm1746</pub-id><pub-id pub-id-type="pmid">18391963</pub-id></element-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llewelyn</surname><given-names>CA</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>PE</given-names></name><name name-style="western"><surname>Knight</surname><given-names>RS</given-names></name><name name-style="western"><surname>Amar</surname><given-names>K</given-names></name><name name-style="western"><surname>Cousens</surname><given-names>S</given-names></name><name name-style="western"><surname>Mackenzie</surname><given-names>J</given-names></name><name name-style="western"><surname>Will</surname><given-names>RG</given-names></name></person-group><article-title>Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)15486-X</pub-id><pub-id pub-id-type="pmid">14962520</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#228;&#228;tt&#228;nen</surname><given-names>P</given-names></name><name name-style="western"><surname>Taschuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Ross</surname><given-names>L</given-names></name><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Bertram</surname><given-names>L</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>PrP<sup>Sc</sup>-specific antibodies do not induce prion disease or misfolding of PrP<sup>C</sup> in highly susceptible Tga20 mice</article-title><source>Prion</source><year>2013</year><volume>7</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.4161/pri.26639</pub-id><pub-id pub-id-type="pmid">24105298</pub-id><pub-id pub-id-type="pmcid">PMC4134347</pub-id></element-citation></ref><ref id="CR141"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mabbott</surname><given-names>NA</given-names></name></person-group><article-title>Prospects for safe and effective vaccines against prion diseases</article-title><source>Expert Rev Vacc</source><year>2015</year><volume>14</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.965691</pub-id><pub-id pub-id-type="pmid">25266267</pub-id></element-citation></ref><ref id="CR142"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mabbott</surname><given-names>NA</given-names></name><name name-style="western"><surname>Alibhai</surname><given-names>JD</given-names></name><name name-style="western"><surname>Manson</surname><given-names>J</given-names></name></person-group><article-title>The role of the immune system in prion infection</article-title><source>Handb Clin Neurol</source><year>2018</year><volume>153</volume><fpage>85</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63945-5.00005-2</pub-id><pub-id pub-id-type="pmid">29887157</pub-id></element-citation></ref><ref id="CR143"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madampage</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#228;&#228;tt&#228;nen</surname><given-names>P</given-names></name><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Brownlie</surname><given-names>R</given-names></name><name name-style="western"><surname>Andrievskaia</surname><given-names>O</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>NR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Binding of bovine T194A PrP<sup>C</sup> by PrP<sup>Sc</sup>-specific antibodies</article-title><source>Prion</source><year>2013</year><volume>7</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.4161/pri.25148</pub-id><pub-id pub-id-type="pmid">23787697</pub-id><pub-id pub-id-type="pmcid">PMC3904316</pub-id></element-citation></ref><ref id="CR144"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahal</surname><given-names>SP</given-names></name><name name-style="western"><surname>Baker</surname><given-names>CA</given-names></name><name name-style="western"><surname>Demczyk</surname><given-names>CA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>EW</given-names></name><name name-style="western"><surname>Julius</surname><given-names>C</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Prion strain discrimination in cell culture: the cell panel assay</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><fpage>20908</fpage><lpage>20913</lpage><pub-id pub-id-type="doi">10.1073/pnas.0710054104</pub-id><pub-id pub-id-type="pmid">18077360</pub-id><pub-id pub-id-type="pmcid">PMC2409240</pub-id></element-citation></ref><ref id="CR145"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahl</surname><given-names>P</given-names></name><name name-style="western"><surname>Clinquet</surname><given-names>F</given-names></name><name name-style="western"><surname>Guiot</surname><given-names>AL</given-names></name><name name-style="western"><surname>Niin</surname><given-names>E</given-names></name><name name-style="western"><surname>Fournials</surname><given-names>E</given-names></name><name name-style="western"><surname>Saint-Jean</surname><given-names>N</given-names></name><name name-style="western"><surname>Aubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>CE</given-names></name><name name-style="western"><surname>Gueguen</surname><given-names>S</given-names></name></person-group><article-title>Twenty-year experience of the oral rabies vaccine SAG2 in wildlife: a global review</article-title><source>Vet Res</source><year>2014</year><volume>45</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s13567-014-0077-8</pub-id><pub-id pub-id-type="pmid">25106552</pub-id><pub-id pub-id-type="pmcid">PMC4423639</pub-id></element-citation></ref><ref id="CR146"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makarava</surname><given-names>N</given-names></name><name name-style="western"><surname>Baskakov</surname><given-names>IV</given-names></name></person-group><article-title>Role of sialylation of N-linked glycans in prion pathogenesis</article-title><source>Cell Tissue Res</source><year>2022</year><pub-id pub-id-type="doi">10.1007/s00441-022-03584-2</pub-id><pub-id pub-id-type="pmid">35088180</pub-id><pub-id pub-id-type="pmcid">PMC9329487</pub-id></element-citation></ref><ref id="CR147"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallucci</surname><given-names>G</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>A</given-names></name><name name-style="western"><surname>Linehan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kl&#246;hn</surname><given-names>PC</given-names></name><name name-style="western"><surname>Brandner</surname><given-names>S</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>871</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1126/science.1090187</pub-id><pub-id pub-id-type="pmid">14593181</pub-id></element-citation></ref><ref id="CR148"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>M&#228;&#228;tt&#228;nen</surname><given-names>P</given-names></name><name name-style="western"><surname>Taschuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Airey</surname><given-names>D</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>NR</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Development of a multivalent, PrPSc-specific prion vaccine through rational optimization of three disease-specific epitopes</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>1988</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.027</pub-id><pub-id pub-id-type="pmid">24486363</pub-id></element-citation></ref><ref id="CR149"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Taschuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy</article-title><source>J Immunol Res</source><year>2013</year><volume>2013</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/473706</pub-id><pub-id pub-id-type="pmcid">PMC3817797</pub-id><pub-id pub-id-type="pmid">24228054</pub-id></element-citation></ref><ref id="CR150"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Trost</surname><given-names>B</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>EpIC: a rational pipeline for epitope immunogenicity characterization</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>2388</fpage><lpage>2390</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv136</pub-id><pub-id pub-id-type="pmid">25750418</pub-id><pub-id pub-id-type="pmcid">PMC4495294</pub-id></element-citation></ref><ref id="CR151"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrero-Winkens</surname><given-names>C</given-names></name><name name-style="western"><surname>Sankaran</surname><given-names>C</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name></person-group><article-title>From seeds to fibrils and back: fragmentation as an overlooked step in the propagation of prions and prion-like proteins</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><issue>9</issue><fpage>1305</fpage><pub-id pub-id-type="doi">10.3390/biom10091305</pub-id><pub-id pub-id-type="pmid">32927676</pub-id><pub-id pub-id-type="pmcid">PMC7563560</pub-id></element-citation></ref><ref id="CR152"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsh</surname><given-names>RF</given-names></name><name name-style="western"><surname>Kincaid</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bartz</surname><given-names>JC</given-names></name></person-group><article-title>Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus)</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>13794</fpage><lpage>13796</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.21.13794-13796.2005</pub-id><pub-id pub-id-type="pmid">16227298</pub-id><pub-id pub-id-type="pmcid">PMC1262585</pub-id></element-citation></ref><ref id="CR153"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name></person-group><article-title>Large animal models for chronic wasting disease</article-title><source>Cell Tissue Res</source><year>2022</year><volume>3</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00441-022-03590-4</pub-id><pub-id pub-id-type="pmcid">PMC8811588</pub-id><pub-id pub-id-type="pmid">35113219</pub-id></element-citation></ref><ref id="CR154"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name><name name-style="western"><surname>Nalls</surname><given-names>AV</given-names></name><name name-style="western"><surname>Seelig</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kraft</surname><given-names>SL</given-names></name><name name-style="western"><surname>Carnes</surname><given-names>K</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KR</given-names></name><name name-style="western"><surname>Hayes-Klug</surname><given-names>J</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name></person-group><article-title>Susceptibility of domestic cats to chronic wasting disease</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>1947</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1128/JVI.02592-12</pub-id><pub-id pub-id-type="pmid">23236066</pub-id><pub-id pub-id-type="pmcid">PMC3571486</pub-id></element-citation></ref><ref id="CR155"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathiason</surname><given-names>CK</given-names></name><name name-style="western"><surname>Powers</surname><given-names>JG</given-names></name><name name-style="western"><surname>Dahmes</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>DA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KV</given-names></name><name name-style="western"><surname>Warren</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Mason</surname><given-names>GL</given-names></name><name name-style="western"><surname>Hays</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hayes-Klug</surname><given-names>J</given-names></name><name name-style="western"><surname>Seelig</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wild</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>LL</given-names></name><name name-style="western"><surname>Spraker</surname><given-names>TR</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name></person-group><article-title>Infectious prions in the saliva and blood of deer with chronic wasting disease</article-title><source>Science</source><year>2006</year><volume>6</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1126/science.1132661</pub-id><pub-id pub-id-type="pmid">17023660</pub-id></element-citation></ref><ref id="CR156"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mead</surname><given-names>S</given-names></name><name name-style="western"><surname>Khalili-Shirazi</surname><given-names>A</given-names></name><name name-style="western"><surname>Potter</surname><given-names>C</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T</given-names></name><name name-style="western"><surname>Nihat</surname><given-names>A</given-names></name><name name-style="western"><surname>Hyare</surname><given-names>H</given-names></name><name name-style="western"><surname>Canning</surname><given-names>S</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>T</given-names></name><name name-style="western"><surname>Darwent</surname><given-names>L</given-names></name><name name-style="western"><surname>Muirhead</surname><given-names>N</given-names></name><name name-style="western"><surname>Ebsworth</surname><given-names>N</given-names></name><name name-style="western"><surname>Hextall</surname><given-names>P</given-names></name><name name-style="western"><surname>Wakeling</surname><given-names>M</given-names></name><name name-style="western"><surname>Linehan</surname><given-names>J</given-names></name><name name-style="western"><surname>Libri</surname><given-names>V</given-names></name><name name-style="western"><surname>Williams</surname><given-names>B</given-names></name><name name-style="western"><surname>Jaunmuktane</surname><given-names>Z</given-names></name><name name-style="western"><surname>Brandner</surname><given-names>S</given-names></name><name name-style="western"><surname>Rudge</surname><given-names>P</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme</article-title><source>Lancet Neurol</source><year>2022</year><volume>21</volume><fpage>342</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(22)00082-5</pub-id><pub-id pub-id-type="pmid">35305340</pub-id></element-citation></ref><ref id="CR157"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer-Luehmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Coomaraswamy</surname><given-names>J</given-names></name><name name-style="western"><surname>Bolmont</surname><given-names>T</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>S</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>C</given-names></name><name name-style="western"><surname>Kilger</surname><given-names>E</given-names></name><name name-style="western"><surname>Neuenschwander</surname><given-names>A</given-names></name><name name-style="western"><surname>Abramowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Frey</surname><given-names>P</given-names></name><name name-style="western"><surname>Jaton</surname><given-names>AL</given-names></name><name name-style="western"><surname>Vigouret</surname><given-names>JM</given-names></name><name name-style="western"><surname>Paganetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>DM</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ghiso</surname><given-names>J</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M</given-names></name><name name-style="western"><surname>Walker</surname><given-names>LC</given-names></name><name name-style="western"><surname>Jucker</surname><given-names>M</given-names></name></person-group><article-title>Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1781</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1126/science.1131864</pub-id><pub-id pub-id-type="pmid">16990547</pub-id></element-citation></ref><ref id="CR158"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Williams</surname><given-names>ES</given-names></name></person-group><article-title>Prion disease: horizontal prion transmission in mule deer</article-title><source>Nature</source><year>2003</year><volume>425</volume><fpage>35</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/425035a</pub-id><pub-id pub-id-type="pmid">12955129</pub-id></element-citation></ref><ref id="CR159"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>GB</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>O'Rourke</surname><given-names>KI</given-names></name><name name-style="western"><surname>Algire</surname><given-names>J</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>NP</given-names></name><name name-style="western"><surname>Walther</surname><given-names>I</given-names></name><name name-style="western"><surname>Spraker</surname><given-names>TR</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>A</given-names></name></person-group><article-title>Experimental oral transmission of chronic wasting disease to reindeer (Rangifer tarandus tarandus)</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>6</issue><fpage>e39055</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0039055</pub-id><pub-id pub-id-type="pmid">22723928</pub-id><pub-id pub-id-type="pmcid">PMC3377593</pub-id></element-citation></ref><ref id="CR160"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moda</surname><given-names>F</given-names></name><name name-style="western"><surname>Vimercati</surname><given-names>C</given-names></name><name name-style="western"><surname>Campagnani</surname><given-names>I</given-names></name><name name-style="western"><surname>Ruggerone</surname><given-names>M</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G</given-names></name><name name-style="western"><surname>Morbin</surname><given-names>M</given-names></name><name name-style="western"><surname>Zentilin</surname><given-names>L</given-names></name><name name-style="western"><surname>Giacca</surname><given-names>M</given-names></name><name name-style="western"><surname>Zucca</surname><given-names>I</given-names></name><name name-style="western"><surname>Legname</surname><given-names>G</given-names></name><name name-style="western"><surname>Tagliavini</surname><given-names>F</given-names></name></person-group><article-title>Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice</article-title><source>Prion</source><year>2012</year><volume>6</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.4161/pri.20197</pub-id><pub-id pub-id-type="pmid">22842862</pub-id><pub-id pub-id-type="pmcid">PMC3609068</pub-id></element-citation></ref><ref id="CR161"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>SJ</given-names></name><name name-style="western"><surname>West Greenlee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kondru</surname><given-names>N</given-names></name><name name-style="western"><surname>Manne</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kunkle</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Greenlee</surname><given-names>JJ</given-names></name></person-group><article-title>Experimental transmission of the chronic wasting disease agent to swine after oral or intracranial inoculation</article-title><source>J Virol</source><year>2017</year><volume>91</volume><fpage>e00926</fpage><lpage>e1017</lpage><pub-id pub-id-type="doi">10.1128/JVI.00926-17</pub-id><pub-id pub-id-type="pmid">28701407</pub-id><pub-id pub-id-type="pmcid">PMC5599732</pub-id></element-citation></ref><ref id="CR162"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>JA</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Insights into mechanisms of transmission and pathogenesis from transgenic mouse models of prion diseases</article-title><source>Methods Mol Biol</source><year>2017</year><volume>1658</volume><fpage>219</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7244-9_16</pub-id><pub-id pub-id-type="pmid">28861793</pub-id><pub-id pub-id-type="pmcid">PMC5902812</pub-id></element-citation></ref><ref id="CR163"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouillet-Richard</surname><given-names>S</given-names></name><name name-style="western"><surname>Ermonval</surname><given-names>M</given-names></name><name name-style="western"><surname>Chebassier</surname><given-names>C</given-names></name><name name-style="western"><surname>Laplanche</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Launay</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kellermann</surname><given-names>O</given-names></name></person-group><article-title>Signal transduction through prion protein</article-title><source>Science</source><year>2000</year><volume>289</volume><fpage>1925</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1126/science.289.5486.1925</pub-id><pub-id pub-id-type="pmid">10988071</pub-id></element-citation></ref><ref id="CR164"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazor</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>F</given-names></name><name name-style="western"><surname>Seward</surname><given-names>T</given-names></name><name name-style="western"><surname>Green</surname><given-names>M</given-names></name><name name-style="western"><surname>Zwald</surname><given-names>D</given-names></name><name name-style="western"><surname>P&#252;rro</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>J</given-names></name><name name-style="western"><surname>Biffiger</surname><given-names>K</given-names></name><name name-style="western"><surname>Power</surname><given-names>AM</given-names></name><name name-style="western"><surname>Oesch</surname><given-names>B</given-names></name><name name-style="western"><surname>Raeber</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name></person-group><article-title>Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice</article-title><source>EMBO J</source><year>2005</year><volume>24</volume><fpage>2472</fpage><lpage>2480</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600717</pub-id><pub-id pub-id-type="pmid">15962001</pub-id><pub-id pub-id-type="pmcid">PMC1173157</pub-id></element-citation></ref><ref id="CR165"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuwelt</surname><given-names>EA</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>B</given-names></name><name name-style="western"><surname>Fahlke</surname><given-names>C</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>G</given-names></name><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name><name name-style="western"><surname>Janigro</surname><given-names>D</given-names></name><name name-style="western"><surname>Leybaert</surname><given-names>L</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>Z</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>ME</given-names></name><name name-style="western"><surname>Povlishock</surname><given-names>JT</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>NR</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>F</given-names></name><name name-style="western"><surname>Stanimirovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Watts</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Drewes</surname><given-names>LR</given-names></name></person-group><article-title>Engaging neuroscience to advance translational research in brain barrier biology</article-title><source>Nat Rev Neurosci</source><year>2011</year><volume>12</volume><fpage>169</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nrn2995</pub-id><pub-id pub-id-type="pmid">21331083</pub-id><pub-id pub-id-type="pmcid">PMC3335275</pub-id></element-citation></ref><ref id="CR166"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>TA</given-names></name><name name-style="western"><surname>Pulford</surname><given-names>B</given-names></name><name name-style="western"><surname>Wyckoff</surname><given-names>AC</given-names></name><name name-style="western"><surname>Meyerett</surname><given-names>C</given-names></name><name name-style="western"><surname>Michel</surname><given-names>B</given-names></name><name name-style="western"><surname>Gertig</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>JE</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name><name name-style="western"><surname>Zabel</surname><given-names>MD</given-names></name></person-group><article-title>Detection of protease-resistant cervid prion protein in water from a CWD-endemic area</article-title><source>Prion</source><year>2009</year><volume>3</volume><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.4161/pri.3.3.9819</pub-id><pub-id pub-id-type="pmid">19823039</pub-id><pub-id pub-id-type="pmcid">PMC2802782</pub-id></element-citation></ref><ref id="CR167"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoll</surname><given-names>JA</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Preventing prion pathogenicity by targeting the cellular prion protein</article-title><source>Infect Disord Drug Targets</source><year>2009</year><volume>9</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2174/1871526510909010048</pub-id><pub-id pub-id-type="pmid">19200015</pub-id></element-citation></ref><ref id="CR168"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoll</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C</given-names></name><name name-style="western"><surname>Steart</surname><given-names>P</given-names></name><name name-style="western"><surname>Markham</surname><given-names>H</given-names></name><name name-style="western"><surname>Weller</surname><given-names>RO</given-names></name></person-group><article-title>Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>448</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/nm840</pub-id><pub-id pub-id-type="pmid">12640446</pub-id></element-citation></ref><ref id="CR169"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikles</surname><given-names>D</given-names></name><name name-style="western"><surname>Bach</surname><given-names>P</given-names></name><name name-style="western"><surname>Boller</surname><given-names>K</given-names></name><name name-style="western"><surname>Merten</surname><given-names>CA</given-names></name><name name-style="western"><surname>Montrasio</surname><given-names>F</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>FL</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Cichutek</surname><given-names>K</given-names></name><name name-style="western"><surname>Kalinke</surname><given-names>U</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>CJ</given-names></name></person-group><article-title>Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>4033</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.7.4033-4042.2005</pub-id><pub-id pub-id-type="pmid">15767405</pub-id><pub-id pub-id-type="pmcid">PMC1061525</pub-id></element-citation></ref><ref id="CR170"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notari</surname><given-names>S</given-names></name><name name-style="western"><surname>Appleby</surname><given-names>BS</given-names></name><name name-style="western"><surname>Gambetti</surname><given-names>P</given-names></name></person-group><article-title>Variably protease-sensitive prionopathy</article-title><source>Handb Clin Neurol</source><year>2018</year><volume>53</volume><fpage>175</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63945-5.00010-6</pub-id><pub-id pub-id-type="pmid">29887135</pub-id></element-citation></ref><ref id="CR171"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orr&#249;</surname><given-names>CD</given-names></name><name name-style="western"><surname>Wilham</surname><given-names>JM</given-names></name><name name-style="western"><surname>Vascellari</surname><given-names>S</given-names></name><name name-style="western"><surname>Hughson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name></person-group><article-title>New generation QuIC assays for prion seeding activity</article-title><source>Prion</source><year>2012</year><volume>6</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.4161/pri.19430</pub-id><pub-id pub-id-type="pmid">22421206</pub-id><pub-id pub-id-type="pmcid">PMC7082091</pub-id></element-citation></ref><ref id="CR172"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paramithiotis</surname><given-names>E</given-names></name><name name-style="western"><surname>Pinard</surname><given-names>M</given-names></name><name name-style="western"><surname>Lawton</surname><given-names>T</given-names></name><name name-style="western"><surname>LaBoissiere</surname><given-names>S</given-names></name><name name-style="western"><surname>Leathers</surname><given-names>VL</given-names></name><name name-style="western"><surname>Zou</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Estey</surname><given-names>LA</given-names></name><name name-style="western"><surname>Lamontagne</surname><given-names>J</given-names></name><name name-style="western"><surname>Lehto</surname><given-names>MT</given-names></name><name name-style="western"><surname>Kondejewski</surname><given-names>LH</given-names></name><name name-style="western"><surname>Francoeur</surname><given-names>GP</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>M</given-names></name><name name-style="western"><surname>Haghighat</surname><given-names>A</given-names></name><name name-style="western"><surname>Spatz</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Head</surname><given-names>M</given-names></name><name name-style="western"><surname>Will</surname><given-names>R</given-names></name><name name-style="western"><surname>Ironside</surname><given-names>J</given-names></name><name name-style="western"><surname>O'Rourke</surname><given-names>K</given-names></name><name name-style="western"><surname>Tonelli</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ledebur</surname><given-names>HC</given-names></name><name name-style="western"><surname>Chakrabartty</surname><given-names>A</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>NR</given-names></name></person-group><article-title>A prion protein epitope selective for the pathologically misfolded conformation</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1038/nm883</pub-id><pub-id pub-id-type="pmid">12778138</pub-id></element-citation></ref><ref id="CR173"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pattison</surname><given-names>IH</given-names></name></person-group><source>Recent Work on Scrapie Pathol Biol (paris)</source><year>1970</year><volume>18</volume><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">4988060</pub-id></element-citation></ref><ref id="CR174"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peretz</surname><given-names>D</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>K</given-names></name><name name-style="western"><surname>Vergara</surname><given-names>J</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmitt-Ulms</surname><given-names>G</given-names></name><name name-style="western"><surname>Mehlhorn</surname><given-names>IR</given-names></name><name name-style="western"><surname>Legname</surname><given-names>G</given-names></name><name name-style="western"><surname>Wormald</surname><given-names>MR</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>PM</given-names></name><name name-style="western"><surname>Dwek</surname><given-names>RA</given-names></name><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Antibodies inhibit prion propagation and clear cell cultures of prion infectivity</article-title><source>Nature</source><year>2001</year><volume>412</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/35089090</pub-id><pub-id pub-id-type="pmid">11507642</pub-id></element-citation></ref><ref id="CR175"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>VH</given-names></name></person-group><article-title>The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease</article-title><source>Brain Behav Immun</source><year>2004</year><volume>18</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2004.01.004</pub-id><pub-id pub-id-type="pmid">15265532</pub-id></element-citation></ref><ref id="CR176"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilon</surname><given-names>JL</given-names></name><name name-style="western"><surname>Loiacono</surname><given-names>C</given-names></name><name name-style="western"><surname>Okeson</surname><given-names>D</given-names></name><name name-style="western"><surname>Lund</surname><given-names>S</given-names></name><name name-style="western"><surname>Vercauteren</surname><given-names>K</given-names></name><name name-style="western"><surname>Rhyan</surname><given-names>J</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L</given-names></name></person-group><article-title>Anti-prion activity generated by a novel vaccine formulation</article-title><source>Neurosci Lett</source><year>2007</year><volume>18</volume><fpage>161</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.10.015</pub-id><pub-id pub-id-type="pmid">18023980</pub-id></element-citation></ref><ref id="CR177"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilon</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rhyan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>LL</given-names></name><name name-style="western"><surname>Davis</surname><given-names>TR</given-names></name><name name-style="western"><surname>McCollum</surname><given-names>MP</given-names></name><name name-style="western"><surname>O'Rourke</surname><given-names>KI</given-names></name><name name-style="western"><surname>Spraker</surname><given-names>TR</given-names></name><name name-style="western"><surname>VerCauteren</surname><given-names>KC</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Gidlewski</surname><given-names>T</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>TA</given-names></name><name name-style="western"><surname>Miller</surname><given-names>LA</given-names></name><name name-style="western"><surname>Nol</surname><given-names>P</given-names></name></person-group><article-title>Immunization with a synthetic peptide vaccine fails to protect mule deer (Odocoileus hemionus) from chronic wasting disease</article-title><source>J Wildl Dis</source><year>2013</year><volume>49</volume><fpage>694</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.7589/2012-07-200</pub-id><pub-id pub-id-type="pmid">23778624</pub-id></element-citation></ref><ref id="CR178"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poduslo</surname><given-names>JF</given-names></name><name name-style="western"><surname>Curran</surname><given-names>GL</given-names></name><name name-style="western"><surname>Wengenack</surname><given-names>TM</given-names></name><name name-style="western"><surname>Malester</surname><given-names>B</given-names></name><name name-style="western"><surname>Duff</surname><given-names>K</given-names></name></person-group><article-title>Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>Neurobiol Dis</source><year>2001</year><volume>8</volume><fpage>555</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1006/nbdi.2001.0402</pub-id><pub-id pub-id-type="pmid">11493021</pub-id></element-citation></ref><ref id="CR179"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polymenidou</surname><given-names>M</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>FL</given-names></name><name name-style="western"><surname>Pellicioli</surname><given-names>EC</given-names></name><name name-style="western"><surname>Urich</surname><given-names>E</given-names></name><name name-style="western"><surname>Miele</surname><given-names>G</given-names></name><name name-style="western"><surname>Braun</surname><given-names>N</given-names></name><name name-style="western"><surname>Wopfner</surname><given-names>F</given-names></name><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Becher</surname><given-names>B</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>14670</fpage><lpage>14676</lpage><pub-id pub-id-type="doi">10.1073/pnas.0404772101</pub-id><pub-id pub-id-type="pmid">15292505</pub-id><pub-id pub-id-type="pmcid">PMC521983</pub-id></element-citation></ref><ref id="CR180"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>DD</given-names></name><name name-style="western"><surname>Porter</surname><given-names>HG</given-names></name><name name-style="western"><surname>Cox</surname><given-names>NA</given-names></name></person-group><article-title>Failure to demonstrate a humoral immune response to scrapie infection in mice</article-title><source>J Immunol</source><year>1973</year><volume>111</volume><fpage>1407</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.111.5.1407</pub-id><pub-id pub-id-type="pmid">4200779</pub-id></element-citation></ref><ref id="CR181"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priola</surname><given-names>SA</given-names></name></person-group><article-title>Cell biology approaches to studying prion diseases</article-title><source>Methods Mol Biol</source><year>2017</year><volume>1658</volume><fpage>83</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7244-9_7</pub-id><pub-id pub-id-type="pmid">28861784</pub-id></element-citation></ref><ref id="CR182"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pritzkow</surname><given-names>S</given-names></name><name name-style="western"><surname>Morales</surname><given-names>R</given-names></name><name name-style="western"><surname>Moda</surname><given-names>F</given-names></name><name name-style="western"><surname>Khan</surname><given-names>U</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>E</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C</given-names></name></person-group><article-title>Grass plants bind, retain, uptake, and transport infectious prions</article-title><source>Cell Rep</source><year>2015</year><volume>11</volume><fpage>1168</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.04.036</pub-id><pub-id pub-id-type="pmid">25981035</pub-id><pub-id pub-id-type="pmcid">PMC4449294</pub-id></element-citation></ref><ref id="CR183"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Novel proteinaceous infectious particles cause scrapie</article-title><source>Science</source><year>1982</year><volume>216</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1126/science.6801762</pub-id><pub-id pub-id-type="pmid">6801762</pub-id></element-citation></ref><ref id="CR184"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><source>Prions Proc Nat Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>13363</fpage><lpage>13383</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.23.13363</pub-id><pub-id pub-id-type="pmid">9811807</pub-id><pub-id pub-id-type="pmcid">PMC33918</pub-id></element-citation></ref><ref id="CR185"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name><name name-style="western"><surname>Scott</surname><given-names>MR</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>FE</given-names></name></person-group><article-title>Prion protein biology</article-title><source>Cell</source><year>1998</year><volume>93</volume><fpage>337</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81163-0</pub-id><pub-id pub-id-type="pmid">9590169</pub-id></element-citation></ref><ref id="CR186"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name><name name-style="western"><surname>Scott</surname><given-names>MR</given-names></name><name name-style="western"><surname>Foster</surname><given-names>D</given-names></name><name name-style="western"><surname>Pan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Groth</surname><given-names>D</given-names></name><name name-style="western"><surname>Mirenda</surname><given-names>C</given-names></name><name name-style="western"><surname>Torchia</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>SL</given-names></name><name name-style="western"><surname>Serban</surname><given-names>D</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>GA</given-names></name><name name-style="western"><surname>Hoppe</surname><given-names>PC</given-names></name><name name-style="western"><surname>Westaway</surname><given-names>D</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name></person-group><article-title>Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication</article-title><source>Cell</source><year>1990</year><volume>63</volume><fpage>673</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90134-Z</pub-id><pub-id pub-id-type="pmid">1977523</pub-id></element-citation></ref><ref id="CR187"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Race</surname><given-names>B</given-names></name><name name-style="western"><surname>Meade-White</surname><given-names>KD</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Barbian</surname><given-names>KD</given-names></name><name name-style="western"><surname>Rubenstein</surname><given-names>R</given-names></name><name name-style="western"><surname>LaFauci</surname><given-names>G</given-names></name><name name-style="western"><surname>Cervenakova</surname><given-names>L</given-names></name><name name-style="western"><surname>Favara</surname><given-names>C</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>D</given-names></name><name name-style="western"><surname>Long</surname><given-names>D</given-names></name><name name-style="western"><surname>Parnell</surname><given-names>M</given-names></name><name name-style="western"><surname>Striebel</surname><given-names>J</given-names></name><name name-style="western"><surname>Priola</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ward</surname><given-names>A</given-names></name><name name-style="western"><surname>Williams</surname><given-names>ES</given-names></name><name name-style="western"><surname>Race</surname><given-names>R</given-names></name><name name-style="western"><surname>Chesebro</surname><given-names>B</given-names></name></person-group><article-title>Susceptibilities of nonhuman primates to chronic wasting disease</article-title><source>Emerg Infect Dis</source><year>2009</year><volume>15</volume><fpage>1366</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.3201/eid1509.090253</pub-id><pub-id pub-id-type="pmid">19788803</pub-id><pub-id pub-id-type="pmcid">PMC2819871</pub-id></element-citation></ref><ref id="CR188"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Race</surname><given-names>B</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K</given-names></name><name name-style="western"><surname>Orr&#250;</surname><given-names>CD</given-names></name><name name-style="western"><surname>Hughson</surname><given-names>AG</given-names></name><name name-style="western"><surname>Lubke</surname><given-names>L</given-names></name><name name-style="western"><surname>Chesebro</surname><given-names>B</given-names></name></person-group><article-title>Lack of transmission of chronic wasting disease to cynomolgus macaques</article-title><source>J Virol</source><year>2018</year><volume>92</volume><fpage>e00550</fpage><lpage>e618</lpage><pub-id pub-id-type="doi">10.1128/JVI.00550-18</pub-id><pub-id pub-id-type="pmid">29695429</pub-id><pub-id pub-id-type="pmcid">PMC6026755</pub-id></element-citation></ref><ref id="CR189"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reimann</surname><given-names>RR</given-names></name><name name-style="western"><surname>Sonati</surname><given-names>T</given-names></name><name name-style="western"><surname>Hornemann</surname><given-names>S</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>US</given-names></name><name name-style="western"><surname>Arand</surname><given-names>M</given-names></name><name name-style="western"><surname>Hawke</surname><given-names>S</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Differential toxicity of antibodies to the prion protein</article-title><source>PLoS Pathog</source><year>2016</year><volume>12</volume><fpage>e1005401</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005401</pub-id><pub-id pub-id-type="pmid">26821311</pub-id><pub-id pub-id-type="pmcid">PMC4731068</pub-id></element-citation></ref><ref id="CR190"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>PH</given-names></name><name name-style="western"><surname>Lauckner</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kachirskaia</surname><given-names>I</given-names></name><name name-style="western"><surname>Heuser</surname><given-names>JE</given-names></name><name name-style="western"><surname>Melki</surname><given-names>R</given-names></name><name name-style="western"><surname>Kopito</surname><given-names>RR</given-names></name></person-group><article-title>Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates</article-title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/ncb1830</pub-id><pub-id pub-id-type="pmid">19151706</pub-id><pub-id pub-id-type="pmcid">PMC2757079</pub-id></element-citation></ref><ref id="CR191"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Requena</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kristensson</surname><given-names>K</given-names></name><name name-style="western"><surname>Korth</surname><given-names>C</given-names></name><name name-style="western"><surname>Zurzolo</surname><given-names>C</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M</given-names></name><name name-style="western"><surname>Aguilar-Calvo</surname><given-names>P</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Andreoletti</surname><given-names>O</given-names></name><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>R</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K</given-names></name><name name-style="western"><surname>Calgua</surname><given-names>B</given-names></name><name name-style="western"><surname>Del R&#237;o</surname><given-names>JA</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>JC</given-names></name><name name-style="western"><surname>Girones</surname><given-names>R</given-names></name><name name-style="western"><surname>Godsave</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoelzle</surname><given-names>LE</given-names></name><name name-style="western"><surname>Knittler</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>F</given-names></name><name name-style="western"><surname>Legname</surname><given-names>G</given-names></name><name name-style="western"><surname>Laeven</surname><given-names>P</given-names></name><name name-style="western"><surname>Mabbott</surname><given-names>N</given-names></name><name name-style="western"><surname>Mitrova</surname><given-names>E</given-names></name><name name-style="western"><surname>M&#252;ller-Schiffmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Nuvolone</surname><given-names>M</given-names></name><name name-style="western"><surname>Peters</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Raeber</surname><given-names>A</given-names></name><name name-style="western"><surname>Roth</surname><given-names>K</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>B</given-names></name><name name-style="western"><surname>Sonati</surname><given-names>T</given-names></name><name name-style="western"><surname>Stitz</surname><given-names>L</given-names></name><name name-style="western"><surname>Taraboulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Torres</surname><given-names>JM</given-names></name><name name-style="western"><surname>Yan</surname><given-names>ZX</given-names></name><name name-style="western"><surname>Zerr</surname><given-names>I</given-names></name></person-group><article-title>The priority position paper: protecting Europe&#8217;s food chain from prions</article-title><source>Prion</source><year>2016</year><volume>3</volume><fpage>165</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1080/19336896.2016.1175801</pub-id><pub-id pub-id-type="pmcid">PMC4981192</pub-id><pub-id pub-id-type="pmid">27220820</pub-id></element-citation></ref><ref id="CR192"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosset</surname><given-names>MB</given-names></name><name name-style="western"><surname>Ballerini</surname><given-names>C</given-names></name><name name-style="western"><surname>Gregoire</surname><given-names>S</given-names></name><name name-style="western"><surname>Metharom</surname><given-names>P</given-names></name><name name-style="western"><surname>Carnaud</surname><given-names>C</given-names></name><name name-style="western"><surname>Aucouturier</surname><given-names>P</given-names></name></person-group><article-title>Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>5168</fpage><lpage>5174</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.9.5168</pub-id><pub-id pub-id-type="pmid">15100253</pub-id></element-citation></ref><ref id="CR193"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosset</surname><given-names>MB</given-names></name><name name-style="western"><surname>Sacquin</surname><given-names>A</given-names></name><name name-style="western"><surname>Lecollinet</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaigneau</surname><given-names>T</given-names></name><name name-style="western"><surname>Adam</surname><given-names>M</given-names></name><name name-style="western"><surname>Crespeau</surname><given-names>F</given-names></name><name name-style="western"><surname>Eloit</surname><given-names>M</given-names></name></person-group><article-title>Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><issue>3</issue><fpage>e4917</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0004917</pub-id><pub-id pub-id-type="pmid">19295917</pub-id><pub-id pub-id-type="pmcid">PMC2654673</pub-id></element-citation></ref><ref id="CR194"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubenstein</surname><given-names>R</given-names></name><name name-style="western"><surname>Kascsak</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Papini</surname><given-names>M</given-names></name><name name-style="western"><surname>Kascsak</surname><given-names>R</given-names></name><name name-style="western"><surname>Carp</surname><given-names>RI</given-names></name><name name-style="western"><surname>LaFauci</surname><given-names>G</given-names></name><name name-style="western"><surname>Meloen</surname><given-names>R</given-names></name><name name-style="western"><surname>Langeveld</surname><given-names>J</given-names></name></person-group><article-title>Immune surveillance and antigen conformation determines humoral immune response to the prion protein immunogen</article-title><source>J Neurovirol</source><year>1999</year><volume>5</volume><fpage>401</fpage><pub-id pub-id-type="doi">10.3109/13550289909029481</pub-id><pub-id pub-id-type="pmid">10463862</pub-id></element-citation></ref><ref id="CR195"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saba</surname><given-names>R</given-names></name><name name-style="western"><surname>Booth</surname><given-names>SA</given-names></name></person-group><article-title>The genetics of susceptibility to variant Creutzfeldt-Jakob disease</article-title><source>Public Health Genomics</source><year>2013</year><volume>16</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1159/000345203</pub-id><pub-id pub-id-type="pmid">23548713</pub-id></element-citation></ref><ref id="CR196"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>T</given-names></name></person-group><article-title>Recent developments in mucosal vaccines against prion diseases</article-title><source>Expert Rev Vaccines</source><year>2007</year><volume>6</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1586/14760584.6.1.75</pub-id><pub-id pub-id-type="pmid">17280480</pub-id></element-citation></ref><ref id="CR197"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>T</given-names></name><name name-style="western"><surname>Ono</surname><given-names>M</given-names></name></person-group><article-title>Regulatory T cells and immune tolerance</article-title><source>Cell</source><year>2008</year><volume>133</volume><fpage>775</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.05.009</pub-id><pub-id pub-id-type="pmid">18510923</pub-id></element-citation></ref><ref id="CR198"><mixed-citation publication-type="other">Sassa Y, Kataoka N, Inoshima Y, Ishiguro N (2010) Anti-PrP antibodies detected at terminal stage of prion-affected mouse. Cell Immunol 263:212&#8211;18<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellimm.2010.03.018</pub-id><pub-id pub-id-type="pmid">20417929</pub-id></mixed-citation></ref><ref id="CR199"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bartelt-Hunt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bartz</surname><given-names>JC</given-names></name></person-group><article-title>Prions in the environment: occurrence, fate and mitigation</article-title><source>Prion</source><year>2008</year><volume>2</volume><fpage>162</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.4161/pri.2.4.7951</pub-id><pub-id pub-id-type="pmid">19242120</pub-id><pub-id pub-id-type="pmcid">PMC2658766</pub-id></element-citation></ref><ref id="CR200"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bartelt-Hunt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bartz</surname><given-names>JC</given-names></name></person-group><article-title>Occurrence, transmission, and zoonotic potential of chronic wasting disease</article-title><source>Emerg Infect Dis</source><year>2012</year><volume>18</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.3201/eid1803.110685</pub-id><pub-id pub-id-type="pmid">22377159</pub-id><pub-id pub-id-type="pmcid">PMC3309570</pub-id></element-citation></ref><ref id="CR201"><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Zou</surname><given-names>W-Q</given-names></name><name name-style="western"><surname>Gambetti</surname><given-names>P</given-names></name></person-group><article-title>Cellular mechanisms of propagation and clearance</article-title><source>Prions and Diseases</source><year>2013</year><publisher-loc>Physiology and Pathophysiology</publisher-loc><publisher-name>Springer</publisher-name><fpage>147</fpage><lpage>160</lpage></element-citation></ref><ref id="CR202"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Da Costa</surname><given-names>M</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>L</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>FE</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Prion protein gene variation among primates</article-title><source>J Mol Biol</source><year>1995</year><volume>245</volume><fpage>362</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1994.0030</pub-id><pub-id pub-id-type="pmid">7837269</pub-id></element-citation></ref><ref id="CR203"><mixed-citation publication-type="other">Sch&#228;tzl HM, Laszlo L, Holtzman DM, Tatzelt J, DeArmond SJ, Weiner RI, Mobley WC, Prusiner SB (1997) A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis.&#160;J Virol 71:8821&#8211;31<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.71.11.8821-8831.1997</pub-id><pub-id pub-id-type="pmcid">PMC192348</pub-id><pub-id pub-id-type="pmid">9343242</pub-id></mixed-citation></ref><ref id="CR204"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>M</given-names></name><name name-style="western"><surname>Foster</surname><given-names>D</given-names></name><name name-style="western"><surname>Mirenda</surname><given-names>C</given-names></name><name name-style="western"><surname>Serban</surname><given-names>D</given-names></name><name name-style="western"><surname>Coufal</surname><given-names>F</given-names></name><name name-style="western"><surname>W&#228;lchli</surname><given-names>M</given-names></name><name name-style="western"><surname>Torchia</surname><given-names>M</given-names></name><name name-style="western"><surname>Groth</surname><given-names>D</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>G</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Westaway</surname><given-names>D</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques</article-title><source>Cell</source><year>1989</year><volume>59</volume><fpage>847</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(89)90608-9</pub-id><pub-id pub-id-type="pmid">2574076</pub-id></element-citation></ref><ref id="CR205"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seelig</surname><given-names>DM</given-names></name><name name-style="western"><surname>Mason</surname><given-names>GL</given-names></name><name name-style="western"><surname>Telling</surname><given-names>GC</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>EA</given-names></name></person-group><article-title>Pathogenesis of chronic wasting disease in cervidized transgenic mice</article-title><source>Am J Pathol</source><year>2010</year><volume>176</volume><fpage>2785</fpage><lpage>2797</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090710</pub-id><pub-id pub-id-type="pmid">20395435</pub-id><pub-id pub-id-type="pmcid">PMC2877840</pub-id></element-citation></ref><ref id="CR206"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shearin</surname><given-names>H</given-names></name><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name></person-group><article-title>Axonal and transynaptic spread of prions</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>8640</fpage><lpage>8655</lpage><pub-id pub-id-type="doi">10.1128/JVI.00378-14</pub-id><pub-id pub-id-type="pmid">24850738</pub-id><pub-id pub-id-type="pmcid">PMC4135969</pub-id></element-citation></ref><ref id="CR207"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigurdson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>KP</given-names></name><name name-style="western"><surname>Hornemann</surname><given-names>S</given-names></name><name name-style="western"><surname>Manco</surname><given-names>G</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Borges</surname><given-names>N</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>P</given-names></name><name name-style="western"><surname>Castilla</surname><given-names>J</given-names></name><name name-style="western"><surname>W&#252;thrich</surname><given-names>K</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>A molecular switch controls interspecies prion disease transmission in mice</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><fpage>2590</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.1172/JCI42051</pub-id><pub-id pub-id-type="pmid">20551516</pub-id><pub-id pub-id-type="pmcid">PMC2898603</pub-id></element-citation></ref><ref id="CR208"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solforosi</surname><given-names>L</given-names></name><name name-style="western"><surname>Criado</surname><given-names>JR</given-names></name><name name-style="western"><surname>McGavern</surname><given-names>DB</given-names></name><name name-style="western"><surname>Wirz</surname><given-names>S</given-names></name><name name-style="western"><surname>S&#225;nchez-Alavez</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugama</surname><given-names>S</given-names></name><name name-style="western"><surname>DeGiorgio</surname><given-names>LA</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>BT</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>E</given-names></name><name name-style="western"><surname>Abalos</surname><given-names>G</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E</given-names></name><name name-style="western"><surname>Gilden</surname><given-names>D</given-names></name><name name-style="western"><surname>Oldstone</surname><given-names>MB</given-names></name><name name-style="western"><surname>Conti</surname><given-names>B</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>RA</given-names></name></person-group><article-title>Cross-linking cellular prion protein triggers neuronal apoptosis in vivo</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>1514</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1126/science.1094273</pub-id><pub-id pub-id-type="pmid">14752167</pub-id></element-citation></ref><ref id="CR209"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonati</surname><given-names>T</given-names></name><name name-style="western"><surname>Reimann</surname><given-names>RR</given-names></name><name name-style="western"><surname>Falsig</surname><given-names>J</given-names></name><name name-style="western"><surname>Baral</surname><given-names>PK</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>T</given-names></name><name name-style="western"><surname>Hornemann</surname><given-names>S</given-names></name><name name-style="western"><surname>Yaganoglu</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>US</given-names></name><name name-style="western"><surname>Wieland</surname><given-names>B</given-names></name><name name-style="western"><surname>Swayampakula</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>MH</given-names></name><name name-style="western"><surname>Das</surname><given-names>D</given-names></name><name name-style="western"><surname>Riek</surname><given-names>R</given-names></name><name name-style="western"><surname>Liberski</surname><given-names>P</given-names></name><name name-style="western"><surname>James</surname><given-names>MN</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein</article-title><source>Nature</source><year>2013</year><volume>501</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nature12402</pub-id><pub-id pub-id-type="pmid">23903654</pub-id></element-citation></ref><ref id="CR210"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taguchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Marrero-Winkens</surname><given-names>C</given-names></name><name name-style="western"><surname>Otaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>N</given-names></name><name name-style="western"><surname>Schatzl</surname><given-names>HM</given-names></name></person-group><article-title>Disulfide-crosslink scanning reveals prion&#8211;induced conformational changes and prion strain&#8211;specific structures of the pathological prion protein PrPSc</article-title><source>J Biol Chem</source><year>2018</year><volume>293</volume><fpage>12730</fpage><lpage>12740</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA117.001633</pub-id><pub-id pub-id-type="pmid">29934306</pub-id><pub-id pub-id-type="pmcid">PMC6102138</pub-id></element-citation></ref><ref id="CR211"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tal</surname><given-names>Y</given-names></name><name name-style="western"><surname>Souan</surname><given-names>L</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>IR</given-names></name><name name-style="western"><surname>Meiner</surname><given-names>Z</given-names></name><name name-style="western"><surname>Taraboulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Mor</surname><given-names>F</given-names></name></person-group><article-title>Complete Freund&#8217;s adjuvant immunization prolongs survival in experimental prion disease in mice</article-title><source>J Neurosci Res</source><year>2003</year><volume>71</volume><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1002/jnr.10474</pub-id><pub-id pub-id-type="pmid">12503092</pub-id></element-citation></ref><ref id="CR212"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamg&#252;ney</surname><given-names>G</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Giles</surname><given-names>K</given-names></name><name name-style="western"><surname>Lemus</surname><given-names>A</given-names></name><name name-style="western"><surname>Glidden</surname><given-names>DV</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Transmission of scrapie and sheep-passaged bovine spongiform encephalopathy prions to transgenic mice expressing elk prion protein</article-title><source>J Gen Virol</source><year>2009</year><volume>90</volume><fpage>1035</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1099/vir.0.007500-0</pub-id><pub-id pub-id-type="pmid">19264659</pub-id><pub-id pub-id-type="pmcid">PMC2804060</pub-id></element-citation></ref><ref id="CR213"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamg&#252;ney</surname><given-names>G</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MW</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>LL</given-names></name><name name-style="western"><surname>Sirochman</surname><given-names>TM</given-names></name><name name-style="western"><surname>Glidden</surname><given-names>DV</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>C</given-names></name><name name-style="western"><surname>Lemus</surname><given-names>A</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name></person-group><article-title>Asymptomatic deer excrete infectious prions in faeces</article-title><source>Nature</source><year>2009</year><volume>461</volume><fpage>529</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nature08289</pub-id><pub-id pub-id-type="pmid">19741608</pub-id><pub-id pub-id-type="pmcid">PMC3186440</pub-id></element-citation></ref><ref id="CR214"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taschuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Carrier protein significantly alters the magnitude, duration, and type of antibody response to a peptide epitope from a self-Protein</article-title><source>J Imm Vac</source><year>2015</year><volume>1</volume><fpage>101</fpage></element-citation></ref><ref id="CR215"><mixed-citation publication-type="other">Taschuk R, Marciniuk K, M&#228;&#228;tt&#228;nen P, Madampage C, Hedlin P, Potter A, Lee J, Cashman NR, Griebel PJ, Napper S (2014) Safety, specificity and immunogenicity of a PrP(Sc)-specific prion vaccine based on the YYR disease specific epitope. Prion 8(1):51&#8211;59. 10.4161/pri.27962. PMID: 24509522; PMCID: PMC7030909<pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/pri.27962</pub-id><pub-id pub-id-type="pmcid">PMC7030909</pub-id><pub-id pub-id-type="pmid">24509522</pub-id></mixed-citation></ref><ref id="CR216"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taschuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Scruten</surname><given-names>E</given-names></name><name name-style="western"><surname>Woodbury</surname><given-names>M</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P</given-names></name><name name-style="western"><surname>Tikoo</surname><given-names>S</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>Induction of PrP<sup>Sc</sup>-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease</article-title><source>Prion</source><year>2017</year><volume>11</volume><fpage>368</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1080/19336896.2017.1367083</pub-id><pub-id pub-id-type="pmid">28968152</pub-id><pub-id pub-id-type="pmcid">PMC5639826</pub-id></element-citation></ref><ref id="CR217"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taschuk</surname><given-names>R</given-names></name><name name-style="western"><surname>Van der Merwe</surname><given-names>J</given-names></name><name name-style="western"><surname>Marciniuk</surname><given-names>K</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P</given-names></name><name name-style="western"><surname>Napper</surname><given-names>S</given-names></name></person-group><article-title>In vitro neutralization of prions with PrP<sup>Sc</sup>-specific antibodies</article-title><source>Prion</source><year>2015</year><volume>9</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1080/19336896.2015.1071761</pub-id><pub-id pub-id-type="pmid">26284508</pub-id><pub-id pub-id-type="pmcid">PMC4601508</pub-id></element-citation></ref><ref id="CR218"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatzelt</surname><given-names>J</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name></person-group><article-title>Molecular basis of cerebral neurodegeneration in prion disease</article-title><source>FEBS J</source><year>2007</year><volume>274</volume><fpage>606</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.05633.x</pub-id><pub-id pub-id-type="pmid">17288549</pub-id></element-citation></ref><ref id="CR219"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tayebi</surname><given-names>M</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name><name name-style="western"><surname>Hawke</surname><given-names>S</given-names></name></person-group><article-title>Unswitched immunoglobulin M response prolongs mouse survival in prion disease</article-title><source>J Gen Virol</source><year>2009</year><volume>90</volume><fpage>777</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1099/vir.0.005041-0</pub-id><pub-id pub-id-type="pmid">19218226</pub-id></element-citation></ref><ref id="CR220"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tranulis</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gavier-Wid&#233;n</surname><given-names>D</given-names></name><name name-style="western"><surname>V&#229;ge</surname><given-names>J</given-names></name><name name-style="western"><surname>N&#246;remark</surname><given-names>M</given-names></name><name name-style="western"><surname>Korpenfelt</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hautaniemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pirisinu</surname><given-names>L</given-names></name><name name-style="western"><surname>Nonno</surname><given-names>R</given-names></name><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name></person-group><article-title>Chronic wasting disease in Europe: new strains on the horizon</article-title><source>Acta Vet Scand</source><year>2021</year><volume>63</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s13028-021-00606-x</pub-id><pub-id pub-id-type="pmid">34823556</pub-id><pub-id pub-id-type="pmcid">PMC8613970</pub-id></element-citation></ref><ref id="CR221"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilotte</surname><given-names>JL</given-names></name><name name-style="western"><surname>Soulier</surname><given-names>S</given-names></name><name name-style="western"><surname>Essalmani</surname><given-names>R</given-names></name><name name-style="western"><surname>Stinnakre</surname><given-names>MG</given-names></name><name name-style="western"><surname>Vaiman</surname><given-names>D</given-names></name><name name-style="western"><surname>Lepourry</surname><given-names>L</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>JC</given-names></name><name name-style="western"><surname>Besnard</surname><given-names>N</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>M</given-names></name><name name-style="western"><surname>Buschmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Groschup</surname><given-names>M</given-names></name><name name-style="western"><surname>Petit</surname><given-names>S</given-names></name><name name-style="western"><surname>Madelaine</surname><given-names>MF</given-names></name><name name-style="western"><surname>Rakatobe</surname><given-names>S</given-names></name><name name-style="western"><surname>Le Dur</surname><given-names>A</given-names></name><name name-style="western"><surname>Vilette</surname><given-names>D</given-names></name><name name-style="western"><surname>Laude</surname><given-names>H</given-names></name></person-group><article-title>Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>5977</fpage><lpage>5984</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.13.5977-5984.2001</pub-id><pub-id pub-id-type="pmid">11390599</pub-id><pub-id pub-id-type="pmcid">PMC114313</pub-id></element-citation></ref><ref id="CR222"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadsworth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Asante</surname><given-names>EA</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Review: contribution of transgenic models to understanding human prion disease</article-title><source>Neuropathol Appl Neurobiol</source><year>2010</year><volume>36</volume><fpage>576</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2010.01129.x</pub-id><pub-id pub-id-type="pmid">20880036</pub-id><pub-id pub-id-type="pmcid">PMC3017745</pub-id></element-citation></ref><ref id="CR223"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadsworth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Molecular pathology of human prion disease</article-title><source>Acta Neuropathol</source><year>2011</year><volume>121</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0735-5</pub-id><pub-id pub-id-type="pmid">20694796</pub-id><pub-id pub-id-type="pmcid">PMC3015177</pub-id></element-citation></ref><ref id="CR224"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadsworth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Joiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Linehan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Jack</surname><given-names>K</given-names></name><name name-style="western"><surname>Al-Doujaily</surname><given-names>H</given-names></name><name name-style="western"><surname>Costa</surname><given-names>H</given-names></name><name name-style="western"><surname>Ingold</surname><given-names>T</given-names></name><name name-style="western"><surname>Taema</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Sandberg</surname><given-names>MK</given-names></name><name name-style="western"><surname>Brandner</surname><given-names>S</given-names></name><name name-style="western"><surname>Tran</surname><given-names>L</given-names></name><name name-style="western"><surname>Vik&#248;ren</surname><given-names>T</given-names></name><name name-style="western"><surname>V&#229;ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Madslien</surname><given-names>K</given-names></name><name name-style="western"><surname>Ytrehus</surname><given-names>B</given-names></name><name name-style="western"><surname>Benestad</surname><given-names>SL</given-names></name><name name-style="western"><surname>Asante</surname><given-names>EA</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name></person-group><article-title>Humanized transgenic mice are resistant to chronic wasting disease prions from Norwegian reindeer and moose</article-title><source>J Infect Dis</source><year>2022</year><volume>13</volume><fpage>933</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab033</pub-id><pub-id pub-id-type="pmcid">PMC9470110</pub-id><pub-id pub-id-type="pmid">33502474</pub-id></element-citation></ref><ref id="CR225"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qin</surname><given-names>K</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>MV</given-names></name><name name-style="western"><surname>Cali</surname><given-names>I</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>P</given-names></name><name name-style="western"><surname>Greenlee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Mastrianni</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zou</surname><given-names>WQ</given-names></name></person-group><article-title>Generation of human chronic wasting disease in transgenic mice</article-title><source>Acta Neuropathol Commun</source><year>2021</year><volume>9</volume><fpage>158</fpage><pub-id pub-id-type="doi">10.1186/s40478-021-01262-y</pub-id><pub-id pub-id-type="pmid">34565488</pub-id><pub-id pub-id-type="pmcid">PMC8474769</pub-id></element-citation></ref><ref id="CR226"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wasmer</surname><given-names>C</given-names></name><name name-style="western"><surname>Lange</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Melckebeke</surname><given-names>H</given-names></name><name name-style="western"><surname>Siemer</surname><given-names>AB</given-names></name><name name-style="western"><surname>Riek</surname><given-names>R</given-names></name><name name-style="western"><surname>Meier</surname><given-names>BH</given-names></name></person-group><article-title>Amyloid fibrils of the HET-s(218&#8211;289) prion form a beta solenoid with a triangular hydrophobic core</article-title><source>Science</source><year>2008</year><volume>319</volume><fpage>1523</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1126/science.1151839</pub-id><pub-id pub-id-type="pmid">18339938</pub-id></element-citation></ref><ref id="CR227"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name></person-group><article-title>Thoughts on mammalian prion strains</article-title><source>Folia Neuropathol</source><year>2009</year><volume>47</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">19618334</pub-id></element-citation></ref><ref id="CR228"><mixed-citation publication-type="other">Weissmann C, Fischer M, Raeber A, B&#252;eler H, Sailer A, Shmerling D, R&#252;licke T, Brandner S, Aguzzi A (1996) The use of transgenic mice in the investigation of transmissible spongiform encephalopathies.&#160;Int J Exp Pathol 77:283&#8211;93<pub-id pub-id-type="pmcid">PMC3230868</pub-id><pub-id pub-id-type="pmid">9155663</pub-id></mixed-citation></ref><ref id="CR229"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Raeber</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Montrasio</surname><given-names>F</given-names></name><name name-style="western"><surname>Hegyi</surname><given-names>I</given-names></name><name name-style="western"><surname>Frigg</surname><given-names>R</given-names></name><name name-style="western"><surname>Klein</surname><given-names>MA</given-names></name><name name-style="western"><surname>Aguzzi</surname><given-names>A</given-names></name></person-group><article-title>Prions and the lymphoreticular system</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2001</year><volume>28</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1098/rstb.2000.0763</pub-id><pub-id pub-id-type="pmcid">PMC1088423</pub-id><pub-id pub-id-type="pmid">11260798</pub-id></element-citation></ref><ref id="CR230"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>GA</given-names></name><name name-style="western"><surname>Wilesmith</surname><given-names>JW</given-names></name></person-group><article-title>The neuropathology and epidemiology of bovine spongiform encephalopathy</article-title><source>Brain Pathol</source><year>1995</year><volume>5</volume><fpage>91</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.1995.tb00580.x</pub-id><pub-id pub-id-type="pmid">7767494</pub-id></element-citation></ref><ref id="CR231"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>AR</given-names></name><name name-style="western"><surname>Enever</surname><given-names>P</given-names></name><name name-style="western"><surname>Tayebi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mushens</surname><given-names>R</given-names></name><name name-style="western"><surname>Linehan</surname><given-names>J</given-names></name><name name-style="western"><surname>Brandner</surname><given-names>S</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>D</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J</given-names></name><name name-style="western"><surname>Hawke</surname><given-names>S</given-names></name></person-group><article-title>Monoclonal antibodies inhibit prion replication and delay the development of prion disease</article-title><source>Nature</source><year>2003</year><volume>422</volume><fpage>80</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/nature01457</pub-id><pub-id pub-id-type="pmid">12621436</pub-id></element-citation></ref><ref id="CR232"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilham</surname><given-names>JM</given-names></name><name name-style="western"><surname>Orr&#250;</surname><given-names>CD</given-names></name><name name-style="western"><surname>Bessen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Atarashi</surname><given-names>R</given-names></name><name name-style="western"><surname>Sano</surname><given-names>K</given-names></name><name name-style="western"><surname>Race</surname><given-names>B</given-names></name><name name-style="western"><surname>Meade-White</surname><given-names>KD</given-names></name><name name-style="western"><surname>Taubner</surname><given-names>LM</given-names></name><name name-style="western"><surname>Timmes</surname><given-names>A</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>B</given-names></name></person-group><article-title>Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays</article-title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><fpage>e1001217</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1001217</pub-id><pub-id pub-id-type="pmid">21152012</pub-id><pub-id pub-id-type="pmcid">PMC2996325</pub-id></element-citation></ref><ref id="CR233"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Will</surname><given-names>RG</given-names></name><name name-style="western"><surname>Alperovitch</surname><given-names>A</given-names></name><name name-style="western"><surname>Poser</surname><given-names>S</given-names></name><name name-style="western"><surname>Pocchiari</surname><given-names>M</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name><name name-style="western"><surname>Mitrova</surname><given-names>E</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>R</given-names></name><name name-style="western"><surname>D'Alessandro</surname><given-names>M</given-names></name><name name-style="western"><surname>Delasnerie-Laupretre</surname><given-names>N</given-names></name><name name-style="western"><surname>Zerr</surname><given-names>I</given-names></name><name name-style="western"><surname>van Duijn</surname><given-names>C</given-names></name></person-group><article-title>Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries</article-title><source>Ann Neurol</source><year>1998</year><volume>43</volume><fpage>763</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1002/ana.410430611</pub-id><pub-id pub-id-type="pmid">9629846</pub-id></element-citation></ref><ref id="CR234"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wille</surname><given-names>H</given-names></name><name name-style="western"><surname>Requena</surname><given-names>JR</given-names></name></person-group><source>The Structure of PrPSc Prions Pathogens</source><year>2018</year><volume>7</volume><issue>1</issue><fpage>20</fpage><pub-id pub-id-type="doi">10.3390/pathogens7010020</pub-id><pub-id pub-id-type="pmid">29414853</pub-id><pub-id pub-id-type="pmcid">PMC5874746</pub-id></element-citation></ref><ref id="CR235"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>ES</given-names></name></person-group><article-title>Chronic wasting disease</article-title><source>Vet Pathol</source><year>2005</year><volume>42</volume><fpage>530</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1354/vp.42-5-530</pub-id><pub-id pub-id-type="pmid">16145200</pub-id></element-citation></ref><ref id="CR236"><mixed-citation publication-type="other">Williams ES, Miller MW (2002) Chronic wasting disease in deer and elk in North America.&#160;Rev Sci Tech 21:305&#8211;16<pub-id pub-id-type="doi" assigning-authority="pmc">10.20506/rst.21.2.1340</pub-id><pub-id pub-id-type="pmid">11974617</pub-id></mixed-citation></ref><ref id="CR237"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>ES</given-names></name><name name-style="western"><surname>Young</surname><given-names>S</given-names></name></person-group><article-title>Chronic wasting disease of captive mule deer: a spongiform encephalopathy</article-title><source>J Wildl Dis</source><year>1980</year><volume>16</volume><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.7589/0090-3558-16.1.89</pub-id><pub-id pub-id-type="pmid">7373730</pub-id></element-citation></ref><ref id="CR238"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>RA</given-names></name><name name-style="western"><surname>Peretz</surname><given-names>D</given-names></name><name name-style="western"><surname>Smorodinsky</surname><given-names>N</given-names></name><name name-style="western"><surname>Bastidas</surname><given-names>R</given-names></name><name name-style="western"><surname>Serban</surname><given-names>H</given-names></name><name name-style="western"><surname>Mehlhorn</surname><given-names>I</given-names></name><name name-style="western"><surname>DeArmond</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Prusiner</surname><given-names>SB</given-names></name><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name></person-group><article-title>Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>7279</fpage><lpage>7282</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.14.7279</pub-id><pub-id pub-id-type="pmid">8692983</pub-id><pub-id pub-id-type="pmcid">PMC38974</pub-id></element-citation></ref><ref id="CR239"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R</given-names></name><name name-style="western"><surname>Plinston</surname><given-names>C</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>N</given-names></name><name name-style="western"><surname>Casalone</surname><given-names>C</given-names></name><name name-style="western"><surname>Corona</surname><given-names>C</given-names></name><name name-style="western"><surname>Tagliavini</surname><given-names>F</given-names></name><name name-style="western"><surname>Suardi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ruggerone</surname><given-names>M</given-names></name><name name-style="western"><surname>Moda</surname><given-names>F</given-names></name><name name-style="western"><surname>Graziano</surname><given-names>S</given-names></name><name name-style="western"><surname>Sbriccoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardone</surname><given-names>F</given-names></name><name name-style="western"><surname>Pocchiari</surname><given-names>M</given-names></name><name name-style="western"><surname>Ingrosso</surname><given-names>L</given-names></name><name name-style="western"><surname>Baron</surname><given-names>T</given-names></name><name name-style="western"><surname>Richt</surname><given-names>J</given-names></name><name name-style="western"><surname>Andreoletti</surname><given-names>O</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M</given-names></name><name name-style="western"><surname>Lockey</surname><given-names>R</given-names></name><name name-style="western"><surname>Manson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Barron</surname><given-names>RM</given-names></name></person-group><article-title>Chronic wasting disease and atypical forms of bovine spongiform encephalopathy and scrapie are not transmissible to mice expressing wild-type levels of human prion protein</article-title><source>J Gen Virol</source><year>2012</year><volume>93</volume><fpage>624</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1099/vir.0.042507-0</pub-id><pub-id pub-id-type="pmid">22495232</pub-id></element-citation></ref><ref id="CR240"><mixed-citation publication-type="other">Wood ME, Griebel P, Huizenga ML, Lockwood S, Hansen C, Potter A, et al. (2018) Accelerated onset of chronic wasting disease in elk (<italic toggle="yes">Cervus canadensis</italic>) vaccinated with a PrPSc-specific vaccine and housed in a prion contaminated environment. Vaccine 36:7737&#8211;7743<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.10.057</pub-id><pub-id pub-id-type="pmid">30414779</pub-id></mixed-citation></ref><ref id="CR241"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wopfner</surname><given-names>F</given-names></name><name name-style="western"><surname>Weidenh&#246;fer</surname><given-names>G</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>R</given-names></name><name name-style="western"><surname>von Brunn</surname><given-names>A</given-names></name><name name-style="western"><surname>Gilch</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>TF</given-names></name><name name-style="western"><surname>Werner</surname><given-names>T</given-names></name><name name-style="western"><surname>Sch&#228;tzl</surname><given-names>HM</given-names></name></person-group><article-title>Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein</article-title><source>J Mol Biol</source><year>1999</year><volume>289</volume><fpage>1163</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1999.2831</pub-id><pub-id pub-id-type="pmid">10373359</pub-id></element-citation></ref><ref id="CR242"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wuertzer</surname><given-names>CA</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name><name name-style="western"><surname>Federoff</surname><given-names>HJ</given-names></name></person-group><article-title>CNS delivery of vectored prion-specific single-chain antibodies delays disease onset</article-title><source>Mol Ther</source><year>2008</year><volume>16</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300387</pub-id><pub-id pub-id-type="pmid">18180775</pub-id></element-citation></ref><ref id="CR243"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S</given-names></name></person-group><article-title>Antibody dependent enhancement: unavoidable problems in vaccine development</article-title><source>Adv Immunol</source><year>2021</year><volume>151</volume><fpage>99</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2021.08.003</pub-id><pub-id pub-id-type="pmid">34656289</pub-id><pub-id pub-id-type="pmcid">PMC8438590</pub-id></element-citation></ref><ref id="CR244"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>D</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>D</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>R</given-names></name><name name-style="western"><surname>Okimura</surname><given-names>N</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T</given-names></name><name name-style="western"><surname>Katamine</surname><given-names>S</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Enhanced mucosal immunogenicity of prion protein following fusion with B subunit of Escherichia coli heat-labile enterotoxin</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>2815</fpage><lpage>2823</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.054</pub-id><pub-id pub-id-type="pmid">16446015</pub-id></element-citation></ref><ref id="CR245"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarosh</surname><given-names>OK</given-names></name><name name-style="western"><surname>Wandeler</surname><given-names>AI</given-names></name><name name-style="western"><surname>Graham</surname><given-names>FL</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>JB</given-names></name><name name-style="western"><surname>Prevec</surname><given-names>L</given-names></name></person-group><article-title>Human adenovirus type 5 vectors expressing rabies glycoprotein</article-title><source>Vaccine</source><year>1996</year><volume>14</volume><fpage>1257</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00012-6</pub-id><pub-id pub-id-type="pmid">8961515</pub-id></element-citation></ref><ref id="CR246"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabel</surname><given-names>MD</given-names></name><name name-style="western"><surname>Avery</surname><given-names>AC</given-names></name></person-group><article-title>Prions&#8211;not your immunologist&#8217;s pathogen</article-title><source>PLoS Pathog</source><year>2015</year><volume>19</volume><fpage>e1004624</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004624</pub-id><pub-id pub-id-type="pmcid">PMC4335031</pub-id><pub-id pub-id-type="pmid">25695738</pub-id></element-citation></ref><ref id="CR247"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zafar</surname><given-names>S</given-names></name><name name-style="western"><surname>Noor</surname><given-names>A</given-names></name><name name-style="western"><surname>Zerr</surname><given-names>I</given-names></name></person-group><article-title>Therapies for prion diseases</article-title><source>Handb Clin Neurol</source><year>2019</year><volume>165</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-64012-3.00004-6</pub-id><pub-id pub-id-type="pmid">31727228</pub-id></element-citation></ref><ref id="CR248"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinkernagel</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hengartner</surname><given-names>H</given-names></name></person-group><article-title>Regulation of the immune response by antigen</article-title><source>Science</source><year>2001</year><volume>293</volume><fpage>251</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1126/science.1063005</pub-id><pub-id pub-id-type="pmid">11452115</pub-id></element-citation></ref><ref id="CR249"><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>S</given-names></name><name name-style="western"><surname>Fang</surname><given-names>CT</given-names></name><name name-style="western"><surname>Schonberger</surname><given-names>LB</given-names></name></person-group><article-title>Transfusion transmission of human prion diseases</article-title><source>Transfus Med Rev</source><year>2008</year><volume>22</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.tmrv.2007.09.003</pub-id><pub-id pub-id-type="pmid">18063192</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>